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Coronary artery disease and coronary microvascular disease, as well as acute myocardial 
infarction and adverse remodelling are often characterised by tissue hypoxia. They 
benefit from the earliest possible diagnosis and treatment.  Positron Emission 
Tomography (PET) is a highly sensitive technique capable of non-invasively imaging the 
biochemistry of the body, with the capacity to track biochemical changes over time.  In 
this project, we aim to characterise a series of novel PET imaging agents able to identify 
and characterise hypoxic myocardium with a view to optimising the treatment of a range 
of cardiovascular diseases. 
 
Bisthiosemicarbazone (BTSC) ligands readily chelate positron emitting copper isotopes, 
and have been demonstrated to selectively accumulate in hypoxic tissue in vitro, in vivo, 
and in isolated perfused hearts. While the lead compound Cu-ATSM has been widely 
investigated, a library of related Cu-BTSC complexes exist which may have better 
pharmacokinetics and selectivity for application in cardiology. 
 
We employed isolated ventricular myocytes and isolated perfused hearts to screen a 
number of 
64
Cu-labelled BTSC complexes, to assess their hypoxia selectivity and 
accumulation in cardiac tissue. For this purpose we developed a novel incubation 
chamber for maintaining isolated cardiomyocytes under hypoxic conditions. We also 
developed a novel gamma radiation detector array comprising three Na/ I γ-detectors, for 
monitoring the flow of radioactivity through isolated perfused hearts in real-time.  
3 
 
We have demonstrated the hypoxia selective accumulation of 
64
Cu-ATSM in adult rat 
ventricular myocytes (ARVM) incubated under hypoxic conditions. Using isolated 
perfused hearts we demonstrated that all 
64
Cu-BTSC readily accumulate within cardiac 
tissue in an oxygen-dependent manner.  We also identified a relationship between the 
structure of Cu-BTSCs and their tissue retention, with lower molecular weight 
complexes providing the greatest hypoxic to oxygenated tissue contrast. In doing this we 
have identified two complexes, Cu-ATS and Cu-CTS, which could potentially supersede 
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1.1   Ischaemic Heart Disease 
According to World Health Organisation statistics ischaemic heart disease is the leading 
cause of mortality in the Western world, and for the foreseeable future its incidence is 
expected to continue to rise (figure 1.1) [1]. There is therefore a need to continually 
improve the means by which ischaemic heart disease is diagnosed and treated. The 
development of hypoxia avid radiotracers, and the application of positron emission 
tomography (PET) and single photon emission computed tomography (SPECT), present 
a means by which hypoxic but viable myocardial tissue could potentially be delineated 
non-invasively. While unlikely to be useful for imaging acute myocardial ischaemia 
where faster, cheaper, and more widely available approaches are more appropriate, PET 
and SPECT demonstrate unique promise in imaging the subtle degrees of hypoxia 
associated with chronic cardiac dysfunction, such as myocardial hibernation, 




Figure 1.1  Projected worldwide causes of mortality 2002- 2030. Reproduced from [1].   
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1.2  Hypoxia/ Ischemia: Definitions and Considerations 
A constant supply of oxygen is required for normal cellular metabolism.  Hypoxia 
manifests in a number of disease states such as; coronary artery disease, acute myocardial 
infarction [2-3], stroke [4], certain types of cancer [5], rheumatoid arthritis [6]  and 
diabetic vasculopathies [7].  Hypoxia may also be present in diseases where oxygen 
tensions are likely to be reduced due to poor respiratory function, e.g. cystic fibrosis and 
chronic bronchitis, sleep apnoea [8], epilepsy [9-10], as well as in benign proliferative 
diseases like psoriasis.   
 
Hypoxia is defined as a disparity between oxygen availability and the amount required 
by a biological system to function optimally, and may be subdivided into two categories; 
supply hypoxia and demand hypoxia.  Supply hypoxia is a condition that is caused by an 
inadequate supply of oxygen. Demand hypoxia on the other hand arises when cellular 
energy consumption increases, for example during exercise, without a concomitant 
increase in oxygen delivery. 
 
Ischaemia, like hypoxia, is also defined as a disparity between supply and demand, but 
refers specifically to blood.  Ischaemia is therefore a more complex situation than 
hypoxia in that blood not only transports oxygen, nutrients and signalling molecules, but 
also removes metabolic waste produces (e.g. lactate).  The accumulation of waste 
metabolites due to low blood flow can have a detrimental effect on cellular function, and 
may compromise cellular integrity and viability. While hypoxia is therefore an intrinsic 
element of ischaemia, the latter is a more complex multifaceted condition.   
29 
 
1.3  The Pathogenesis of Cardiac Ischaemia/ Hypoxia 
1.3.1 Ischaemic Cardiomyopathies 
Cardiac ischaemia is caused by diseases which occur as the result of structural and 
functional changes to the coronary vasculature and cardiac tissue. It is therefore pertinent 
to provide a brief introduction of the ischaemic cardiomyopathies, in order to 
demonstrate how and why hypoxia avid agents could be used to diagnose, and assess the 
progression and treatment of these diseases. 
 
1.3.2 Coronary Artery Disease 
Coronary artery disease (CAD) is caused by the formation and growth of atherosclerotic 
plaques within the walls and lumen of the coronary arteries [11]. This is a chronic 
process, and it may take many years for the pathophysiological consequences of CAD to 
manifest into clinical symptoms [12]. Progressive narrowing of the coronary arteries 
compromises the supply of blood to the affected region of the heart, initially causing 
demand ischaemia. The supply of blood is inversely correlated to the severity of the 
occlusion, and while sufficient nutrients may be delivered to the affected region when the 
sufferer is at rest, as the demand for energy substrates and oxygen increases, such as 
during exercise (or in severe cases by simply walking or even standing), perfusion may 
fail to meet the requirements of the contracting myocardium. The repercussion of this is 
the manifestation of angina pectoris (chest pain) [11]. CAD is associated with stable 
angina, whereby the symptoms usually abate within a few minutes of resting. While 
angina may be discomforting and painful to the sufferer, it is not necessarily life 
threatening. However other complications that may coincide or arise as result of CAD are 
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considerably more serious, and may be life threatening. Coronary artery spasm (CAS) 
may occur in the presence or absence of stenosis, and can alone be a cause of cardiac 
ischaemia [13]. However when CAS occurs in conjunction with CAD, it is more likely to 
lead to complete occlusion of the effected artery/s, which will then starve the 
myocardium of blood, and lead to myocardial infarction (heart attack).  
 
1.3.3 Atherosclerotic Plaque Rupture 
The progressive development of atherosclerotic plaques, also pose a serious risk to 
cardiac viability in the acute setting. The rupturing of an atherosclerotic plaque releases a 
thrombus into the coronary vasculature. As the coronary arteries branch into the 
prearterioles and arterioles, and become narrower, the thrombus can become lodged. This 
may severely restrict, or even completely impede blood flow to myocardium distal to the 
occlusion. In experimental animals with a coronary perfusion rate that is 10% of normal 
flow, cardiomyocytes begin to die after about 20 min [14-15].  In sufferers this acute 
event may cause severe unabated pain in the left arm and chest (unstable angina). As a 
result of restricted or inhibited perfusion a wave of cell death (infarction) begins to 
spreads from the subendocardial zone, which requires the most energy, outwards towards 
the epicardium [14].  If treatment is not administered in order to breakdown or remove 
the thrombus and restore blood flow, the most severely ischaemic regions of the 




1.3.4 Cardiac Hibernation 
In ~40 % of patients with chronic cardiac ischaemia down-regulation of myocardial 
contractility has been observed, as a means of limiting the possibility of myocardial 
infarction, in a response commonly referred to as “myocardial hibernation” [16-17]. 
Diagnosis of myocardial hibernation is particularly important because it has been shown 
that upon the restoration of blood flow, these areas recover and contraction improves [18-
19], meaning that once identified this group of patients have an excellent prognosis. 
While the mechanisms underlying this phenomenon remain poorly understood despite 
having been described almost 30 years ago [20], the two most prominent theories suggest 
the existence of either “perfusion contraction matching” [21] or “repetitive stunning” 
[22], or possibly a combination of the two. 
 
Perfusion contraction matching has been described as a state of chronic hypoperfusion 
with reduced function in the absence of significant necrosis [23]. One may therefore 
expect these regions to be chronically hypoxic but viable. In the absence of a sufficient 
supply of oxygen, contractility is down-regulated in the affected region in order to 
preserve myocardial viability [18-19]. If this is the prevalent mechanism by which 
myocardium hibernates, then a hypoxia-specific imaging agent would potentially have 
some utility in its diagnosis. 
 
Myocardial stunning is the delayed recovery of contractility following a transient 
ischaemic episode. Calcium overload that results from the reperfusion of ischaemic tissue 
is thought to cause the production of reactive oxygen species (ROS), which may cause 
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damage to cellular membranes, and the contractile apparatus of cardiomyocytes. 
Myocardial stunning is completely reversible but before normal contractility can resume 
a period of repair is required, during which time there will be a contractile deficit [22, 
24]. In this context it may be likely that for much of the time hibernating myocardium is 
actually relatively well perfused, and therefore normoxic. The current gold standard 
technique for identifying hibernating myocardium is demonstration of elevated 




FDG) PET, coupled with 
demonstration of either normal or down-regulated flow (usually by perfusion imaging 
with 
15
NH3) – a “perfusion-metabolism mismatch”. If hibernating myocardium is 
predominantly normoxic and chronically stunned, then the lack of retention of a hypoxia 
imaging agent where hibernation has already been suggested by 
18
FDG accumulation, 
could possibly be used to confirm this mechanism.  
 
1.3.5 Coronary Microvascular Dysfunction 
Coronary microvascular dysfunction (CMD) refers specifically to the narrowing of the 
prearterioles and intramural arterioles, which branch off of the main epicardial coronary 
arteries. This compromises blood flow to the endocardium, but unlike CAD, CMD 
affects the entire microvasculature of the heart. CMD may occur in the presence or 
absence of other cardiomyopathies, and has many causes which include, luminal 
obstruction, vascular remodelling, hormonal changes in females, and microvascular 
spasms [25]. The clinical symptoms of CMD are often persistent episodes of angina in 
the absence of CAD [26]. CMD is also associated with other factors such as smoking, 
hyperlipidaemia, and diabetes and because of this there is some debate as to whether the 
33 
 
causes of CMD are cardiac or non-cardiac [27]. CMD is more prevalent in females and 
often occurs in patients with normal coronary angiograms. What is apparent is that after 
almost 40 years since Arbogast and Bourassa [28], and Kemp [29] described CMD, the 
mechanisms that cause it remain elusive, and it is still somewhat difficult to diagnose. 
Hypoxic radiotracers could therefore provide a means of confirming global hypoxia 
resulting from CMD, and aid in the diagnosis of this condition.  
    
1.3.6 Pathological Cardiac Hypertrophy 
Pathological cardiac hypertrophy or adverse remodelling is the enlargement of cardiac 
myocytes, and therefore the heart muscle, without adequate compensatory angiogenesis. 
It usually occurs in response to vascular hypertension, valvular disorders, myocardial 
hibernation, or infarction. This is because the heart has to increase the amount of 
contractile force that it generates to overcome additional vascular resistance, or to 
compensate for loss of contractile function elsewhere [30-31]. Pathological hypertrophy 
is characterised by increased cell size, which results in decreased vascular density, and 
increased diffusion distance between blood vessels and myocytes. This combination of 
insufficient angiogenesis and increased diffusion distance may then lead to ischaemia or 
hypoxia. There is also evidence to suggest that hypertrophic cardiac myocytes have a 
reduced T-tubule network [32]. This in combination with the other effects of hypertrophy 
would further restrict the diffusion of oxygen to the mitochondria within each myocyte, 




This brief introduction highlights the complex and interlinked nature of the ischaemic 
cardiomyopathies, and also demonstrates similarities between the pathological 
consequences of these diseases. It also provides some insight into why a hypoxia specific 
imaging agent may be useful in cardiology. In addition hypoxia radiotracers may also be 
useful for assessing the effectiveness of drug therapy and revascularisation surgery, by 
confirming the reversal of tissue hypoxia.  
 
 
1.4  Carbohydrate Metabolism and Cellular Respiration 
Aerobic respiration is fundamental to the existence all vertebrates.  Some unicellular 
organisms, for example yeast, function adequately even optimally without oxygen. 
However an inadequate supply of oxygen to tissues in multicellular organisms is almost 
invariably linked to a pathological process.  Before discussing hypoxia and its relevance 
to diseases of the heart, normal cellular energy metabolism should be reviewed. 
 
1.4.1 Cardiac Energy Metabolism 
The heart is an omnivorous organ capable of metabolising fatty acids, glucose, lactate, 
and ketone bodies as substrates to feed the electron transport chain, and drive ATP 
synthesis. In the healthy heart, cardiomyocytes preferentially metabolise fatty acids by β- 
oxidation, because of their higher energetic yield [33-35]. While the complete oxidation 
of a molecule of glucose yields 30 molecules of ATP, the complete oxidation of palmitic 
acid, which has an acyl chain length of sixteen carbon atoms, yields 129 molecules of 




1.4.2 β-Oxidation of Fatty Acids 
Fatty acids are bound to albumin before being transported around the body, and are taken 
up into by the myocardium in the unbound form, which is mediated by transport proteins 
in the sarcolemma [38-39]. Inside the cardiomyocyte, fatty acids are activated by the 
addition of acyl-CoA by the action of acyl-CoA synthetase. To aid its entry in the 
mitochondria this acyl group is first passed from acyl-CoA to carnitine by carnitine-acyl 
transferase I, to form acyl-carnitine. Fatty acid transport across the inner mitochondrial 
membrane is facilitated by the exchange of acyl-carnitine for carnitine, by carnitine- 
acyl-carnitine translocase. Once inside the matrix, carnitine is cleaved off of the fatty 
acid chain and replaced again with CoA, by carnitine-acyl transferase II. The acyl-CoA 
molecule is then metabolised in a sequence of four reactions; oxidation, hydration, 
further oxidation, and a final thiolysis reaction. These reactions continue until the acyl 
molecule is fully degraded. Each cycle of reactions yield a molecule of acyl-CoA that has 
been shorted by two carbon atoms and a molecule of acetyl-CoA (figure 1.2), that passes 
on to the tricarboxylic acid cycle (TCA). The first oxidation reaction also generates one 
molecule each of FADH2 and NADH, both of which pass directly on to the electron 




Figure 1.2. β- oxidation of fatty acids. Adapted from [11, 36] 
 
1.4.3 The Glycolytic Pathway 
The reactions of the glycolytic pathway (figure 1.3) take place in the cytosol, and may 
progress in the presence or absence of oxygen. In the presence of oxygen glycolysis leads 
to the formation of pyruvate, which is further oxidised by the tricarboxylic acid (TCA) 
cycle. The pathway is capable of providing a substantial amount of ATP, as there is a net 
production of two molecules of ATP and one molecule of NADH, from the conversion of 
one molecule of glucose to pyruvate [36-37]. Under anaerobic conditions glycolysis 
prevails as the major source of ATP synthesis, also producing two molecules of ATP per 
molecule of glucose, although the NADH that is formed is consumed in the formation of 
lactate. However, unless the products of glycolysis are metabolised by the tricarboxylic 
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acid cycle in the mitochondria, glycolysis alone cannot produce enough to ATP to meet 
the energy requirements of the contracting heart [11].  
 
 
Figure 1.3. The glycolytic pathway. Adapted from [36]. 
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1.4.4 The Tricarboxylic acid cycle  
The majority of carbohydrate, fatty acid, and amino acid oxidation takes place in the 
mitochondrial matrix, via the enzymatic reactions of the tricarboxylic acid (TCA) (Krebs, 
or citric acid) cycle (figure 1.4) [36-37]. 
 
 





ATP is not synthesised directly by the enzymes of the TCA cycle, although some of the 
energy from acetyl-CoA is conserved in the phosphate bond of GTP, which is then 
passed on to ADP to form ATP by nucleoside diphosphate kinase. More importantly the 
TCA cycle also reduces three molecules of NAD+ and one molecule of FAD, to form 
NADH and FADH2 respectively [36-37]. NADH and FADH2 are then oxidised by the 
electron transport chain to generate a proton gradient which drives ATP synthesis [36-
37]. 
 
1.4.5 The Electron Transport Chain and Oxidative Phosphorylation 
The reduced coenzymes NADH and FADH2 donate electrons to the electron transport 
chain (ETC) (figure 1.5), which serves to convert the energy of these electrons into the 
high energy phosphate bonds of ATP, in a gradual and controlled manner.   The protein 
complexes of the ETC contain a series of redox centres with gradually increasing 
reduction potentials.  This allows the passage of electrons up the reduction gradient, 
whilst simultaneously pumping protons (H
+
) from the mitochondrial matrix into the inner 
mitochondrial membrane space. The proton gradient between the two compartments is 
then used by ATP synthase to synthesise ATP from ADP and inorganic phosphate (Pi). 
The process of electron transport is entirely dependent on molecular oxygen, which acts 
as the terminal electron acceptor. If the supply of oxygen is compromised then the 
protein complexes of the ETC remain in the reduced form. This inhibits generation of the 
mitochondrial membrane potential by proton efflux, and therefore also inhibits the 










The ETC is dependent upon the availability of molecular oxygen. In the absence of 
sufficient oxygen the ETC shuts down, followed by the TCA cycle, and inhibition of 
pyruvate dehydrogenase. Pyruvate arising from glycolysis is then converted to lactate by 
anaerobic glycolysis, as a compensatory (but significantly less effective) mechanism of 
ATP synthesis.  
 
1.5  The Biochemical Effects of Ischaemia/ Hypoxia 
The cellular damage that occurs when cardiac tissue is subjected to ischaemia or hypoxia 
is largely governed by the severity and duration of that insult. When oxygen is no longer 
available as the terminal electron acceptor, the ETC, proton efflux, and ATP-synthase 
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activity are inhibited, and anaerobic glycolysis becomes the major source of ATP 
synthesis. 
 
As already discussed in section 1.4.3, glycolysis alone cannot produce sufficient ATP to 
maintain normal contractility, which means that when the supply of oxygen is limited 
myocytes use ATP faster than it can be re-synthesised. The hydrolysis of ATP to ADP 
releases protons which decrease the intracellular pH. Although this is somewhat buffered 
by the efflux of lactate which is coupled to proton efflux, ATP hydrolysis occurs at a 
faster rate [11]. In prolonged ischaemia or hypoxia, these excess protons and elevated 
NADH/ NAD+ ratio inhibit phosphofructokinase activity, which down-regulates 
anaerobic glycolysis [11, 36-37, 40].  
 
Not only is the amount of ATP that is synthesised during ischaemia and hypoxia 
significantly less than in oxygenated hearts, the activity of ATP synthase is reversed in 
order to maintain the mitochondrial membrane potential, and a significant amount of 
ATP is actually consumed in order to pump protons out of the mitochondrial matrix and 
into the inner membrane space, which further exacerbates cellular acidosis [41].  
 
As myocytes no longer have any means of synthesising ATP, they also lose their 
capacity to maintain ionic homeostasis through ATP-dependent ion exchangers and 
pumps [11]. Intracellular acidosis drives the cytosolic influx of sodium (Na
+





-exchanger. The excess Na
+
 is transported out of the cell via the 




-exchanger. This results in intracellular calcium 
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overload, because lack of ATP prevents the activity of sarcoplasmic endoplasmic 
reticulum Ca
2+
 ATPase (SERCA), which in normoxic cells is responsible for calcium 
reuptake into the sarcoplasmic reticulum [11]. In this situation the mitochondria act as a 
sink for calcium, which is taken up via the Ca
2+
 uniporter. However, this can lead to 
mitochondrial calcium overload [42]. It is currently unclear whether calcium overload in 
itself is capable of causing mitochondrial membrane potential collapse through the 
generation of reactive oxygen species (ROS) [43], or whether this is caused by opening 
of mitochondrial permeability transition pores (mPTP), although the later mechanism is 
usually considered more important during the oxidative burst upon reperfusion [44-45]. 
Opening of these pores disrupts the proton gradient between the mitochondrial matrix 
and inner membrane space, which inhibits the normal activity of ATP synthase even 
further. The open mPTP also allow water and small metabolites in to the mitochondria 
causing them to swell, which can eventually cause the outer mitochondrial membrane to 
rupture [45]. Opening of the mPTP also allows leakage of cytochrome c into the cytosol, 
which both increases free radical production via complex I and IV of the ETC, as well as 
initiating apoptosis through caspase activation [46].  
 
Increases in cytoplasmic Ca
2+
 concentrations also activate proteases which damage the 
cytoskeleton, and phospholipases which deplete phospholipids in the cell membrane 
thereby compromising cell integrity [42]. This cascade of events combine and eventually 
cause irreversible cellular damage, which lead to necrosis and myocardial infarction. It is 
therefore of paramount importance to identify ischaemic (or hypoxic) tissue, and 
intervene as soon as possible.     
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1.6  The Current State of the Art for Estimating/ Measuring Tissue 
Oxygenation 
There are numerous techniques available that can be used for the assessment of blood 
perfusion, blood oxygenation, or cellular metabolic status. However as will now be 
discussed, only hypoxia specific tracers will be able to provide an index of intracellular 
oxygenation status. Techniques that are used to assess this parameter can be split into 
four categories: those that measure tissue oxygen tensions directly, those that assess 
tissue perfusion, those that assess hypoxia indirectly using metabolic processes as 
parallel biomarkers, and hypoxia avid radiotracers.  The majority of these techniques 
have recently been reviewed by Krohn et al [47] and Lapi et al [48].   
 
 
1.6.1 Commonly Employed Invasive Methods  
Invasive methods such as coronary angiography [49], temperature and pressure sensors 
[50], and Doppler flow wires [51] are widely used in the chatherisation lab to assess 
myocardial perfusion, intracoronary pressure, and coronary flow velocity, respectively. 
However these techniques can be unreliable especially when repeated analyses are 
performed, as it is often difficult to accurately re-target the exact same region of tissue 
[52]. On a practical note with respect to our original definition of hypoxia, these 
techniques are unable to determine whether the affected tissue is sufficiently oxygenated, 




1.6.2 Oxygen Probes 
Oxygen probes are widely used in the clinical setting for measuring tissue and tumour 
pO2, but this is an invasive procedure that relies on operator accuracy for repeated 
measurements. The Oxylab™ and Oxylite™ systems developed by Oxford Optronix 
(Oxford, UK) employ a fluorescent probe, the accuracy of which increases as the level of 
tissue oxygenation decrease.  The signal from the probe is quenched by O2 and therefore 
the signal strength is inversely correlated to O2 concentration [47, 53-55].  Although this 
instrument has improved the accuracy of direct pO2 measurement, it is only able to 
provide a measure of vascular or interstitial oxygen tensions, rather than intracellular 
oxygenation status. While it can be used to compare the oxygenation status of normally 
perfused and stenosed tissue, it is impossible to determine whether or not cellular 
metabolism has been affected. To our knowledge, oxygen probes of this sort have not 
previously been evaluated in the myocardium, presumably because it would be a 
potentially risky invasive procedure, which would be complicated by difficulty of 
accessing the heart, and compounded by cardiac motion. While it possible to access the 
coronary vasculature using a coronary catheter, oxygen probes would only provide 
information on local blood oxygen saturations, with no insight into the oxygenation of 





1.6.3 Non-Invasive Imaging Modalities 
Practically all non-invasive imaging techniques have been applied to the investigation, 
diagnosis, and prognosis of the ischaemic cardiomyopathies (see table 1.1). However 
none of the techniques summarised in table 1.1 are able to answer the question “is the 
heart truly hypoxic”? The majority of these techniques provide a measurement of 
coronary perfusion, and rely on detecting a contrast between normally perfused and 
ischaemic tissue. While hypoperfusion may infer that the heart is hypoxic, because of its 
high work rate, it does not directly address the question of whether it is actually oxygen 
deficient. Furthermore, perfusion deficit provides no indication of whether or not the 












CT Scan Iodinated contrast agents [56] 
 MRI 1H Gadolinium enhanced [57-59] 
 Echocardiography Gas filled micro-bubbles [60-61] 
 SPECT 201Thallium [62-63] 
  99mTc-Sestamibi [64-65] 
 PET 13NH3 [66-67] 
  H2
15O2 [68] 
  18F-BMS747158-02 [69-72] 












heptadecanoic acid (FTHA) 
 
[80-82] 
  11C-octanoate [83] 
  11C-palmitate [83-85] 









Monitoring of cellular metabolism has a distinct advantage over the use of perfusion 
measurement. An increase in 
18
F-FDG uptake for example, reflects the switch from beta 
oxidation of fatty acids to glycolysis during hypoxia [92]. However metabolic 
radiotracers do not respond solely to cellular oxygenation status. The uptake of these 
energy substrate radiotracers can also be affected by factors such as diet, and the 
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presence of other disease states such as diabetes [93-94]. This can confound image 
interpretation and make it difficult to discern healthy from hypoxic tissue. 
 
Magnetic resonance imaging (MRI) modalities have been developed, that can provide an 
index of either blood or myoglobin oxygenation status. While oxyhaemoglobin is 
diamagnetic, deoxyhaemoglobin is paramagnetic [89-90]. This increase in haemoglobin’s 
magnetisation as it becomes deoxygenated causes a more rapid relaxation of the water 
molecules around it (via T2* weighted decay), such that MR scans sensitive to T2* show 
increased signal from oxygenated blood and decreased signal from deoxygenated blood 
[47, 95-97]. However BOLD MRI does not provide information regarding intracellular 
pO2 within the myocardium. A variant of this technique, myoglobin oxygen level 
dependent (MOLD) MRI, is being developed as a means of specifically assessing the 
intracellular oxygenation status of cardiac tissue. However, this technique is still in its 
infancy, and its application is hampered by the significantly weaker signal that 
deoxymyoglobin has, compared to that of deoxyhaemoglobin [98].  
 
 
1.6.4 Nuclear Imaging Techniques 
The non-invasive imaging techniques single-photon emission computed tomography 
(SPECT) and positron emission tomography (PET), rely on the use of gamma radiation 
and positron emitting radionuclides respectively to detect, localise, or monitor biological/ 
biochemical events. These techniques are usually combined with computed tomography 
(CT), which is used to orientate PET and SPECT images with anatomical features such 
as organs and bone. 
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The rationale for the development of PET and SPECT occurred around the same time, 
and the techniques have many similarities. The development of SPECT and PET for 
clinical applications can be divided into three separate phases; the development of the 
cameras or scanners for imaging, the development of reconstruction algorithms to 
generate cross sectional and three-dimensional images, and the development of targeted 
radiotracers which are able to track biological processes or mimic biological molecules. 
It is this unique attribute that allows the nuclear imaging techniques to be used as 
diagnostic and prognostic indicators of disease states. 
 
SPECT was first described by Kuhl and Edwards in 1964 [99]. Their crude system 
consisted of several sodium-iodide scintillation detectors for transaxial tomography. It 
was not until 1979 that the first whole body scanner, which consisted of multiple Anger 
cameras, was described by Jaszcak et al [100]. SPECT employs gamma (γ) radiation 
emitting radionuclides (see table 1.2), which are detected by a single collimated camera 
that rotates around the patient to acquire multiple 2-D images. These are then 
reconstructed to form a 3-D image. 
 
The first ringed PET tomographs were described by Ter-Pogossian et al in 1975 [101]. 
PET employs positron (β+) emitting radionuclides. When β+-particles collide with 
electrons they annihilate to produce two γ-photons which travel in opposite directions 
from the point of annihilation. PET scanners work by registering the almost simultaneous 
coincidence of two β+-particles, by two separate detectors along a 180º plane. This is 
used to build up multiple 2-D images, which are then reconstructed into 3-D images. 
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PET scanners therefore employ a ring of static detectors, to be able to detect two β+-
particles travelling in opposite directions along the same axis.  
 
Although PET and SPECT are very similar techniques each has advantages and 
disadvantages. SPECT isotopes are generally obtained from generators or as waste 
products from the nuclear fuel industry, and are therefore cheaper to obtain. Conversely 
the majority of PET isotopes are produced using a cyclotron. SPECT is therefore more 
widely used in the clinical setting. However this is now being overcome by the use of 
mobile PET imaging units, such as the National Health Service PET/CT Diagnostic 
Imaging Service in the UK [102]. A disadvantage of SPECT is that the image resolution 
is usually of lower quality compared to PET, because it detects only single γ-photons. 
Table 1.2 demonstrates there are more PET isotopes available than there are for SPECT. 
With regards to the development of new radiotracers this allows for more versatile 
radiolabelling chemistry. Furthermore non-metallic PET radionuclides, such as 
11
C, can 
be incorporated into naturally occurring molecules without the need for bifunctional 
chelators, which are required to bind metallic radionuclides to biomolecules. This allows 
the direct measurement and monitoring of biological processes without the biochemistry 
of the compound being altered by the addition of a chelator group.  
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11C PET 20.33 min Cyclotron 
13N PET 9.97 min Cyclotron 
15O PET 122 sec Cyclotron 
18F PET 109.77 min Cyclotron 
60Cu PET 23.7 min Cyclotron 
61Cu PET 3.33 h Cyclotron 
62Cu PET 9.67 min Cyclotron/ Generator 
64Cu PET 12.70 h Cyclotron/ Reactor 
68Ga PET 67.71 min Generator 
76Br PET 16.2 h Cyclotron 
82Rb PET 1.27 min Generator 
99mTc SPECT 6.01 h Generator 
111In SPECT 2.81 days Cyclotron 
123I SPECT 13.22 h Cyclotron 
124I PET 4.17 day Cyclotron 
131I SPECT 
(Research) 
8.02 days Cyclotron/ Reactor 





1.7  Hypoxia Selective Imaging Agents 
1.7.1 Potential Application to Cardiac Molecular Imaging  
Krohn et al stated that ‘the best way to measure hypoxia would be with a probe that 
competes directly with intracellular O2, one in which the indicator was not trapped when 
O2 supply was keeping up with demand, but is retained when the O2 supply is inadequate 
to accommodate all of the electrons being produced in the electron- transport chain’ [47].  
In addition to this Strauss et al have stated the potential applications for hypoxic tracers 
in cardiology as [104]: 
 To identify the regions at risk in patients with stable angina 
 To evaluate patients admitted as ‘rule out’ myocardial infarction 
 To delineate hibernating myocardium 
 To identify transient ischaemia 
 
Nunn et al have also suggested that the ideal hypoxia selective tracer should demonstrate 
high accumulation in hypoxic tissue, but clear rapidly from blood and non-target tissues 
to give a target to background ratio of 3:1 or greater [105].  
 
In the search for hypoxia-specific imaging tracers two distinct classes of radiolabelled-








Our group has recently published a review article which summaries the data that have so 







and radiocopper-labelled ATSM, as PET imaging agents for myocardial hypoxia [106].  
 
The hypoxia avidity of the 2-nitroimidazoles was discovered by Nakamura in 1955, 
whilst trying to develop antimicrobial drugs that were effective against microorganisms 
that proliferate under anaerobic conditions [107].  During the 1970s the 2-nitroimidazoles 
were also assessed as radiosensitising agents, to enhance the treatment of tumours with 









I [118] and 
131
I [119-
120], for both PET and SPECT imaging applications. 
 
The nitroimidazoles are thought to enter cells by passive diffusion through the 
membrane. In normally oxygenated cells they diffuse directly back out of the cell, or 
undergo bioreduction to form an unstable anion. In oxygenated tissues this unstable 
anion is rapidly reoxidised back to the neutral form, which is once again able to traverse 
the cell membrane and leave the cell.  In hypoxic tissues reoxidation is less likely to take 
place and the anion is further reduced to nitroheterocycles, hydroxylamines, or amines 
(figure 1.6). Each of these species is capable of forming covalent bonds with intracellular 
macromolecules, which would trap the radionuclide within the cell [121-122]. The 
identity of the bioreductants is currently unclear, although a number of candidates 





Figure 1.6 Proposed retention mechanism for nitroimidazole based tracers in hypoxic tissue. 
Reproduced from [106]. 
 
1.7.2.1 Fluoromisonidazole (FMISO) 
In terms of hypoxia imaging, FMISO (figure 1.7) is perhaps the most extensively studied 
of the 2-nitroimidazole based compounds. The synthesis of 
18
F-FMISO was first 
described by Jerabek et al in 1986 [124], to over come the need for an onsite cyclotron 
Grunbaum et al described a method for the synthesis of 
3
H-FMISO in 1987 [125]. Later 
that year Mathias et al demonstrated increased accumulation of 
18
FMISO in vivo using a 





Figure 1.7. Structure of Fluoromisonidazole [126]. 
 
The preliminary work by the Mathias group was furthered by Shelton et al, who 
employed Langendorff isolated perfused hearts in combination with Na/ I scintillation 
detection to characterise
 
this tracer. The constant infusion of 
18
FMISO under oxygenated 
conditions resulted in 18 % retention of radioactivity by the heart. However during 
hypoxia and ischaemia the accumulation of 
18
FMISO more than doubled, to 41 % and 48 
% respectively. Reperfusion with oxygenated buffer or normalising the perfusate flow 
rate to control values had little effect on the rate of tracer clearance. This lead them to 
conclude that in all cases, the 
18
F label became essentially irreversibly bound to hypoxic 
tissue [127]. This provided support for the feasibility of using 
18
FMISO as a cardiac 
imaging agent. However the hypoxic: normoxic tissue contrast was only 2:1, which is 
lower than the ideal ratio of 3:1 that was suggested by Nunn et al [105]. 
 
In the same year Martin et al also began to investigate FMISO as an agent for cardiac 
imaging [128], using an open chest canine model of myocardial ischaemia to assess 
3
H-
FMISO uptake in vivo. The plasma clearance of 
3
H-FMISO was biphasic with an initial 
rapid phase, and a slower secondary phase with a half-life of 275 min. The liver and 
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kidney demonstrated the highest average retention compared to other organs, but the 
main route of excretion was via the kidneys. In normally perfused tissue there was no 
relationship between myocardial blood flow and 
3
H-FMISO accumulation, but in 
ischaemic regions an inverse correlation was observed. Furthermore, cardiac tissue 
sampling demonstrated that a 10– 60 % reduction in flow produced a 1.8- 2.4-fold 
increase in 
3
H-FMISO retention, compared to non-ischaemic tissue. This was important 
because it demonstrated that the tracer was able to accumulate within poorly perfused 
tissue. 
 
In order to confirm that the accumulation of FMISO was purely due to hypoxia 
selectivity alone and not dependent upon perfusion, Martin et al then went on to employ 
an isolated cardiac myocyte model. The accumulation of 
3
H-FMISO in cardiomyocytes 
incubated under oxygenated conditions, was compared to that in cells maintained under 
hypoxia (5000ppm O2) or anoxia. After 1 h they observed 4 and 8-fold increases in tracer 
retention in the respective groups, compared to controls (room air). 
3
H-FMISO continued 
to accumulate for the duration of these experiments, and after 3 h they observed a 15-fold 
increase in cells incubated under hypoxia, and a 26- fold increase under anoxia [112].  
 
In a continuation of their previous in vivo study Shelton et al then applied 
18
FMISO PET, 
once again using a canine model  to determine whether 
18
F-FMISO was capable of 
delineating ischaemic but salvageable myocardium [129]. The left anterior descending 
(LAD) coronary artery of forty six animals were completely occluded for 3, 6, or >24 h.  
Myocardial perfusion was assessed with H2
15
O, with complete LAD occlusion observed 
56 
 
in twenty four of the animals. Tissue infarction was confirmed using histochemical 
staining, and the extent on the infarction zone was determined using Lissamine green. 
Accumulation of 
18
FMISO was inversely related to the length of the occlusion period and 
myocardial blood flow. This further demonstrated that 
18
FMISO preferentially 
accumulated in hypoxic but viable tissue. However, the group also performed PET 
imaging on selected animals and found that at least 45 min was required after the tracer 
was administered, to allow for sufficient blood pool clearance before imaging could take 
place. This was unfavourable because of the relatively short half-life of 
18
F. Furthermore 
PET imaging showed that the contrast between ischaemic and normally perfused tissue 
was 1.5: 1, much lower that Nunn et al suggested.  
 
Despite these unfavourable results Martin et al attempted a final in vivo PET study with 
18
FMISO [130]. In this study they observed a contrast of 1.6: 1 for partially occluded 
tissue, and 1.8: 1 for fully occluded regions compared to normally perfused tissue, but 
again this was consider too low for clinical applications. 
 
Although all of these studies have demonstrated that 
18
FMISO selectively accumulates in 
ischaemic/ hypoxic cardiac tissue, it has not been adopted as a radiotracer for routinely 
delineating myocardial hypoxia clinically. This is because 
18
FMISO has poor first pass 
uptake, leading to suboptimal contrast between ischaemic and normally perfused tissue. 
Its slow blood pool clearance means the period between injection and imaging is 
relatively long. This coupled with the relatively short half-life of 
18
F necessitates having 




FMISO has not been adopted in the clinic, its synthesis and application served well as a 
proof of concept for hypoxia tracers. FMISO signified the beginning of the development 
of hypoxia avid radiotracers for molecular imaging, after which a plethora of novel 2-
nitroimdazole and non-nitroimidazole tracers have continued to be developed.  
 
1.7.2.2 BMS181321 
Propyleneamine oxime-1-(2-nitroimidazole) (BMS181321) is a 
99m
Tc-coordinating 
misonidazole derivative (figure 1.8). It was developed by Bristol-Myers Squibb in an 
attempt to circumvent the requirement for a cyclotron, and overcome difficulties such as 
synthesis time, which affect the short half life 
18
F-containing tracers.   
 
 
Figure 1.8. Structure of Propyleneamine oxime-1-(2-nitroimidazole) (BMS181321) [131].  
 
Reduction of  the complex by nitroreductases had been demonstrated in vitro [131], and 
accumulation of BMS181321 was approximately two-fold higher in hypoxic isolated 
cardiac myocytes compared to normoxic cells [132]. This was confirmed in isolated heart 
studies, where an inverse correlation was observed between buffer oxygen saturation and 
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tracer accumulation [133-134].  Rumsey et al demonstrated that it was possible to obtain 
SPECT images of sufficient contrast after 1 hour, with well resolved images acquired 
after 2 hours; significantly less time than the 4 hours required for 
18
FMISO imaging 
[135].  The faster blood pool clearance of BMS181321 was attributed to its being more 
lipophilic than FMISO. However this unfortunately also gave rise to considerably higher 
hepatic retention, which seriously hampered attempts to use BMS181321 for cardiac 
SPECT imaging [136]. The work with BMS181321 demonstrated that it was possible to 
significantly alter the structure of 2-nitroimidazoles, whilst still retaining their hypoxia 
avidity. Furthermore the replacement of the 
18
F radiolabel with 
99m
Tc was a practically 
attractive approach. However the poor pharmacokinetics of BMS181321 halted its 





I-(Iodovinyl)misonidazole (IVM) (figure 1.9) was also developed with the aim of 
avoiding the practical limitations of 
18
FMISO described above.  In vitro studies using 
isolated cardiomyocytes demonstrated that the hypoxic to normoxic retention ratio of 
IVM was 10: 1 and 22: 1, at 1 and 3 h respectively [120]. This was similar to 
18
FMISO 
despite IVM being significantly more lipophilic [137]. In vivo studies using open chest 
dogs then demonstrated that the blood clearance of IVM was biphasic with a half-life of 
4.6 h, similar to 
18
FMISO.  In these animals, reduction of myocardial blood flow to 70% 
of normal or less led to a proportionate increase in IVM deposition within the heart. 
Induction of additional demand ischemia by pacing or catecholamine stimulation 
enhanced tracer uptake further still.  IVM exhibited the potential to delineate hypoxic 
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myocardial tissue, however its slow blood clearance and significant liver uptake (three 










1.7.2.4 Other Nitroimidazole Analogues 
A number of other nitroimidazole based tracers have also been investigated, with varying 




Tc-BAPN) (figure 1.10) 
was screened in isolated myocytes, but the complex did not selectively accumulate in 
anoxic cultures [138].   
 
 








Tc-BRU-59-21) (figure 1.11) 
an analogue of BMS181321, exhibited hypoxia selectivity in vitro in CHO cells [139] 
and  in vivo [140-141], with a contrast of 2.4: 1 observed between ischaemic and 
normally perfused canine myocardium [136]. Unfortunately, a subsequent study showed 
that tracer accumulation only occurred when administered less than 5 minutes pre-
occlusion, but not when administered post-occlusion [141]. This extremely short window 
of usefulness would limit the clinical application of this tracer to acute ischemic 
episodes, such as delineating transient ischemia in patients with unstable angina.   
 
 







Hoffend et al synthesised and screened 2,10-dimercapto-2,10-dimethyl-4-,8-diaza-6-[4-




(figure 1.12) [142]. 
They demonstrated preferential accumulation in ischemic rat myocardium (0.65% ID/ g 
ischemic, versus 0.2 % ID/ g remote), but hepatic (7.64% ID/g), stomach (1.31 %ID/g) 
and thyroid (12.7 % ID/g) were significantly higher. This low uptake and low contrast in 
target tissue led the authors to suggest that this complex is unlikely to have any useful 
clinical applications.  
 
 
Figure 1.12. Structure of 2,10-dimercapto-2,10-dimethyl-4-,8-diaza-6-[4-(2-





1-(2-hydroxy-1-[hydroxyl-methyl]ethoxy)methyl-2-nitroimidazole (RP170) is a hypoxic 
cell radiosensitiser with an octanol-water partition coefficient of 0.09, significantly lower 
than that of misonidazole (0.35) [143]. For this reason RP170 has recently been labelled 
with 
18
F (figure 1.13) for PET imaging, as it was thought that the lower lipophilicity of 
this tracer, relative to other nitroimidazole based tracers, may decrease its hepatic 
retention. In a preliminary clinical trial the main route of excretion was indeed shown to 
be through the kidneys, with the tracer demonstrating the capacity to delineate hypoxic 
lung tumours [144]. Liver uptake was initially high (~7 SUV) but decreased by ~50 % 
over the first 30 min. Accumulation of 
18
F-FRP170 has subsequently been demonstrated 
in LAD occluded rat hearts by autoradiography, with increased retention in the left 
ventricular free wall, concurrent with increased 
14
C-DG uptake, and decreased 
accumulation of the perfusion tracer 4-N-methyl-
14
C-iodoantipyrine (IAP), and fatty acid 
metabolism tracer 
125
I-BMIPP [113]. Further studies are warranted to characterise and 
validate the hypoxia selectivity of this tracer, and to assess its possible clinical 
application in cardiology because of these interesting and promising preliminary data. 
 
 
Figure 1.13. Structure of 18F-1-(2-hydroxy-1-[hydroxyl-methyl]ethoxy)methyl-2-nitroimidazole 
(18FRP170). Adapted from [143]. 
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Other nitroimidazole based radiotracers that have been assessed as candidate hypoxia 
imaging tracers include; Radio-iodine [145]/ 
18





F-METRO [126] and 
18
F-EF5 [147]. However at 
the time of writing these tracers have yet to be characterised in cardiac tissue. 
 
 




4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime (HL91), first reported in 
1995, retains the ability to coordinate 
99m
Tc but lacks a nitroimidazole moiety (figure 
1.14) [148].  However despite this 
99m
Tc-HL91 has demonstrated hypoxia selectivity. 
 
 
Figure 1.14. Structure of Tc-4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime (HL91) 
(Tc-HL91) Adapted from [148]. 
 
The exact trapping mechanism for this tracer has yet to be established, and its evaluation 
has produced somewhat contradictory results. In isolated hearts, Okada et al 
demonstrated 7-fold and 1.4-fold increases in 
99m
Tc-HL91 retention during low-flow 
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ischaemia (1/6th normal flow), and constant flow hypoxia (95% N2/ 5% CO2) 
respectively [149].  They also demonstrated low uptake in aerobic myocardium 
irreversibly injured by cyanide, implying that ischemia and/or low oxygen are 
responsible for tracer uptake rather than non-specific tissue injury [150].  Imahashi et al 
subsequently demonstrated 
99m
Tc-HL91 uptake to be inversely proportional to perfusion 
buffer oxygen content  with an almost 4-fold greater tracer retention at 0% O2 [151]. 
 
The results of an initial in vivo imaging study by Okada et al were positive, with 
99m
Tc-
HL91 delineating regional myocardial ischemia in dogs within 15 minutes of tracer 
injection [152] (significantly faster than had been achieved with 
18
FMISO and 
BMS181321). Fukuchi et al then compared 
99m
Tc-HL91 uptake to that of the metabolic 
tracer 
14
C-2-deoxyglucose (DG), using an ischaemia reperfusion model [153]. By 
performing autoradiography on myocardial tissue sections, they found that 
99m
Tc-HL91 
was unable to delineate the infarct zone, while 
14
C-2-DG could.  However they did 
observe a 4-fold increase in 
99m
Tc-HL91 retention in the non-infarcted tissue that 
surrounded the infarct zone, which was considered to be at risk.  This suggests that 
99m
Tc-HL91 may have some application in identifying ischaemically compromised but 
viable cardiac tissue, but not infarcted tissue.  
 
Subsequent in vivo evaluations of 
99m
Tc-HL91 have been less promising.  In LAD 
occluded pigs, greater than 95% stenosis resulted in significant hypokinesia and 
perfusion deficit, as demonstrated by 
201
Tl scintigraphy. However there was no 
significant uptake of 
99m
Tc-HL91 in the hearts of these animals [154].  While this study 
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did not confirm tissue hypoxia by any parallel means, the inability of 
99m
Tc-HL91 to 
identify ischaemic tissue cast some doubt over its potential usefulness for clinical 
imaging.  However despite this Yang et al conducted the first in patient trail of 
99m
Tc-
HL91 in 2008 [155]. Thirty three acute myocardial infarction patients received 
99m
Tc-
HL91, followed 3 h later by an injection of 
201
Tl. Dual tracer SPECT was then 
performed. 
99m
Tc-HL91 distribution was seen to be perfusion-dependent and also 
ischemia-sensitive. However significant background uptake was observed in normally 
perfused cardiac tissue and hepatic tissue, which meant that distinction between normal, 
ischemic/viable, or necrotic tissue could only be made with the aid of the additional 
information provided by the perfusion images. 
 
In a recent study that was conducted by Liu et al using SPECT/ CT [156], the myocardial 
distribution of 
99m
Tc-HL91 was compared to that of 
99m
Tc-MIBI. This second patient 
study included forty one individuals suffering from coronary artery disease. Thirty five 
patients underwent 
99m
Tc-MIBI perfusion imaging for 1.5 - 2 h followed four hours later 
by 3 h of 
99m
Tc-HL91 SPECT. The remaining patients were not administered with 
99m
Tc-
MIBI, so that accumulation of 
99m
Tc-HL91 could be quantified. The patients then 
underwent revascularisation surgery, which was followed up 3- 18 months later by 
99m
Tc-MIBI perfusion imaging. When the quantitative method was employed an 
ischaemic to normal tissue ratio of 1.7: 1 was observed at 1 h post injection, increasing to 
2.6: 1 at 3 and 4 h. Follow up 
99m
Tc-MIBI scans demonstrated perfusion recovery in sixty 
six segments. In this study the authors did not report the direct effects of 
revascularisation therapy on the prognosis of the patients. They only discuss their data in 
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terms of the number of imaging segments with improved perfusion. Nevertheless this 





imaging to delineate ischaemic yet viable myocardium, with a desirable contrast between 
normal and ischaemic tissue. They then used this data to guide revascularisation surgery, 
which succeeded in improving cardiac perfusion. With respect to imaging the hypoxic or 
ischaemic myocardium, this work possibly represents the most successful in vivo pilot 
study of any hypoxia specific radiotracer to date.  
 
1.7.4 Cu-Bis(thiosemicarbazone) Complexes 
The carcinostatic and carcinolytic properties of bis(thiosemicarbazones) (BTSC) were 
first described by French and Freedlander in 1958 [157-158]. A number of publications 
then demonstrated increased antineoplastic activity of copper(II)-labelled 
bis(thiosemicarbazones) (Cu-BTSC) [159-161]. BTSC are neutral, lipophilic, square 
planar molecules, with an N2S2 coordination sphere through which they are able to form 
stable complexes with copper (figure 1.15). 
 
 




It is thought that as Cu-BTSC complexes are relative lipophilic, they are able to passively 
traverse the cell membrane into the cytoplasm, where the copper(II) moiety undergoes a 
one electron bioreduction [164-165] to form the anion Cu(I)-BTSC
-
 [166-167], which is 
trapped within the cell due to its negative charge. Once reduced, the complex then either 
slowly dissociates or the copper moiety is removed by binding to intracellular 
macromolecules, through interactions with intracellular thiol groups [168-169] or 
complex I of the electron transport chain [165] (figure 1.16). This led to the proposal that 
it may be possible to use BTSCs labelled with radio-copper for in vivo imaging. 
 
 







-methylthiosemicarbazone) (Cu-PTSM) (figure 1.17) was the 
first Cu-BTSC complex to be assessed as a PET imaging agent. Green et al reported that 
the complex was well retained in heart and brain tissue [73, 170]. Shelton et al then used 
Cu-PTSM for monitoring myocardial and renal blood flow [75-76]. Following this a 
study of seventeen 
67
Cu-labelled BTSCs, conducted by John and Green, demonstrated 
that it was possible to alter the physiochemical properties of these complexes by altering 




 groups [171]. They suggested that this could 
potentially improve the in vivo stability and pharmacokinetics of Cu-BTSC complexes, 
and lead to the development of better radiotracers.  
 
 
Figure 1.17. Structure of Cu-pyruvaldehyde-bis-(N4-methylthiosemicarbazone) (Cu-PTSM) 
[162-163]. 
 
Blower et al then suggested that Cu-BTSC complexes could be used as bifunctional 
chelators, to radiolabel biomolecules or other tracers with copper isotopes [172]. In an 
attempt to further decrease the redox potential compared to Cu-PTSM, Fujibayashi et al 
synthesised diacetyl-bis(N
4
- methylthiosemicarbazone) (ATSM) (figure 1.18), by further 





Figure 1.18. Structure of Cu-diacetyl-bis(N4- methylthiosemicarbazone) (Cu-ATSM) [162-163]. 
 
The addition of a methyl-group at the R
2
 position did indeed lead to a decreased redox 
potential, from  -208mV  for Cu-PTSM [173], to -297mV for Cu-diacetyl bis(N4- 
methylthiosemicarbazone (Cu-ATSM) [174]. Dearling et al also observed this shift in 
redox potential, and reported values of -0.51 V for Cu-PTSM and -0.59 V for Cu-ATSM 
[167]. The difference in redox potential values obtained by these groups was probably 
because they used different reference electrodes for their experiments. The shift in redox 
potential compared to Cu(II)-PTSM, means that copper(II)-ATSM is more resistant to 
bioreduction, and also infers greater stability on the complex, once it is in the anionic 
form. In well oxygenated tissue bioreduction of Cu-ATSM does not lead to dissociation 
of the copper moiety, meaning that in the presence of oxygen it can be reoxidised back to 
the uncharged form which is then able to diffuse out of the cell, or become reduced once 
again. In hypoxic tissue however, reoxidation is less likely to take place and the complex 
dissociates or the copper moiety is removed by reactions with, as yet unidentified, 
intracellular macromolecules. It is the ability of Cu-ATSM to undergo reoxidation which 
is thought to imbue it with hypoxia specificity [174].  
71 
 
Copper radionuclides demonstrate a wide array of decay characteristics [172], and 
because of this radiocopper-ATSM has been intensely investigated in the field of 
oncology, both in vitro and in vivo as a diagnostic and prognostic indicator [167, 175-
193], and as a therapeutic agent [194-198]. Cu-ATSM has also been assessed as a 
radiotracer for delineating cerebral ischaemia [199], and more recently as a means of 
assessing mitochondrial dysfunction and oxidative stress in patients with Parkinson’s or 
Alzheimer’s  disease [200-201].  
 
While radiocopper-ATSM has been widely investigated for application in oncology, only 
a limited number of articles have been published investigating its suitability as an agent 
for imaging cardiac hypoxia [174, 202-204]. Wada et al initially reported that at 
pharmacological concentrations Cu-ATSM exhibited superoxide dismutase-like 
properties, halving the amount of creatine kinase washing out of hearts, post-ischaemia- 
reperfusion injury [205]. The focus of this group then moved onto assessing Cu-ATSM 
as molecular probe for delineating hypoxic tissue. Fujibayashi et al observed 4-fold 
higher retention of 
62
Cu-ATSM in isolated hearts that were perfused with hypoxic buffer, 
or subjected to low flow ischaemia, compared to hearts that were perfused with 
oxygenated buffer [174]. They demonstrated that tracer clearance from non-target tissue 
was rapid, and that retention of 
62
Cu-ATSM was inversely related to the accumulation of 
the perfusion tracer 
201
Tl. This provided the first evidence that Cu-ATSM was hypoxia 




The accumulation of 
64
Cu-ATSM in cardiac tissue was then assessed by Fujibayashi et al 
using ex vivo imaging [202]. Rats were subjected to acute LAD ligation and injected with 
64
Cu-ATSM 10 min later. A bolus of 
11
C-Acetate was administered after a further 9 min 
to delineate myocardial perfusion. Post-mortem autoradiographic imaging of the hearts 





Cu-ATSM accumulation. When blood flow was reduced to 35- 40 % of 
normally perfused controls the retention of
 64
Cu-ATSM began to decrease, and when the 
flow was reduced to 20 % or less no uptake was observed. As there was also no 
accumulation of 
11
C-actetate in these areas, the authors suggested that the occlusion may 
have been too severe, and that blood flow could have been completely inhibited. 
However, areas surrounding the regions of zero flow demonstrated high uptake of 
64
Cu-
ATSM, suggesting that this tissue was ischaemic but viable.   
 
The translation of Cu-ATSM to cardiac research then very rapidly moved to the clinical 
setting, due to the fact that the 
62
Cu-ATSM had already been cleared for use in cancer 





FDG PET [204]. Of these, six had prior infarcts but were clinically stable 
and the seventh had been diagnosed as having unstable angina. PET imaging 
demonstrated increased glucose metabolism in five patients, but increased 
62
Cu-ATSM 
retention was only observed in the patient with unstable angina. The authors suggest that 
the lack of 
62
Cu-ATSM uptake in the remaining patients, when 
18
FDG uptake was 
observed, could be due to the fact that chronically hypoperfused myocardium was in a 
state of hibernation, and therefore the tissue may not have been hypoxic. They further 
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suggested that previous infarcts may have damaged the biological pathways required for 
62
Cu-ATSM bioreductive trapping. They concluded that Cu-ATSM may not be useful for 
imaging the chronically ischaemic myocardium, but that it could potentially be used for 
delineating acute ischaemia. In terms of patient numbers this was a very limited trial, but 
it was still promising that 
62
Cu-ATSM uptake was observed in one patient with unstable 




At the time of writing, Lewis et al were the last group to apply of Cu-ATSM PET to 
cardiac hypoxia imaging [203]. In this study systemic hypoxia, acute myocardial 
ischaemia, and demand ischaemia were initiated in vivo in a canine model. During 
systemic hypoxia, induced by inhalation of 90% N2/ 10% O2, the cardiac accumulation of 
60
Cu-ATSM increased 2-fold. An increase in the average myocardial accumulation of 
Cu-ATSM was also observed in regions of the myocardium that had been made acutely 
ischaemic by LAD ligation. Significantly more 
60, 61
Cu-ATSM was detected in ischaemic 
but viable tissue compared to non-ischaemic regions, especially when the size of the 
infarct was considered by the authors to be relatively small.  The third and perhaps most 
clinically relevant protocol was that which modelled demand ischaemia, initiated by 
LAD stenosis. This model represents the pathophysiology of ischaemic yet salvageable 
myocardium. The authors observed a contrast between normally perfused and ischaemic 
tissue. Moreover, kinetic modelling demonstrated that at just 13 min post-injection, the 




Despite the very promising preliminary results, it has now been 10 years since Cu-ATSM 
was last investigated as a cardiac hypoxia imaging agent. This is mostly likely because 
hypoxia imaging per se has been perceived to have limited application in cardiology 
when compared with oncology, where hypoxia tracers show potential as diagnostic, 
prognostic, and therapeutic agents. However we would argue that hypoxia as a facet of 
ischaemia remains an important biomarker of cardiac pathology, which warrants further 
investigation and development. The initial patient study by Takahashi et al [204] may not 
at first appear to have been wholly successful. However it is important to remember that 
this was a small study, and six of the seven patients were considered clinically stable 
after myocardial infarction. It is therefore feasible that the infarcted tissue was necrotic, 
and unable to accumulate the tracer. It is also feasible that even though these patients had 
been diagnosed with coronary artery disease and demonstrated increased 
18
FDG uptake, 
the remaining viable myocardium may not have been hypoperfused at the time of 
imaging and therefore not pathologically hypoxic. The data that was acquired from the 
single patient where increased 
62
Cu-ATSM accumulation was observed, demonstrate the 
potential for using 
62
Cu-ATSM PET to image transiently ischaemic viable myocardium. 
This is supported by the results from the third protocol described Lewis et al, where they 
initiated demand ischaemia by partial ligation of the LAD, and observed a contrast 
between ischaemic and normoxic tissue of ~3: 1 [203]. Finally, with the insight from the 
successful recent patient trial with 
99m
Tc-HL91, we suggest that there is a need for a 
larger patient trial with Cu-ATSM, using 
99m
Tc-MIBI as a comparative agent. 
99m
Tc-
MIBI would not only delineate myocardial perfusion, but as it accumulates within 
mitochondria to it may also be able to provide an index of mitochondrial function. The 
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mitochondrial electron transport chain has been implicated in the bioreductive trapping 
of Cu-ATSM [174, 195, 206]. 
99m
Tc-MIBI could therefore be used to determine whether 
these bioreductive components are functional. We also suggest that such a trial must 
include CAD patients that have not suffered a heart attack, as these should present viable 
but salvageable myocardium. 
 
These very promising results suggest that Cu-ATSM PET most certainly warrants further 
investigation, both in the research and clinical setting. Moreover Cu-ATSM is just one of 
a family of Cu-BTSC complexes that have already demonstrated some degree of hypoxia 
selectivity. However, to date none of the novel complexes that were reported by Dearling 
et al  [162-163, 167], Blower et al [207] and McQuade et al [208], have been 
characterised in the heart. In fact with the exception of these early studies, the novel Cu-
BTSC complexes described by these authors have not been investigated at all. It is 
logical that with so much attention having been paid to the 2-nitroimidazole based 
tracers, none of which has demonstrated any significant improvement over FMISO, the 
Cu-BTSC complexes should also be thoroughly investigated. A library of Cu-BTSC 
complexes was developed because further methylation of the ligand backbone of the 
PTSM, led to the development of the hypoxia specific complex Cu-ATSM. However it 
was noticed early on that Cu-ATSM is only retained in cells exposed to extreme hypoxia 
[167, 209], therefore a library of other BTSC ligands were synthesised with a range of 
redox potentials, and lipophilicities with a view to targeting cells subjected to less 





positions did little to affect the redox potential of the complexes [162], increasing their 
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molecular weight by varying the alkylation pattern at the R
3
 position did alter their 
lipophilicity relative to Cu-ATSM. This could potentially affect the tissue accumulation 
of these complexes as well as the rate at which they elute from cells. This in turn would 
mean that they could potentially demonstrate higher uptake, or more rapid clearance 
from non-target tissue and blood, compared to Cu-ATSM. Our work will therefore focus 
on characterising the myocardial accumulation of the most promising Cu-BTSC 
complexes described by Dearling, Blower, McQuade, and their co-workers. 
 
1.8  Aims of this Project 
We have recently summarised what needs to be done to develop and validate the Cu-
BTSCs for cardiac imaging application [106]: 
 Further screening of the Cu-BTSC library  
 Determine the effect of perfusion, oxygen, and acidosis 
 Determine the site of intracellular reduction and bioreductants 
 Determine the fate of radiocopper released from the complexes 
 
The aim of this thesis was to build upon the structure activity work of Dearling, Lewis, 
Blower, McQuade et al, focusing on whether any of the novel Cu-BTSC complexes are 
suitable for cardiac imaging, or more specifically better than Cu-ATSM. For this purpose 
we have employed isolated cardiac myocytes and isolated perfused hearts, to screen and 
characterise the accumulation of Cu-BTSC complexes in oxygenated and hypoxic 
cardiac tissue. This necessitated the careful development and construction novel purpose 
built experimental apparatus, and its testing and calibration. The viability of isolated 
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myocytes and perfused hearts was also assessed, to confirm that the procedures used in 
this lab resulted in cells and organs that were fit for experimental purposes, before 







Development of an Isolated Ventricular 





2.1  Introduction  
The first method that we planned to use in order to characterise our library of novel 
64
Cu-
BTSC complexes, was an isolated adult rat ventricular myocyte (ARVM) based 
screening assay. However before assessing the accumulation of 
64
Cu-BTSC in ARVM, 
we first had to validate the adult rat ventricular myocyte (ARVM) isolation procedure. 
This involved monitoring the cells in culture, in terms of their viability and morphology, 
which was done in order to determine the optimum time-frame for their use. We then had 
to design, build, and characterise an incubation chamber that was suitable for maintaining 
ARVM cultures under oxygenated or hypoxic conditions.  
 
2.1.1 Why use Adult Rat Ventricular Myocytes? 
In vitro cultures of primary cardiac ventricular myocytes are been widely applied in 
cardiovascular research. They have been employed for the morphological, biochemical, 
biophysical, and molecular investigation of myocardial function at the cellular level 
[210-215], as well as for assessing the effects of pharmaceuticals and toxins [216]. 
ARVM based models have the advantage that they are uniform cell populations, free 
from the influence other cell types, neuronal or hormonal signalling, and can be 
maintained in a stable and controllable environment. Data from these types or 
experiments are therefore more likely to be reproducible, compared to those from 
isolated perfused hearts for example, as multiple conditions or replicates can be run in 
parallel. Finally, using ARVM based models may be more cost effective than in vivo or 




Canavaugh first described a method for the isolation of cells from embryonic chick 
hearts in 1955 [217]. Although these cells were used initially, there was a need to isolate 
mammalian cardiac cells to more accurately model the human heart. In 1960 Harary and 
Farley reported the successful isolation of cells from neo-natal rat hearts. The focus then 
moved on to isolating cardiac myocytes from adult animals, this was first achieved by 
Kono in 1969 [218]. In the years following Kono’s work, cardiac myocytes were 
successfully isolated from the hearts of numerous mammalian species including; rat 
[210-211, 218] rabbit [219], guinea pig [220], ferret [221] and more recently mouse 
[222]. Of all the species from which cardiac myocytes have been successfully isolated, 
the adult rat heart is perhaps the most widely employed. This is because the rat heart is of 
a convenient size for experimental purposes, and yields ~2- 5x 10
6
 cells/ heart, with 
between ~70- 98 % intact rod shaped myocytes [211, 223-226]. Other factors which 
make the rat heart a popular choice include lower upkeep costs compared to larger 
mammals, and the wealth of experimental data available relating to the characterisation 
of this system. 
 
A variety of cardiac myocyte preparations are available, these include neonatal, adult, 
and immortalised cells. There is a certain amount of debate amongst cardiac researchers 
as to which is the better preparation, but each has its advantages and disadvantages. 
Cardiac myocytes isolated from embryonic or neonatal hearts, are immature cells that 
have yet to fully differentiate. For this reason they tend to be used for studying the 
developing heart. Immature cells lose their characteristic rectangular or rod-shaped 
morphology once isolated, but they are more robust than adult myocytes and therefore 
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they endure the isolation process better. The robustness of immature cardiomyocytes 
compared to the fragility of adult cells, is highlighted by the gap of more than a decade 
between the first successful isolation of embryonic cardiomyocytes [217], and Kono’s 
first successful isolation of adult cardiomyocytes [218]. Immature cardiomyocytes also 
undergo a small number of division cycles when initially placed in culture, which may 
somewhat increase the yield of cells and offset the relatively small size of these hearts. 
However the main advantage of using immature cells is their ability to spontaneously 
contract in culture. Their demand for nutrients and metabolites therefore more closely 
reflects the metabolism of cardiac myocytes in vivo.  
 
Adult cardiac myocytes are large, rod-shaped, terminally differentiated cells that have 
ordered sarcomeres, and form strong interactions with other cardiac cells and the extra-
cellular matrix.  Adult cardiac myocytes cultured in vitro maintain their in vivo 
phenotype for up to two weeks. They are therefore considered by some to be a more 
accurate model of the mature myocardium. A distinct disadvantage to using adult 
cardiomyocytes is that healthy cells are essentially quiescent in culture and accordingly 
their demand for nutrients is not comparable with that of cardiomyocytes in vivo. They 
do however respond to externally applied electrical stimuli. Another disadvantage is that 
mature cells cannot proliferate, and therefore the number of cells is entirely limited by 
the efficiency of the isolation procedure.  
 
Recently Claycomb et al have derived the immortalised cell line HL-91, from murine 
AT-1 tumours cells line [227]. In vitro these cells displays an organised sarcomeric 
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structure and spontaneous contraction, a phenotype that is sustained through serial 
passages. However this is a relatively new cell line that requires further characterisation, 
before it can be considered a suitable model for cardiac research. They therefore were not 
considered suitable for our studies. 
 
The in vitro differentiation of human embryonic stem cells (hESC) into cardiomyocytes 
has been demonstrated by Kehat et al [228], and more recently by Zhu et al [229]. In the 
future these cells may prove useful as a model for cardiac research. They could also 
potentially be implanted into humans to repair damaged cardiac tissue. However at the 
present time the source of these cells is limited, and therefore it is unlikely that these 
cells will become a widely used research tool in the foreseeable future. Due to the 
difficulty in obtaining these cells, and because of the lack of data available for them, we 
did not consider them for use in our experiments. 
 
Unless the focus of a particular area of research dictates that cells are obtained from a 
specific region of the heart, adult ventricular myocytes are most widely used for basic 
cardiac research. As digestion of the ventricles provides a uniform cell population, and 
yields the greatest number of myocytes, we employed ARVM throughout the cell based 
radiotracer characterisation experiments in this study. 
 
2.1.2 Considerations of Ventricular Myocyte Isolation and Culture 
Cardiac myocytes used in the first phase of this study were obtained from the ventricles 
of adult male Wistar rats. As discussed previously the isolation and culture of viable, 
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calcium tolerant ARVM has been refined over many years. It is therefore important to 
discuss some of the finer points of ARVM isolation, and culture techniques that we have 
incorporated into our own methodologies. 
 
2.1.2.1 Tissue Disruption Methods 
In vivo, mature cardiac myocyte form strong interactions with other cells and the 
extracellular matrix, which are difficult to disrupt. Early attempts to obtain isolated 
cardiac myocytes used mechanical means to dissociate cells, but this proved to be too 
harsh and compromised cell viability. Enzymatic digestion of tissue fragments is another 
method which is still used to isolate cells from embryonic or neo-natal hearts. This is 
because the small size of these organs makes them extremely difficult to cannulate for 
perfusion digestion. The problem with this approach is that the enzyme solution does not 
penetrate into the core of the tissue, which limits its efficiency. Wherever possible, 
retrograde perfusion of hearts in the Langendorff mode with a digestion solution is 
generally accepted to be the most efficient means of obtaining viable cardiac myocytes. 
A series of oxygenated solutions that contain EGTA and/ or collagenase are then 
perfused through the heart to breakdown the extracellular matrix. This is followed by 
mechanical tissue disruption, which usually involves cutting the heart into small pieces 
(~1mm), and then aspirating these numerous times using a Pasteur pipette to disperse the 





2.1.2.2 Calcium Tolerance and Cell Substratum Attachment  
Not only is the meticulous regulation of intracellular Ca
2+
 an integral component of the 
contraction-relaxation cycle, but Ca
2+
 is also instrumental to the formation of interactions 
between cells and with the extra-cellular matrix. A calcium free perfusion step is 
therefore incorporated into the isolation procedure, to reduce the extracellular Ca
2+
 
concentration and weaken these interactions. At this point a metal chelator, such as 
EGTA, is often used to increase the efficiency of this process. However, reintroduction 
of Ca
2+
 at a physiological concentration may cause calcium overload, which can lead to 
massive cellular injury including myofibrillar hypercontraction, membrane disruption, 
and mitochondrial damage. This is accompanied by the release of intracellular enzymes, 
and changes in myocyte morphology, and can ultimately compromise cell viability. This 
process, which is known as the ‘calcium paradox,’ was possibly the most difficult 
obstacle for the pioneers of adult cardiomyocyte isolation to overcome [211, 234-236]. It 
is solved by the gradual repletion of Ca
2+
 in a step-wise manner to prevent overload, by 
allowing time for gap junctions to seal and the sarcolemma to repair. 
 
In order to maintain viable cultures of ARVM for more than a few hours, the cells 
require a substratum to which they can attach [237]. Without this attachment myocytes 
enter “anoikis”, which is a form of apoptosis that is initiated when normally adherent 
cells become detached from tissues of organs [238-239]. ARVM cannot form 
attachments to glass or plastic cultureware, so culture vessels have to be pre-coated with 




2.1.3 Ultrastructure of the Cardiac Myocyte 
As their name suggests cardiomyocytes (figure 2.1) are only found in the heart. They are 
shorter in length than skeletal myocytes and do not connect to bone. Cardiomyocytes 
also have gap junctions between the intercalated discs of individual cells, which allow 
the exchange of small molecules. Contraction of skeletal muscle is controlled by the 
somatic nervous system, whereas contraction of cardiac muscle is controlled 
automatically by the sinoatrial node [11, 240]. 
 
Although smaller than skeletal myocytes, cardiomyocytes are still relatively large cells. 
They contain an extensive network of myofibrils, which are organised into units called 
sarcomeres. The sarcomere is composed of a Z- disc at each end, to which the proteins 
CapZ and titin are attached, which respectively anchor actin and myosin to the Z-disc. 
Contraction occurs when myosin head units interacts with actin filaments, and pull the 
filaments towards the centre of the sarcomere [11, 240]. 
 
 




The sarcolemma of cardiomyocytes is invaginated with a network of transverse (T) 
tubules. The T-Tubular network allows for more efficient delivery of oxygen, and other 
nutrients into the cytoplasm. This is achieved by decreasing the diffusion distance 
between the sarcolemma and cellular organelles. Cardiomyocytes also contain many 
flattened mitochondria that are located in close proximity to T-tubules, and an extensive 





2.1.4 Incubating Cells in a Controlled Environment 
2.1.4.1 Criteria for the Ideal Cell Incubation Chamber 
The ideal incubation chamber for the studies that we envisage should be low cost and 
reusable. It should also be airtight, and have a small internal volume to allow for rapid 
gas exchange. The chamber should also have a gas line, as well as ports for the insertion 
of a pO2 sensor, the addition of radiotracers, and for the removal of aliquots of culture 
medium. Furthermore the system must be temperature controlled so that cell cultures can 
be maintained at 37 ºC.   
 
2.1.4.2 Why the need for a purpose built incubation chamber? 
Incubating mammalian cells under hypoxic/ anoxic conditions is practically very 
difficult. Apart from the obvious difficulty of attaining and maintaining a steady state of 
hypoxia/ anoxia, there is the need to maintain an adequate temperature of 37ºC. The cells 
also have to be provided with sufficient medium and nutrients. While there are a number 
of commercially available pieces of apparatus that can be used to maintain cells in a 
hypoxic/ anoxic environment, none of them meet all of the criteria discussed previously. 
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This has lead several laboratories to develop their own apparatus for incubating cells 
under hypoxic/ anoxic conditions [162-163, 167, 241-242]. 
 
2.1.4.3 Methods and Apparatus for Hypoxic Cell Incubation 
We will now discuss the methods/ apparatus that are currently available for maintain 
cells under hypoxic conditions, to highlight the current state of the art.  
2.1.4.3.1 Hypoxic Solutions  
One of the most basic methods used to attain a state of hypoxia is to use “hypoxic 
solutions” or “hypoxia bags”, which contain an oxygen scavenger such as sodium 
dithionite. The problem with these approaches is that air tends to slowly diffuse in to the 
solution/ bag, and eventually saturate the oxygen scavenger. Oxygen then contaminates 
the system and causes a rise in pO2. While these approaches are relatively cost effective, 
they are neither reliable nor reusable, and they do not have the capacity to regulate 
temperature. After careful consideration we decided that these methods were not 
appropriate for our study. 
 
2.1.4.3.2 Hypoxia Chambers 
There are a number of commercially available anaerobic/ hypoxia chambers. These are 
large sealed systems that have inbuilt gloves, to allow the manipulation of samples and 
equipment within the chamber. However because of their size this type of chamber takes 
a long time to purge of oxygen. Furthermore they do not have the capacity to maintain 
cultures at 37ºC. Some commercially available hypoxia chambers, such as the modular 
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incubation chamber (Billups-Rothenburg Inc.) [243] are designed to fit into standard lab 
incubators. These are airtight chambers, but the manufacturer reports that the lowest pO2 
that can be achieved is 35mmHg, which is much too high for the purpose of this study. 
Furthermore the chamber needs to be sealed, purged with the required gas mixture, and 
then remain unopened for the duration of the experiment. In addition this system does not 
have a dedicated tracer administration/ sampling port, only a gas inlet and outlet. We 
would therefore have to add our complexes to the culture medium before the system is 
sealed and equilibrated with the required gas mixture, to avoid the possibility of 
radioactivity being blown out as it is injected onto the cells. This would also make it 
practically difficult to acquire samples of culture medium or cells during an experiment. 
This approach was therefore also rejected. 
 
2.1.4.3.3 Coverslip/ Thin Film Hypoxia 
Coverslip hypoxia (CSH) is a novel in vitro method for studying the effect of hypoxia/ 
ischaemia [244-246]. Cells are grown on culture plates, and then coverslips are gently 
rested on top of them to create a thin film of medium between the culture vessel and the 
slip. The slip limits the diffusion of oxygen from the larger volume of medium which 
surrounds the covered area, whilst also limiting the diffusion of metabolic waste products 
from beneath the slip. This restricts the delivery of fresh medium and nutrients to cells, 
which generates a pseudo- ischaemic environment as the only point for nutrient and gas 
exchange is the small area around the edges of the slip. CSH is a relatively low cost, low-
tech approach. Depending upon the size of the cells, the space between the cells and the 
coverslip is around 9.8µm [245], which means that it is not possible to measure the pO2 
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of medium that is beneath the slip using commercially available oxygen sensors. Since 
this is a relatively new (2004) technique there is very little data available regarding its 
validation/ optimisation, and therefore it has yet to be widely adopted. It was however an 
interesting approach that we briefly considered. We performed a preliminary study to 




Cu-ATSM into hypoxic cells underneath the 
coverslip. Unfortunately we found that removal of the coverslip, which was necessary to 
wash off excess tracer in order to perform autoradiography, dislodged the majority of 
ARVM that were attached to the vessel. We therefore did not pursue this method any 
further.   
 
Mineral oil suspended over culture medium to form an air tight film has also been used 
to maintain hypoxic environments [247-248]. With this approach the volume of medium 
is only restricted by the volume of the culture vessel. It would therefore in theory be 
possible to select a vessel that would hold sufficient medium, to allow the pO2 to be 
measured using conventional oxygen probes. However we intended to use certified gas 
mixtures in order to generate oxygenated or hypoxic conditions, and we soon realised 
that the culture medium would have to be equilibrated before it was added to the ARVM 
cultures. This is because if the medium was gassed after plating the gas bubbles would 
agitated the cells and potentially cause them to detach from the culture vessel. This posed 
another practical problem, if we equilibrated the medium with gas before it was plated, it 
would be technically difficult to then plate the medium without exposing it to 
atmospheric oxygen. Furthermore, afterwards there would be no way of maintaining the 
medium pO2. We therefore decided that this method was not suitable. 
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The thin film technique described by Koch [249] also seemed a potentially useful 
approach, as this method was employed by Martin et al for investigating 
3
H-FMISO 
accumulation in cardiac myocytes [112]. In this technique cells are cultured on cover-
slips which are then placed on a raised platform in the centre of a culture vessel. Enough 
medium is then added to the vessel so that the coverslip and cells are only slightly 
submerged by a thin film of medium. However unlike CSH the supply of nutrients and 
removal waste products is not restricted, because diffusion from or to the larger volume 
of medium beneath the slide can freely occur. The main advantage of this system is that 
the thin film allows for rapid gaseous exchange (~6 sec). This means that when cells are 
exposed to hypoxic condition less time is required to equilibrate the medium before 
adding the tracer, which decreases the potential damaging effects of incubating cells 
under this condition. However a disadvantage of this approach is that because the 
medium film is so thin, it would not possible to use an oxygen probe to measure the pO2 
of the culture medium to confirm that it is hypoxic. For these reasons this method was 
not employed. 
 
2.1.4.4 Development of a Purpose-built Cell Incubation Chamber  
After careful consideration of the commercially available equipment and techniques that 
have been previously used to study hypoxia in isolated cells, it was decided that none of 
these approaches fulfilled the criteria that we originally established. It was therefore 
necessary to develop a purpose built system ourselves.  Our first crude prototype 
chamber was built from plastic kitchenware (figure 2.2). After finalising our design 
based on what we had learned for this prototype, We commissioned Labglass Ltd 
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(Cambridge, UK) [250] to manufacture our MKII incubation chamber (figure 2.3 and 
2.4).  
 
The prototype chamber system is shown in figure 2.2. The chamber was a plastic 
sandwich box into which ARVM cultures were placed. The lid of the box was pierced 
four times to accommodate a gas line inlet, a gas outlet, an injection port, and a pO2 
probe port. To ensure that the culture medium was warmed the incubation chamber was 
then placed into a water-bath set to 37 ºC, and weighed down do prevent movement. Gas 
was introduced into the system after first bubbling through a smaller plastic box 
containing water, which acted as a gas humidification chamber to prevent the culture 
medium from drying out.     
 
 





A schematic representation of the MKII incubation chamber is shown in figure 2.3. This 
chamber had an internal diameter of 9.2 cm, and a depth of 6.0 cm. The internal and 
external walls and base of the chamber were moulded so that there was a hollow space 
between them, to allow the circulation of thermostatically warmed water via inlet and 
outlet ports. The top of the system was sealed with a large rubber bung with two pieces 
of steel tubing (5 mm diameter) inserted through it, to serve as a gas inlet, and outlet. A 
third plastic tube was inserted through the bung in order to accommodate a pO2 probe, 
and also to serve as a sampling/ tracer injection port.  A petroleum jelly based lubricant 
was often applied to the outer rim of the bung, to ease it’s insertion into and removal 
from the chamber. This also helped form an airtight seal between the bung and the 
chamber, which was maintained by placing two lead weights on top of the bung once it 
was in position.  
 
 




Figure 2.4 presents the completed MKII incubation chamber system. The chamber was 
positioned on top of a plate rocker, which was in turn was placed on top of a water 
heater/ circulator. Behind this equipment (not shown in figure) are two glass 
humidification chambers that were incorporated into the gas line. Gas flowed into the 
chamber via a heated gassing line, and out through a separate port. Although the system 
was always under positive pressure when gas was flowing through it, a tube led from the 
gas outlet port into a water filled flask to ensure that atmospheric air could not flow into 
the chamber via this port. A pO2 probe and the Oxylab™ system are also shown in place.  
 
 





The aims of this part of the study were; (i) to assess the ARVM isolation procedure to 
ensure that cells were viable and to ascertain the optimum time-frame for using ARVM 
for experiments. (ii) to develop and characterise a cell incubation chamber that was able 
to maintain ARVM cultures, and fulfil the criteria that we set out in set out section 
2.1.4.1. (iii) Determine the linear range of the laboratory gamma well counter in terms of 






2.2  Materials and Methods 
2.2.1 Chemicals and Reagents 
Unless stated otherwise all chemicals were of analytical grade and were purchased from 
Sigma-Aldrich (Poole, Dorset, UK).  
 
2.2.2 Gas mixtures  
All gas mixtures were purchased from BOC, UK. Specialist gas mixtures were certified 
by the manufacturer. Gas mixtures used for this series of experiments were: oxygenated 




Cu production  
64
Cu was kindly provided by Dr K. Shaw or Dr R. Paul, and was produced at the PET 
Imaging Centre, St. Thomas’ Hospital, London, [251-252]. The concaved tip of a solid 




Cu was generated using a CTI 
RDS 112 cyclotron, accelerating protons to 11MeV. The 
64
Cu was then dissolved off of 
the target using 9 M HCl, and transferred to a column packed with AG1-8X anion 
exchange resin (Bio-Rad, UK) made up in 9 M HCl.  
64
Cu was eluted from the column 
by titrating with HCl (9- 0.1 M), and the amount of radioactivity was measured using a 
dose calibrator (CRC-25R Capintec, USA). Co-impurities were removed in fractions just 
before the 
64





2.2.3.1 Measurement of the Amount of Radioactivity in Radionuclide Stock 
Solutions 
In all experiments where radioactive isotopes were used, a dose calibrator (CRC-25R 
Capintec, USA) was employed to measure the amount of radioactivity in the stock 
solutions. These stocks were always in excess of 20 MBq so that they could be 
accurately measured using the dose calibrator. The specific activity of the solutions was 
then calculated according to a known volume, and from this smaller aliquots were 
removed as necessary.  
 
2.2.4 Isolation and Culture of Adult Rat Ventricular Myocytes 
 
Table 2.1. Formulation of modified Tyrode stock solution. 
Chemical Mol. Wt Concentration (mM) Amount/ l 
Sodium Chloride 58.44 130 7.6g 
Potassium Chloride 74.55 5.4 0.4g 
Magnesium Chloride 1M solution 95.21 1.4 1.4ml 
Sodium Hydrogen Phosphate 142 0.4 0.06g 
HEPES 283.3 4.2 1.2g 
D-Glucose 180.16 10 1.8g 
Taurine 125.1 20 2.5g 
Creatine 131.1 10 1.3g 
 
 
A stock solution of Tyrode’s was made up according to Table 2.1, heated to 37 ºC and 
adjusted to pH 7.4 with 0.5 M NaOH. In order to accurately manipulate the Ca
2+
 
concentration at each step of the isolation procedure, the Tyrode’s stock solution was 
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split into 5x 50 ml aliquots and modified by adding or omitting CaCl2, EGTA, or 
collagenase.  
 
Mature ventricular myocytes were isolated from the hearts of male Wistar rats (220-240 
g) (B&K Universal, U.K.) by enzymatic digestion, as described previously [233]. 
Briefly, rats were anaesthetised with sodium pentobarbitone (100 mg/ kg i.p.). Once the 
animal was sedated to the point that no reflex actions were observed, heparin (200IU) 
was injected into the femoral vein. The heart was then rapidly excised, immersed in ice 
cold Tyrode’s stock solution containing 0.75 mM CaCl2. Excess tissue was carefully 
removed and the heart was cannulated in the Langendorff mode. Hearts were then 
perfused at 37- 37.4 ºC as follows: (1) with modified Tyrode’s solution containing 0.75 
mM CaCl2, for 4 min, (2) with nominally calcium-free modified Tyrode’s solution 
containing 0.1 mM EGTA, for 4 min, and (3) with modified Tyrode’s solution containing 
0.1 mM CaCl2 and 0.75 mg/ ml collagenase (Worthington Biochemical Corp. USA) for 7 
min. All solutions were gassed with 100% O2 and coronary flow rate was maintained at 8 
ml/ min. Hearts were then cut down from the cannula, the atria were removed and the 
ventricles were chopped into ~1 mm pieces in modified Tyrode’s solution containing 0.1 
mM CaCl2 and 0.75 mg/ ml collagenase. The tissue fragments were then gently gassed 
with 100% O2 for ~15 min to facilitate cell dispersion before being allowed to settle iso-
gravimetrically. The calcium concentration of modified Tyrode’s solution was increased 
in two steps to 1 mM. Isolated myocytes were then washed with Medium 199 (M199) 
(Invitrogen, UK) containing  penicillin (100IU/ml), streptomycin (100IU/ml), L-carnitine 
(2mM), creatine (5mM) and Taurine (5mM). Myocytes were then resuspended in 50 ml 
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M199 ready for plating on 90 mm Petri dishes pre-coated with laminin (15 µg/ ml) 
(Sigma- Aldrich, UK). Cells were allowed to settle and attach for two hours, after which 
the culture medium was removed along with dead/ unattached cells, and replenished with 
10 ml fresh M199. Culture medium was changed before the start of each experiment, or 
every 24 h when experiments required that cells be maintained in culture. 
 
2.2.5 Ventricular Myocyte Plating Density Study 
Cell attachment is essential for maintaining ARVM in culture. The number of cells that 
can attach is therefore limited by the surface area of the culture vessel. To maximise the 
number of cells and to avoid wastage through plating at too high a density, a series of 
experiments were performed to ascertain the optimum volume for diluting ARVM 
suspensions prior to them being plated. 
 
Freshly isolated calcium tolerant ARVM from one heart were suspended in 12 ml M199. 
2 ml of the suspension was then diluted with various volumes of M199 (Table 2.2).  
 
Table 2.2. Dilution volumes for ARVM plating study 
 
Number of  
Plates coated 




Final Volume (ml) 
1 2 0 2 
2 2 2 4 
3 2 4 6 
4 2 6 8 
5 2 8 10 




In order to allow all of the dilutions to be made using myocytes from the same heart, the 
experiment was scaled from 6 to 24 well plates.  
 
2.2.6 Quantification of Cell Numbers 
In order to quantify the number of ARVM per culture well/ plate, a bright-field 
microscope fitted with an eyepiece mounted reticule (GX Optical, UK) was employed. In 
all cell based experiments the number of ARVM attached to culture vessels was 
estimated by counting the number of cells in a 1 mm grid that was etched onto the 
reticule. This was repeated multiple times and the cell number was calculated as: 
 
Total cell number = cells counted x (area of plate (mm)/ area counted (mm))   (Eqn 2.1) 
 
2.2.7 ARVM Cell Culture Stability Study 
In order to monitor the characteristics of ARVM in culture, their cell number and 
morphology were recorded over seven days.  This also served as a means of validating 
the quality of the ARVM used throughout the study in terms of cell number, and viability 
which is closely related to cell morphology. 
 
Freshly isolated ARVM were diluted in 50 ml M199, and 2 ml of this suspension were 
then added to each well of a six well plate. Cell cultures were incubated at 37 ºC with 95 
% air/ 5 % CO2 for one week. Every 24 h the culture medium was replaced with fresh 
M199, before counting the number of rod-shaped, distorted rod-shaped, and rounded 




2.2.8 Trypan Blue Viability Staining  
Trypan Blue (Tetrasodium 3,3'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[5-
amino-4-hydroxynaphthalene-2,7-disulphonate]) is a commonly used vital staining 
method for assessing cell viability. Cells are exposed to Trypan Blue for usually no more 
than one minute. Trypan Blue cannot traverse the intact cell membrane of viable cells, 
and the dye therefore positively stains compromised/ dead cells. 
 
Trypan Blue (Sigma, UK) was used to monitor cell viability over seven days. ARVM 
were cultured on 2x 12-well plates and each day three wells were used to assess cell 
viability. 10% Trypan blue was added to each well for 30 seconds the medium was then 
removed, and replaced with 500 μl of fresh M199. The cell numbers were then counted, 
and viability was calculated as the percentage of unstained (live) vs. stained (dead) cells. 
 
2.2.9 MTT Assay for Assessing ARVM Viability 
The 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay 
was first described by Mossman (1983) [253]. It has previously been used to measure the 
activity of dehydrogenase enzymes [254], and to assess the metabolic activity and 
viability of many cell types, including cardiac myocytes [255-257]. We employed the 
assay to measure the metabolic status of ARVM over seven days, to determine the 
maximum length of time that ARVM cultures would remain fit for experimental use. The 
principal of the assay is that MTT, which forms a yellow solution when dissolved in 
water, is taken up by cells. In viable cells MTT is then reduced by intracellular NADH/ 
NADPH dependent reductases, to form 1-(4,5-Dimethylthiazol-2-yl)-3,5-
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diphenylformazan (MTT formazan). MTT formazan is a purple solid that is insoluble in 
aqueous solutions, which causes it to precipitate and accumulate within cells. The purple 
solid can be dissolved using an organic or acidic solvent, which then elutes from cells. 
The solution is then collected, and the optical density measured at between 500 - 600nm. 
The relative absorbance can then be used to compare the viability of cells over time, as 
more metabolically active (viable) cells will reduce MTT at a faster rate than 
compromised or dead cells.  
 
2.2.9.1 Assay Optimization 
Before using the MTT assay to monitor cell viability the assay protocol was optimised to 
determine the most appropriate concentration of MTT and incubation time.   
 
2.2.9.1.1 MTT Formazan Titration Curve 
A titration curve was produced to convert the optical density of solutions containing 
MTT formazan to concentration.   
 
A stock solution was prepared by dissolving 2mg/ ml MTT formazan in dimethyl 
sulfoxide (DMSO). From this stock solution a 1 in 2 dilution series was made from 0.5- 
3x10
-5
 mg/ ml.  100 μl of each solution was added in triplicate to a 96 well plate and the 
optical absorbance at 570nm (Abs570nm), was read on a multiwell plate reader 
(SpectraMax Plus, Molecular Devices, UK). The results were plotted as Abs570nm vs. 
concentration. In all cell based experiments least squares regression was used to relate 
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the amount of MTT formazan produced per well. These data were then normalised, and 
expressed as the amount of MTT formazan (pg)/ cell.  
2.2.9.1.2 MTT Assay Timescale Optimisation  
To determine the optimum time for incubating ARVM with MTT cells were exposed to 
the compound for between 1- 5 h.  
 
A stock solution was prepared by dissolving MTT (1mg/ ml) in PBS. MTT solution 
(20% v/v) was then added to ARVM cultures. At various times from 1-5 h the medium 
was removed and the cultures were washed once with PBS to remove excess medium. 
120 µl of DMSO was then added to each well to dissolve the MTT formazan precipitate. 
The cells were incubated for a further 20 min to allow MTT to diffuse from the cells.  
After this the DMSO-MTT solution was removed and centrifuged at 2000g for 2 min, to 
pellet any contaminating cells. 100 µl of the supernatant was then removed from each 
well and the Abs570nm was recorded.    
 
2.2.9.1.3 Optimisation of MTT Concentration 
ARVM were then incubated with various concentrations of MTT, to determine the 
optimum concentration to use in our experiments,  
 
MTT was dissolved in H2O to give a range of solutions from 0.25- 4 mg/ml. An aliquot 
of each was added to ARVM cultures (24 h after plating) at 20 % MTT solution per 
volume of medium, and the cultures were incubated for 2 h. Each well was then washed 
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once with PBS, before 120 µl of DMSO was added. The cells were incubated for a 
further 20 min to allow MTT to diffuse from the cells.  After this the DMSO-MTT 
solution was removed and centrifuged at 2000g for 2 min. 100 µl of the supernatant was 
then removed from each well, and the Abs570nm measured. 
 
 
2.2.10 ARVM Viability Assessed by MTT Assay 
To determine the optimum time for using ARVM cultures, cell viability was assessed 
over seven days using the fully optimised MTT assay protocol that we established above. 
 
Freshly isolated ARVM were cultured on 12 well plates as above. To start the assay 20 
% (v/v) MTT in PBS (1mg/ ml) was added to three wells. The cells were then incubated 
at 37ºC 95 % air/ 5% CO2 for 1 h. After this period the culture medium was removed, 
and the cells were washed once with PBS. 200 μl DMSO was then added to each well to 
dissolve MTT formazan precipitate. After 20 min the DMSO-MTT formazan solution 
was removed and centrifuged at 2000g for 2 min to remove cells. 150 µl of the DMSO-
MTT formazan solution was then removed, and the amount of MTT formazan in the 




2.2.11 Rapid Attachment versus Suspension ARVM Culture 
In order to maintain viable ARVM cultures for more than a few hours, cardiac myocytes 
must be allowed to attach to the surface of their culture vessel. However this limits the 
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number of cells that can be maintained in that vessel. This is problematic because if there 
are not enough cells in the vessel, the amount of radiotracer that is extracted from the 
medium by cells may not be sufficient for quantifying by gamma well counting. In an 
attempt to maximise the number of cells a feasibility study was conducted, to determine 
whether it would be possible to use ARVM cultured in suspension. In order to ascertain 
the time frame over which ARVM remain viable when kept in suspension, a comparison 
was made between cells which had been plated as normal, and cells which had been 
maintained in suspension for 1- 5 h.  
 
ARVM were isolated as in section 2.2.4 and diluted with 50 ml M199. They were then 
divided into two lots. Half of the cells were plated immediately, and the remaining cells 
were incubated in suspension at 37ºC 95 % air/ 5% CO2, for between 1- 5 h. Every 60 
min triplicate aliquots of cells from the suspension culture were plated, and allowed to 
attach as normal. After being incubated for 2 h to allow cells to attach the cell numbers 
were recorded, and the MTT assay was used to assess their viability.   
 
 
2.2.12 Calibration of Cell Incubation Chamber  
2.2.12.1 pO2 and Temperature Measurement 
During the course of each experiment it was necessary to measure both the pO2 and 
temperature of the cell culture medium. This was done in order to confirm that the 
culture conditions were oxygenated or hypoxic/ anoxic. For this purpose an OxyLab 
pO2™ system coupled with a combined pO2-temperature sensor (BF/OT/E) (Oxford 
Optronix, Oxford, UK) was employed [54]. This system is designed to function under 
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physiological conditions and has been applied in oncology, stroke research, and organ 
transplantation. The system uses fibre-optic sensors tipped with a fluorescent dye, which 
sends a photon signal to the main instrument controller. The fluorophore signal is 
quenched by molecular oxygen, and therefore the strength of the signal is inversely 
proportion to the level of oxygen. This means the accuracy of the Oxylab pO2™ 
increases as the level of oxygen decreases, unlike traditional oxygen probes such as the 
Clarke type oxygen sensor, which consume oxygen and therefore lose accuracy at low 
pO2. The sensors used by the Oxylab pO2™ are also much smaller than the Clarke 
electrode, and therefore more amenable to use in low volumes of liquid. On their website 
the manufacturer stipulates that OxyLab pO2™ and the sensors that are used with it 
accurately measure pO2 in the range 0- 100 mmHg, as the fluorophore is totally 
quenched above this level of oxygen. However in a personal communication with a 
representative of the company, they suggested that the equipment could measure up to 
150 mmHg, but the error may be as much as ± 15 %. This unfortunately meant that it was 
not possible to obtain measurements of pO2 with this system when using a 95% O2/ 5% 
CO2 gas mixture. However because 95% oxygen is much greater than that of atmospheric 
O2 (21%), we assumed that all media and buffers were maximally oxygenated under this 
condition. 
 
2.2.12.2 Calibration of Incubation Chamber Temperature and pO2 
Before the MKII incubation chamber was used a series of calibration experiments were 
performed, to determine the time required for the pO2 to fall below 0.8 mmHg in the 





Cu-ATSM [209]. The time taken for the temperature of the culture 
medium to reach 37°C was also ascertained. 
 
A Petri dish containing ARVM and 10 ml medium was placed inside the chamber. The 
chamber was then sealed and gently gassed with 95% N2/ 5% CO2 until the pO2 of the 
culture medium reached 0.8mmHg. Temperature and pO2 were recorded using an 
OxyLab pO2™ coupled with a combined pO2/ temperature sensor (Oxford Optronix, 
Oxford, UK).  
 
2.2.13 Universal Gamma Counter Linearity 
Before embarking on a series of experiments to assess the accumulation of 
64
Cu-ATSM 
in ARVM, it was necessary to determine the sensitivity and linear range of the universal 
gamma counter (1282 Compugamma, LKB Wallac, Australia). This equipment was to be 
used to measure the amount of radioactivity within ARVM cell pellets. By determining 
the counts per minute (cpm) emitted by a given amount of 
64
Cu, it would enable us to 
accurately convert this to the amount of radioactivity associated with the cell pellets from 
our experiments. Furthermore the data from this study were also used to determine how 
much radioactivity was required for our cell based experiments. This ensured that the 
amount of radioactivity within the pellets was detectable, whilst also ensuring that the 
cpm did not exceed the upper limit of the gamma counter. 
 
2 MBq was removed from a stock solution of 
64
CuCl2 (aq) containing 20 MBq, the 





 to 1.0 MBq per vial. The radioactive decay (cpm) was then measured 
using the universal gamma counter. The results were plotted as KBq vs. cpm, which 





2.3  Results 
2.3.1 Determine Optimal ARVM Culture Conditions 
2.3.1.1 ARVM Plating Density Study 
Results of the ARVM plating density study are shown in figure 2.5. The dilution series 
produced a bell shaped distribution. The maximum average number of rod-shaped 
ARVM was observed using a 1 in 4 dilution of cell suspension to M199. This dilution 
was therefore used for all subsequent experiments in this section. 
 
 
Figure 2.5. Number of rod shaped ARVM per field. A dilution series of ARVM was used to 
determine the titre, which resulted in attachment of the highest number of rod-shaped ARVM. 





2.3.1.2 ARVM Cell Number and Morphology over Time 
The changes in ARVM cell number and morphology over a seven day period are shown 
in figure 2.6. On day 0 the average number of ARVM per well was: Rod-shaped (27764 
± 3371), distorted rods (1435 ± 566) and rounded (5840 ± 2594). On day 1 the cell 
numbers remained similar to day 0, with: rod-shaped (27406 ± 3376), distorted rods 
(3329 ± 824) and rounded (6098 ± 3049). However by day 2 the number of rod-shaped 
ARVM had decreased by 23 % (21531 ± 4487) compared to day 0. Up to day 7 the 
number of rod-shaped cells/ well continued to decrease to 3576 ± 1158. Conversely the 










On day one rod- shaped ARVM comprised on average 80.0 ± 8.0 % of the total cell 
population, distorted rods represented 4.1 ± 3.2 %, and rounded cells 16.2 ± 7.2 % 
(figure 2.7). Throughout the experiment the number of rod shaped ARVM declined 
steadily, falling to 18.5 ± 11.23 % on day 7. Conversely the number of distorted rods 
increased to 43.2 ± 13.6 % over the same time. The number of rounded cells remained 
constant at 16% between days 0- 2, but increased to 25.9 ± 10.9% on day 3 and 
continued to rise to 38.0 ± 11.3 % of the total cell population by day 7. By day 7 the total 
number of cells/ well had decreased to 51% of the day 0 counts but the number of rod 
shaped ARVM had decreased by 77 %.  
 
 
Figure 2.7. Cell morphology over seven days, expressed as a percentage of the total cell 





2.3.1.3 Cardiac Myocyte Images  
Images of ARVM cultures were acquired using bright-field microscopy at x10 and x40 
objective magnification (figure 2.8). The number of cells can be seen to decrease each 
day, with their morphology gradually changing from the distinctive rod-shape of cardiac 








Figure 2.8. Bright-field microscopy images of ARVM, x10 and x40 objective magnification. 
Images were taken every 24 h for 4 days.  
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2.3.1.4 ARVM Viability over time Trypan Blue Viability  
The percentage of viable cells on day 0 was on average 83.8 ± 6.6 %, which increased 
steadily to a maximum of 97.0 ± 5.6 % on day 4 before declining to 87.4 ± 18.3 on day 7 
(figure 2.9).  
 
 
Figure 2.9. Viability of ARVM cultures over seven days, assess by Trypan Blue exclusion. Data 






On day 0, 19.2 ± 18.8 % of the rounded cell population were capable of excluding 
Trypan Blue. This increased to 88.4 ± 20.7 % on day 4, before declining to 70.9 ± 27.1 % 
on day 7 (figure 2.10). 
 
  
Figure 2.10. Percentage of viable rounded ARVM over seven days. Assessed by Trypan Blue 






2.3.1.5 MTT Assay Optimisation 
2.3.1.5.1 MTT Formazan Titration Curve 
The concentration titration curves (figure 2.11) demonstrate that the relationship between 
the concentration of MTT and Abs570nm remained linear between 0.09-3.03 (R
2
 = 
0.9984). This represented a concentration range of 7.8 x 10
2
- 5 x 10
4




Figure 2.11. MTT formazan titration curve. Relationship between the concentration of MTT 
formazan (ng/ well) and Abs570nm, 0 – 5.0 x 10





2.3.1.5.2 Optimisation of MTT Incubation Time 
Experiments to ascertain the optimum time for incubating ARVM with MTT, initially 
demonstrated that a 3 h incubation period would be optimal (figure 2.12). However 
during these experiments it was noticed that from 2 h onwards, a proportion of viable 
rod-shaped ARVM had become detached from the laminin substratum. This was most 
likely due to the intracellular precipitation of formazan crystals. 
 
 
Figure 2.12. Optimisation of MTT incubation time. Abs570nm versus the amount of time that 





2.3.1.5.3 Optimisation of MTT Concentration 
By screening a range of solutions which contained various concentration of MTT (0.25- 
4.0 mg/ ml), we determined that a 1 mg/ ml MTT stock provided the highest average 
Abs570nm after 1 hr (figure 2.13). At concentrations of MTT greater than 1mg/ ml ARVM 
began to detach from the surface of the culture vessel.  
 
 
Figure 2.13. Optimisation of MTT concentration, Abs570 nm versus MTT stock concentration. Data 





2.3.1.5.4 Assessment of ARVM Viability over Time Using the MTT Assay 
The MTT assay was used to assess the viability of ARVM on each day, over 5 day 
period (figure 2.14). The results show the capacity of the cells to convert MTT to MTT 
formazan. The average amount of MTT formazan associated with each cell on day 0 was 
299.3 ± 92.2 pg/ cell. By day 1 this decreased to 265.0 ± 51.3 pg/ cell. MTT Formazan 
production continued to decrease throughout the experiment with an average of only 92.8 
± 33.0 pg/ cell observed on day 4. The experiment was terminated on day 5 because all 
of the cells detached from the culture vessel. This presumably occurred because the cells 
were no longer able to tolerate exposure to MTT or the MTT formazan precipitate.  
 
 
Figure 2.14. MTT Formazan production per ARVM. Optimised MTT assay was performed on 





2.3.1.6 Static versus Suspension Culture of ARVM 
2.3.1.6.1 Comparison of Viability using the MTT Assay  
A comparison was made between cells that were cultured as normal, and cells that were 
maintained in a suspension of M199 for 1- 5 h and then plated. This was done in order to 
assess the feasibility of performing radiotracer accumulation studies, using ARVM in a 
suspension of M199. At all time points the ability of cells that were kept in suspension to 
convert MTT to MTT formazan, was comparable to cells that were plated immediately 
(figure 2.15).  
 
 
Figure 2.15. MTT Assay Attached versus suspension cells. Comparison between the reduction of 
MTT to the formazan product by ARVM. Cells were either plated immediately or kept in 






2.3.1.6.2 Comparison of Cell Numbers  
Over 5 h the number of cells in the control group decreased from an average of 1.08 x 
10
4
 ± 1.78 x10
3






 cells/ well. However cells that were 
kept in suspension gradually lost their ability to attach to the laminin substratum. After 1 
h in suspension the number of cells that attached was 7.5 x 10
3 
± 1.36 x 10
3
  cell/ well, 
much lower than the control group numbers at 5 h. After 5 h in suspension only 4.0 x 10
3
 
± 1.30 x 10
3
 cells/well were observed. Throughout these experiments the number of 




Figure 2.16. Static versus suspension ARVM culture. Number of myocytes attached to culture 
vessel and ability to reduce MTT. Cells were either plated immediately post-isolation (Control) 






2.3.2 pO2 and Temperature of Medium within the MKII Incubation Chamber  
Within 5 min of switching to the hypoxic gas mixture the pO2 of the culture medium had 
decreased to 2.23 mmHg. By 15 min it had decreased to 0.91 mmHg, and after 20 min it 
was 0.67mmHg. This was sufficiently low enough for us to evaluate tracer hypoxia 
selectivity tracer, at our nominal threshold of 0.8mmHg. The pO2 continued to decrease 
to 0.33mmHg by 35 min, and then remained stable until the experiment was stopped at 
60 min (figure 2.17).  
 
 
Figure 2.17. MKII incubation chamber pO2 calibration. Medium pO2 vs. time for a culture of 




After moving the cultures from the incubator to the cell incubation chamber, the average 
temperature of the culture medium was 32.8°C (0 min). By 20 min the temperature had 
risen to 37.0°C, and from 20- 60 min the temperature of the culture medium remained 
constant (figure 2.18). 
 
 
Figure 2.18. MKII incubation chamber temperature calibration. Temperature (ºC) of culture 
medium versus time (min), for a Petri dish containing ARVM, incubated in the MKII chamber. 
Data represent mean (n = 2) ± SD. 
 
 
2.3.3 Linear Range and Dead Time of Universal Gamma Counter 
Measurements taken by the universal gamma counter remained linear over the range 135- 
5.6 x 10
6
 cpm (9.5 x10
-7
- 1.0 MBq) (R
2
= 0.9983) (figure 2.18). Below 135 cpm (15 Bq) 
linearity decreased slightly (R
2
= 0.9928) (figure 2.20), therefore values below 135 cpm 
were not plotted for least squares regression. In order to convert cpm to Becquerels the 








The dead time is the time taken by the universal gamma counter to register, and if 
necessary, extrapolate the number of counts in order to determine the cpm. As the 
amount of radioactivity increased the counting efficiency decreases, because an 
increasing number of decay events are missed during the time that it takes the gamma 
counter to calculate the cpm. Samples of greater than 62 KBq had a dead time that 
exceeded 10% of the total counting time. However, as the results shown in figure 2.20 
demonstrate, the universal gamma counter was able to accurately compensate for the 
detector dead time up to 3.2 x10
6
 cpm. We therefore decided to use no more than 500 
KBq of radioactivity for our cell based experiments.  
 
 
Figure 2.19. Gamma counter linearity curve showing the entire range of activities (9.5 x10-7- 1.0 







Figure 2.20. Gamma counter linearity curve non-linear range. Range of radioactivity (0.95- 30.5 








Figure 2.21. Gamma counter linearity curve linear range. Range of radioactivity (1.5x10
-5
- 0.5 
MBq per vial) which allowed the most accurate conversion of cpm to KBq (R2=0.9999). Data 




2.4  Discussion and Conclusions 
2.4.1 ARVM Culture, viability and morphology 
The optimum plating density was determined to ensure that cells were not wasted by 
over-plating. ARVM can be lost if the plating density is too high because the cells will 
tend to lie on top of each other, but only those that make contact with laminin substratum 
are able to attach. This exercise also ensured that the maximum practical number of cells 
was used, to achieve the highest possible range of uptake in the subsequent cell based 
experiments. We found that a 1 in 4 dilution of the original 12 ml suspension of ARVM 
gave the highest number of rod-shaped ARVM. When freshly isolated ARVM were 
plated the cell population comprised of 80 % rod shaped cells, a value that is within the 
60- 85% range reported by others [223-224, 231, 237]. We had therefore validated our 
ARVM isolation protocol.  
 
As discussed previously cell morphology is intrinsically linked to ARVM viability. 
Monitoring cell morphology serves as a simple yet effective means of qualitatively 
assessing the efficiency of the isolation procedure, and cell viability [219, 223, 231, 258]. 
De Young et al  defined a rod shaped myocyte as a cell that has a length to width ratio of 
5 to 1 [223].  Cell morphology was therefore employed as a means of determining the 
maximum time frame for maintaining ARVM in culture, before they were used for 
experiments. Morphology was monitored over seven days, and bright-field microscopy 
was used to acquire images of the cells during this time, to provide a visual reference to 
accompany data from cell viability assays. These results in section 2.3.1.2, and images in 
section 2.3.1.3 demonstrate the well documented transition of ARVM in culture from 
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morphologically distinct viable rod-shaped cardiac myocytes, to distorted rod-shaped 
cells. These distorted cells then undergo further morphological, ultra-structural, and 
biochemical changes which include increased membrane permeability, loss of calcium 
regulation, and hypercontraction of the myofibrils. This causes the cells to round up 
before they die and detach from the culture vessel [219, 223, 231, 237]. On day 0, 80 % 
of cells were rod-shaped ARVM, with regular myofibrils striations observable even 
under the light-microscope. On day 1 the number of cells and their morphology 
distribution were similar to day 0. Images taken on day 1 show that cells were rounded at 
the intercalated discs, because they had internalised their gap junctions in order to seal 
them [259-260]. From day 2 the total number of rod-shaped myocytes began to decline, 
but the percentage of rounded and distorted ARVM started to increase. This pattern 
continued for the duration of the study. Our observations were similar to those previously 
reported by others [219, 231, 261-262].  
 
Trypan Blue exclusion was employed over the course of seven days, to assess ARVM 
sarcolemmal integrity. However the data obtained using this approach provide a false 
impression of what actually happened during these experiments, as it appears from these 
results that cell viability actually increased throughout the course of these experiments. 
However ARVM do not divide, and therefore their viability cannot increase.  As dead 
cells detached from the cultureware and were removed each time the culture medium was 
changed, live cells became fractionally enriched although their total number decreased at 
each measurement time. However these results provided valuable insight into how the 
viability of ARVM in culture alters over time. At no point during the experiment was the 
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accumulation of Trypan Blue observed in any distorted/ rod-shaped ARVM, but 
interestingly the data also show that even rounded cells are capable of excluding Trypan 
Blue. Thus although the majority of rounded cells may be progressing towards cell death 
on day 0, it is possible that after 48 h in culture, some rounded cells may also be adapting 
to cell culture conditions. For this reason we used the total cell number, which included 
rod-shaped, distorted, and rounded cells, for normalising the data from our cell based 
radiotracer characterisation experiments. We did this because it was likely that Cu-BTSC 
complexes would also accumulate within rounded cells if they were still viable, and 
therefore omitting these cells could potentially distort our experimental results.  
 
The cleavage of MTT to the formazan product provides an index of the integrity of 
intracellular reductases, which is used to infer of cell viability [253]. In these 
experiments the assay was employed in conjunction with other methods, to determine the 
maximum time frame for using ARVM cultures. Although there are a number of studies 
that have used the MTT assay with cardiac myocytes [255-257], we optimised the assay 
to determine the most suitable concentration of MTT and exposure time. Through this 
process we found that a stock concentration of 1mg/ ml MTT, used at a ratio of 1: 5 per 
volume of culture medium, and an exposure time of 1 h were optimal. We demonstrated 
that MTT formazan production decreased continuously throughout the experiment, which 
shows that the cellular and metabolic integrity of ARVM became compromised from the 
moment the cells were isolated. The assay also highlighted to us the fragility of isolated 
ARVM, and demonstrated that when maintained in culture the viability of these primary 
cells quickly diminishes.  
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Claycomb et al demonstrated that for the first twelve hours after being isolated,  cultured 
ARVM preferentially metabolise glucose instead of fatty acids (FA) [263]. They 
postulated that this was most likely due damage to the mitochondria, which occurred 
during the isolation process. A period of repair is therefore required before oxidative 
phosphorylation can be re-established. This is an important consideration for our study, 
because the mitochondrial electron transport chain is thought to be involved in the 
reductive trapping of Cu-BTSC complexes. It was therefore thought necessary to allow 
mitochondrial repair to take place before we used ARVM for experiments. Collation of 
the data from sections 2.3.1.2 and 2.3.1.5.4 demonstrated that the maximum number of 
rod shaped ARVM was present on day 0. Day 0 cells also had the greatest ability to 
reduce MTT. There was however little difference between the number of ARVM, and 
their morphology and viability on day 1. We therefore concluded from the results of our 
experiments and the previous observations by Claycomb et al, that our radiotracer 
accumulation studies should be conducted using cells that were cultured over-night, to 
allow cellular repair to take place. However, in all of our experiments the cells were used 
within 24 h of being isolated. 
 
We then assessed the viability of ARVM kept in suspension for between 1- 5 h, and 
compared this to cells that had been plated immediately after being isolated. At all time 
points the ability of cells kept in suspension to reduce MTT was comparable to the 
control cells, which suggested that these cells were equally viable. However the number 
of cells that were capable of attaching to culture vessels decreased over time, to only 46 
% of the control cell numbers after 5 h in suspension. While we did not investigate this 
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any further, we assumed that their inability to attach signified that they were undergoing 
changes that would ultimately lead to cell death. We therefore concluded that if we chose 
to use ARVM that had been maintained in suspension, they should be used immediately 
after being isolated.  
 
2.4.2 Incubation Chamber Calibration 
The prototype incubation system was built to assist in the development of the 
professionally manufactured MKII chamber. We conducted a number of 
64
Cu-ATSM 
extraction experiments using the prototype chamber, which allowed us to develop a 
detailed experimental protocol. Furthermore, we also learned from these experiments that 
aliquots of culture medium taken in order to monitor radiotracer extraction were often 
contaminated with cells, and this significantly increased the variance between sample 
replicates. We therefore included a centrifugation step in future experiments to negate 
this issue.  
 
The MKII chamber system was a considerably more effective design. This glass chamber 
was water-jacketed and connected to a temperature controlled water heater/ circulator. 
This allowed the culture medium to be warmed to 37 °C within 20 min, and maintained 
at this temperature. The heater/circulator was also connected to a coil of tubing that was 
wrapped around the gassing line, thereby preventing the formation of condensation in the 
line. Condensation could potentially spill over into the chamber and contaminate the 
culture medium. Such contamination could compromise cell viability and also dilute the 
culture medium, thereby lowering the effective radiotracer dose, factors that would 
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certainly compromise the accuracy of our experiments. The chamber was placed on a 
plate rocker in order to facilitate gas exchange between the culture medium and the 
internal chamber environment. This significantly decreased the time taken for the culture 
medium pO2 to reach ≤0.8mmHg, from 100 min for the prototype chamber, to between 
15- 20 min. The diameter of the chamber was also reduced to prevent culture vessels 
from moving. This prevented medium spillage and radioactive contamination of the 
vessel. The reduced internal volume of the MKII chamber also facilitated gas exchange 
between culture medium and the environment within the chamber.  
 
2.4.3 Gamma Counter Linearity and Dead Time   
The linear range of the gamma counter when measuring the radioactivity of 
64
Cu was 
between 135- 3.2 x 10
6
 cpm (1.5 x 10
-5
- 0.5 MBq). During our cell based radiotracer 
characterisation experiments (discussed in chapter 3), the amount of radioactivity that 





our initial experiments with the prototype system, the accumulation of 
64
Cu-ATSM was 
assessed using various amounts of radioactivity. As a result of this we determined that 
after adding 100 KBq 
64
Cu-ATSM to the culture medium, the amount of radioactivity 
that was retained by ARVM was within the linear range of the gamma counter. We 
therefore used 100 KBq of 
64
Cu-ATSM for all our cell based experiments. 
 
2.4.4 Conclusions  
Having determined the linear range of the gamma counter, ensuring that isolated ARVM 
were of a suitable standard for our experiments, and after designing, constructing, and 





Cu-BTSC complexes. In the first instance 
64
Cu-ATSM accumulation 
was to be characterised in isolated ARVM to assess the feasibility of developing a high-















3.1  Introduction 
In chapter 2 we demonstrated that we were able to isolate and maintain viable rod-shaped 
ARVM, for longer than the anticipated time-frame of our experiments.  We also 
demonstrated that the MKII cell incubation system was able to maintain ARVM cultures 
at a stable temperature, under both oxygenated and hypoxic conditions. We were 
therefore in a position were would could move on to the next phase of our study, which 
was to develop a high throughput screen for assessing our library of novel Cu-BTSC 
complexes in cardiac tissue.  As a first step it was necessary to determine whether this 
isolated cell approach would be suitable for this purpose.  Cell-based assays could be 
advantageous to this end, as they would allow multiple replicates of the same tracer or 
multiple tracers to be assessed at the same time using cells from the same heart. This 
approach could be a more efficient means of screening our library of Cu-BTSC 
complexes, by decreasing inter-preparation variability. 
 
Our first aim was to determine whether we could observe hypoxia-dependent retention of 
64
CuATSM in ARVM.  If we were able to easily observe a contrast using our relatively 
large scale system, we could then establish to what degree it would be possible to scale 
down the assay for the purpose of high throughput screening. This is because we had 
envisaged that such a system would use multiwell culture plates, which would 
accommodate fewer cells per well.  
 
In cell based radiotracer characterisation experiments there are two approaches for 
quantifying radiotracer uptake, either i) measuring the extraction of tracer from the 
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culture medium, or ii) by directly measuring intracellular accumulation.  In the case of 
attached cells the measurement of uptake from culture medium allows for longitudinal 
studies. However it was necessary to determine if this approach would be sufficiently 
sensitive, and also whether it would allow us observe a contrast between 
64
Cu-ATSM 
retention in hypoxic and normoxic cells. We therefore investigated both methods to 
determine which was the most appropriate for our experiments.   
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3.2  Materials and Methods 
3.2.1 Gas mixtures  
Gas mixtures used for this series of experiments were: oxygenated (21 % O2/ 5 % CO2/ 
74 % N2) and (95 % O2/ 5 % CO2), and anoxic (95 % N2/ 5 % CO2). 
 
3.2.2 Synthesis of ATSM 
ATSM was kindly provided by Prof. P Blower and Dr R. Paul (Dept. Imaging Sciences 
and Medical Engineering, King’s College, London). Ligands were synthesised as 
previously reported [172, 264].   
 
3.2.3 Radiolabelling ATSM with 
64
Cu 
3.2.3.1 Radiolabelling Methodology 
ATSM was dissolved in DMSO (1mg/ ml). 10 µl of the ligand solution, and 30 MBq of 
64
Cu were then added to 1 ml ultrapure water. The solution was gently shaken to mix, 
stored at room temperature for 20 min, and then filtered through a SEP-PAK® C18 
Classic cartridge (Waters, UK). The cartridge was then washed through with 2 ml H2O to 
remove excess 
64
Cu and HCl, before 
64
Cu-ATSM was eluted using 0.5 ml ethanol. 30µl 
of ascorbic acid (aq) (10mg/ ml) was then added immediately to restrict radiolysis. The 
amount of radioactivity in the stock vial was then measured using a radioisotope dose 
calibrator (CRC-25R Capintec, USA), before the radioactivity was adjusted to 1 MBq/ 





3.2.3.2 Assessment of Radiolabelling Efficiency  
Ligand labelling efficiency was assessed by radio-ITLC, using Silica Gel 60 F254 strips 
(Merck, Germany) as the stationary (sorbent) phase, and 100 % ethanol as the mobile 





 interacts with the sorbent phase and remains at the origin. 
 
1µl of the labelled solution was pipetted onto an ITLC strip (1 cm x 10 cm), which was 
then placed in ethanol to a depth of 0.5 cm. The mobile phase was allowed to run to 90 
mm before it was removed and allowed to dry. The ITLC strip was then placed onto a 
Flow Count (B-FC-3600) ITLC plate reader, fitted with a β-/+ detector (B-FC-3600) 
(LabLogic, UK). The radiolabelling efficiency was then determined using Laura (v. 
4.0.3.75) software (LabLogic, UK). The radiolabelling efficiency was always greater 
than 97% (Fig.3.1).   
 
Figure 3.1. Assessment of BTSC ligand radiolabelling efficiency: An example of a typical ITLC 
trace. 64CuCl2 remained at the origin, but 




3.2.3.3 Assessment of 
64
Cu-ATSM Stability in Medium 199 
In our cell based studies 
64
Cu-ATSM was diluted to with M199 before being used for 
experiments. We therefore assessed the stability of 
64
Cu-ATSM in a solution of M199 to 
ensure that the complex remained stable throughout the day.   
 
ATSM was first labelled with 
64
Cu, and the radiolabelling efficiency was determined as 
described in section 3.3.3.2. This provided the control, 0 h time point. 
64
Cu-ATSM was 
then diluted to 5 MBq/ ml with M199. The stock was stored on the bench throughout the 
day, and refrigerated overnight. At 1, 3, 6, and 24 h, 2- 5 µl of the solution was removed 




Cu-ATSM Characterisation Using ARVM 
3.2.4.1 Extraction of 
64
Cu-ATSM from Cell Culture Medium 
In order to monitor the uptake of Cu-BTSC complexes over time, the majority of studies 
to date have used cells that were suspended in culture medium [162-163, 167, 209, 241].  
However, the rapid attachment method of ARVM culture that we used made this 
approach more complicated, because cell samples cannot be aspirated using a pipette or 
syringe. With our system this would mean that the chamber would have to be opened to 
retrieve cell samples, which would equilibrate the atmosphere within the chamber with 
the external atmosphere, and invalidate the experiment.  We therefore chose to monitor 
the accumulation of 
64
Cu-ATSM indirectly, by measuring the amount of radioactivity 
that ARVM extracted from the culture medium. Aliquots of medium were taken via the 
sampling port, which allowed rapid repeated sampling without perturbing the system.  
138 
 
3.2.4.2 The Effect of Hypoxia on the Extraction and Intracellular Accumulation of 
64
Cu-ATSM in ARVM 
ARVM cultures were prepared on 90 mm Petri dishes using the attachment method and 
incubated overnight. The following day, culture medium was replaced with 15 ml fresh 
medium and the cell numbers were recorded. The dish of cells was placed inside the 
MKII chamber, which was then sealed. Depending upon the condition to be examined 
the system was gently gassed with either an oxygenated (95% O2/ 5% CO2), or anoxic 
(95% N2/ 5% CO2) gas mixture for 20 min. Cultures were then agitated on a rotary plate-
shaker at 10 RPM to facilitate gas exchange. After 20 min, 100 KBq of 
64
Cu-ATSM was 
added to the medium. Between 1- 30 min, triplicate aliquots of 100 μl of culture medium 
were removed. The aliquots were spun at 2000 g for 2 min, to ensure that they were not 
contaminated by cells, before 80 µl of supernatant was removed from each aliquot for 
gamma well counting. At the end of each experiment cells were washed once with 5 ml 
fresh M199, and the number and morphology of the cells was recorded. ARVM were 
then gently detached from the plate using a cell scraper, and pelleted by centrifuging at 
2000 g for 2 min. The wash step was repeated with 1 ml PBS, which was then aspirated 
before the radioactivity in the pellet was counted. The counts were then decay corrected, 
before the amount of radioactivity within the sample was determined using least squares 
regression. For this purpose the gamma count linearity curve (figure 2.21) was used.  
 
 
3.2.4.3 The Effect of Time on the Retention of 
64
Cu-ATSM 
ARVM cultures were prepared as described in section 2.2.4, and incubated overnight. 
The following day the culture medium was replaced with 5 ml fresh medium, and the cell 
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number was recorded. A dish of cells was placed into the MKII incubation chamber, 
which was sealed and supplied with either an oxygen rich (95% O2/5% CO2) or anoxic 
(95% N2/5% CO2) gas mixture. To assist gas exchange the culture medium was gently 
agitated by rocking at 18 RPM, and then allowed to equilibrate for 20 min at 37°C. After 
this period 100 KBq of 
64
Cu-ATSM was added and the cultures were incubated for a 
further 30 or 60 min. The cultures were then removed from the chamber, and the culture 
medium was replaced with 5ml fresh M199, before cells were counted. ARVM were then 
gently detached from the dish using a scraper, and pelleted (2000 g, 2 min). The wash 
and pelleting steps were then repeated with 1 ml PBS, which was removed before the 
radioactivity was measured. The counts were then decay corrected, and the amount of 
radioactivity associated with the cells pellets was determined by least squares regression, 
using the gamma count linearity curve (figure 2.21). The data were then expressed as the 
amount of radioactivity per cell. 
 
3.2.4.4 The Effect of Oxygen Concentration on 
64
Cu-ATSM Accumulation 
The first experiments with the MKII chamber employed extremely low (0 % O2) and 
high (95% O2) and levels of oxygen. In our next series of experiments we included a gas 
mixture which contained 21 % O2, alongside the 0 % and 95 % O2 mixtures. This was 
done to assess the effects of reducing the concentration of oxygen to a more 
physiologically relevant level. A similar method to that described in section 3.2.4.3 was 






Cu-ATSM Accumulation in ARVM Cell Suspensions  
One advantage of using cells in suspension is that cell numbers would not be restricted 
by substrate surface area; in fact the only factor that could limit the number of cells, 
would be the efficiency of the isolation procedure. Having a greater number of cells 
should decrease the time taken for tracer accumulation to reach a steady state, and could 
increase the contrast between normoxic and hypoxic cell uptake, thereby increasing the 
sensitivity of the method. These results would also be more comparable to those obtained 
by other groups using cancer cell lines suspended in culture medium [162-163, 167, 
209]. Another advantage is that if cells are not plated the costs associated with the day to 
day maintenance, particularly that of laminin, are reduced. We therefore assessed the 
feasibility of using this approach.   
 
ARVM were isolated as described in section 2.2.4. The cells were then suspended in 10 
ml of M199. ARVM were filtered through a 200 µm mesh to remove undigested tissue 
and cell aggregates. The suspension was placed directly into an uncoated Petri dish, 
which was then placed inside the chamber. The cultures were then gently agitated by 
rocking the chamber at 18 RPM, while the medium was equilibrate with either an oxygen 
rich (95% O2/5% CO2) or anoxic (95% N2/5% CO2) gas mixture. After 5 min, when the 
pO2 of the culture medium was below 0.8 mmHg, 100 KBq Cu-ATSM was added via the 
injection port. At 1, 5, 10, 15, 30, 45 and 60 min, 3x 100 µl aliquots were removed and 
centrifuged at 2000g for 2 min, to obtain a cell pellet and medium fraction. The 
supernatant was aspirated, and the radioactivity in both the cell pellet and supernatant 
was counted. Radioactivity in the cells was then expressed as the percentage of the total 
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counts in the original 100 μl sample. The counts were also converted to radioactivity 
(KBq) using the gamma counter linearity curve, and expressed as Bq/ mg protein. The 
total protein content of the cell pellet was determined using a commercial BCA assay 
(GE Healthcare, UK). 
 
3.2.5 Measurement of Cell Protein Content by BCA Assay 
During the cell suspension study it was not possible to accurately determine the number 
ARVM using a conventional haemocytometer (although attempts were made using 
number of different chambers, with counting well depths of 100- 250 µm). This was 
mainly due to the relatively large size of the ARVM, which prevented them from being 
evenly distributed between the counting chambers of the haemocytometers. We therefore 
utilised the total protein content of the cell pellets, to relate radiotracer accumulation the 
size of the cell population. For this purpose we used a commercial bicinchoninic acid 
(BCA) protein assay (Merck, Germany). The BCA assay is a colourmetric assay that 
relies on the Biuret reaction, a process whereby Cu
2+
 is reduced to Cu
+
 by peptide bonds. 
BCA solution is added to the sample to form a complex with Cu
+
. This process causes 
the solution to turn from light blue to purple, which is proportional to the amount of 
protein present in the sample. The optical density of this solution is measured 
spectrophotometrically at 560nm, and compared to protein standards of known 
concentration, to determine the actual amount of protein in the sample.   
 
At the end of each 
64
Cu-ATSM accumulation experiment the cell pellets were frozen and 
stored at -80 ºC. To prepare samples for the BCA assay, on the day of the experiment the 
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pellets were slowly thawed on ice. They were then washed twice with 1 ml of PBS (pH 
7.4), and centrifuged at 3000g for 5 min. The PBS was removed and cells were lysed by 
adding 0.5 ml mammalian protein extraction buffer (GE Healthcare, UK), before being 
quickly frozen at -80ºC, and then immediately thawed at room temperature to facilitate 
cell lysis. The cell pellet and debris was then resuspended using a pipette, and incubated 
on ice for 30 min, during which time the samples were regularly vortexed. A protease 
inhibitor cocktail (Sigma-Aldrich, UK) was also added to the samples at a ratio of 1: 25 
(vol/ vol). The samples were then mixed and centrifuged at 20000g for 30 min, after 
which the supernatant was carefully removed and analysed using the BCA assay. The 
cell debris and pellet fractions were discarded.  
 
The BCA assay was performed in accordance with the manufacturers recommended 
procedure. Briefly, a range of protein standards were made from a stock solution of 
bovine serum albumin (2mg/ ml). 25 µl of each of the protein standards and the cell 
lysate samples was then added in triplicate to a 96 well plate. 200 µl of BCA solution 
was then added to each well, and the plates were incubated for 30 min at 37.0 ºC. The 
plate was then cooled on ice, before the Abs562nm of each well was measured using a 
multiwell plate reader. 
 
3.2.6 Data and Statistical Analysis 
 Data analysis was performed using Microsoft Office Excel® 2007. Statistical analyses 
were performed using GraphPad Prism® (Version 5.04) (GraphPad Software Inc, USA). 
All values are expressed as the mean ± SD. Data were compared using either unpaired t-
143 
 
test, or a one way analysis of variance (ANOVA) with the Dunnett’s post test where 




3.3  Results 
3.3.1 ATSM Radiolabelling Efficiency and Stability 
The radiolabelling efficiency of ATSM at 0 h was always greater than 97 %. The amount 
of radiolabelled complex in a solution of M199 remained at 97 % of the total 
radioactivity for up to 6 h. However after 24 h this decreased to 94 % (figure 3.2).     
 
 
Figure 3.2. Stability of 64Cu-ATSM in a solution of M199 over 24 h, measured using radio-ITLC. 






3.3.2 Characterisation of 
64
Cu-ATSM Using ARVM 
3.3.2.1 Extraction of 
64
Cu-ATSM by ARVM 
After 1 min the amount of radioactivity in aliquots of medium exposed to 0% O2 and 
95% O2 was on average 0.41 KBq/ 100 µl.  This decreased over 30 min to 0.31 ± 0.1 and 
0.35 ± 0.1 KBq/ 100 µl medium, at 0% O2 and 95% O2 respectively (figure 3.3). While 
tracer extraction tended to be slightly greater in cells under hypoxic conditions from 5 
min onwards, at no point did this reach statistical significance. 
 
 
Figure 3.3. Extraction of 64Cu-ATSM from culture medium using the MKII Cell Incubation 
Chamber. ARVM were incubated with 64Cu-ATSM for 60 min, under oxygenated and hypoxic 
conditions. Data were compared using an unpaired Student’s t- test. Data represent mean (n = 







Cu-ATSM Accumulation in ARVM using the Attachment Culture Method  
3.3.2.2.1 Accumulation 
64
Cu-ATSM in ARVM after 30 min incubation 
The amount of radioactivity in each cell pellet was normalised for the total number of 
cells attached to the Petri dish at the end of each experiment. After 30 min incubation 
with 
64
Cu-ATSM the amount of radioactivity that had accumulated was 2.6 ± 0.8 mBq/ 
cell under hypoxia, and 1.7 ± 0.5 mBq/ cell under oxygenated conditions (figure 3.4). 
Although tracer accumulation was consistently higher under hypoxia in each paired 
experiment, the variability in tracer uptake between experiments meant that this did not 
reach statistical significance. 
   
 
Figure 3.4. Accumulation of 64Cu-ATSM in ARVM exposed to an oxygenated (95% O2) or 
deoxygenated (0% O2) atmosphere. Data were compared using an unpaired Student’s t- test. 









Cu-ATSM in ARVM after 30 and 60 min incubation 
In this study the volume of culture medium used during the experiments was reduced to 5 
ml, to increase the concentration of 
64
Cu-ATSM without having to use more 
radioactivity. A 1 h time point was also included, to ascertain whether increasing the 
incubation time would also increase the contrast between normoxic and hypoxic cells. 
After 30 min hypoxic 20.6 ± 11.1 mBq/ cell was retained, compared to 9.9 ± 3.1 mBq/ 
cell in normoxic controls. When the incubation period was extended to 60 min the 
accumulation of radioactivity increased to 33.8 ± 8.4, and 17.1 ± 3.4 mBq/ cell 
respectively. While the contrast between hypoxic to normoxic cells was 2: 1 after 30 min, 
it decreased to 1.6: 1 after 60 min. Nonetheless the accumulation of 
64
Cu-ATSM was 
always higher in cells that were incubated under hypoxia, but this was only statistically 
significant (p<0.05) after 60 min (figure 3.5). Data were normalised as described in 
section 3.3.2.2.1, and compared using an unpaired Student’s t- test. 
 
 
Figure 3.5. Accumulation of 64Cu-ATSM after 30 or 60 min. ARVM were incubated under 
deoxygenated (white), or oxygenated (black) conditions. Data were compared using an unpaired 





Effect of Oxygen Concentration on the Accumulation of 
64
Cu-ATSM  
A second series experiments were performed to compare 
64
Cu-ATSM uptake at a mid-
range oxygen level (21% O2). The average amount of radioactivity that was retained by 
cells was 36.1 ± 3.1 (0 % O2), 27.3 ± 5.1 (21 % O2), and 23.9 ± 2.5 mBq/ cell (95 % O2). 
Tracer uptake in hypoxic cells was significantly higher (p<0.05) than in cells incubated 
under hypoxic conditions, with contrast between hypoxic to oxygenated cells of 1.3: 1 at 
21% O2, and 1.5:1 at 95% O2 (figure 3.6). Data were normalised as described in section 
3.3.2.2.1, and compared using a one way ANOVA with a Dunnett’s post test.  
 
 
Figure 3.6. Accumulation of 64Cu-ATSM in ARVM exposed to 0, 21 and 95 % O2. ARVM were 
incubated under an atmosphere comprised of 0, 21, and 95 % oxygen for 1 h. Data are expressed 
as amount of radioactivity (mBq) per cell, and compared using a one way ANOVA with a 




We then normalised these data for protein content using the data obtained from the BCA 
assay. When the 0% O2 samples are compared to those obtained after gassing with 21 
and 95% O2, the ratios of the amount of radioactivity accumulated in each cell were 1.5:1 
and 1.4:1. The amount of radioactivity per µg protein was 37.3 ± 8.2 (0 % O2), 25.2 ± 5.6 
(21 % O2), and 25.9 ± 4.1 Bq/ µg protein. (95 % O2) (figure 3.7). However, tracer uptake 




Figure 3.7. Cellular accumulation of 64Cu-ATSM normalised for total protein content. Data were 
compared using a one way ANOVA with a Dunnett’s post test and represent the mean (n = 4) ± 









Figures 3.8 and 3.9 summarise the cells counts for the number of rod-shaped ARVM per 
90mm Petri dish, before and after the 
64
Cu-ATSM accumulation experiments. Before 
each experiment there were on average between 1.8 x 10
5
- 2.2 x 10
5
 rod shaped cells/ 90 
mm Petri dish, and after 30 or 60 min incubation under both oxygenated and hypoxic 




Figure 3.8. Average number of rod-shaped ARVM per 90mm Petri dish after 0, 30 or 60 min 
incubation. ARVM were incubated under oxygenated or hypoxic conditions for 30 or 60 min, and 
cell counts were recorded before and after each incubation period. Data represent mean (n = 5) 





Figure 3.9. Total number of rod-shaped ARVM per 90mm Petri dish at the start (0 min) and end 
(60 min) of each experiment. Cell were exposed to 0, 21 or 95 % O2. Data represent mean (n = 






Cu-ATSM Accumulation in ARVM in a Suspension of M199  
The accumulation of 
64
Cu-ATSM by ARVM maintained in a suspension of M199 is 
shown in figure 3.10. Data are expressed as a percentage of the total radioactivity in a 
100 µl aliquot of the cell suspension. 1 min after the addition of 
64
Cu-ATSM, the retained 
fraction was 31.8 ± 16.6 %, and 23.5 ± 4.9 % of the total radioactivity at 0 and 95 % O2 
respectively. These values increased to 63.2 ± 14.1 % and 53.4 ± 10.9% at 30 min 
respectively, (p<0.05). The amount of tracer that was associated with the cells then 
remained constant until the experiment was stopped at 60 min. 
 
 
Figure 3.10. Accumulation of 64Cu-ATSM in ARVM maintained in suspension. Tracer retention 
was compared under oxygenated (square), or hypoxic (circle) conditions. Data represent mean 




When the data were normalised using the total protein content of cell pellets, similar 
patterns for 
64
Cu-ATSM accumulation were observed. Under oxygenated conditions 
accumulation of 
64
Cu-ATSM remained constant between 1- 60 min (~ 15 Bq/ µg 
protein). However under hypoxia the accumulation of 
64
Cu-ATSM increased from 17 
Bq/µg protein at 1 min, to 25 Bq/µg protein at 45 min (figure 3.11), reaching statistical 





Figure 3.11. Accumulation of 64Cu-ATSM accumulation normalised for total protein. The total 
protein content of each of the ARVM cell pellets was ascertained using the BSA assay. Data 




3.4  Discussion and Conclusions 
The purpose of these cell based experiments was to characterise the accumulation of 
64
Cu-ATSM in ARVM under hypoxic and oxygenated conditions. The experiments were 
conducted to determine whether it would be possible to employ an ARVM based system, 
to characterise the hypoxia specificity and myocardial accumulation of novel 
64
Cu-BTSC 
complexes. The results were also be used to determine whether the ARVM system could 
be scaled-down, and used as a high-throughput screening assay. 
 
3.4.1 ATSM Radiolabelling Efficiency and Stability 
Before starting our cell based experiments we assessed the radiolabelling efficiency and 
stability of 
64
Cu-ATSM, in a solution of M199. This was to ensure that the constituents 
of the medium did not react with the complex and affect its stability. At 0 h the 
radiolabelling efficiency was 97 %. After adding M199 the stability of the complex 
remained stable for 6 h. However after 24 h the percentage of radiolabelled complex had 
decreased to 94 %. We therefore concluded that the efficiency of the initial ligand 
radiolabelling and the stability of the 
64
Cu-ATSM in M199 were sufficient for our 
experiments. 
 
3.4.2 Extraction of 
64
Cu-ATSM from Culture Medium 
We have assessed the extraction of 
64
Cu-ATSM from cell culture medium by isolated 
cardiac myocytes incubated under oxygenated or hypoxic conditions. The results of these 
experiments (figure 3.3) demonstrated that tracer extraction was generally greater under 
hypoxic conditions, i.e. the amount of radioactivity in the culture medium during hypoxia 
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was lower than under oxygenated conditions, but at no point was the contrast between 
the two data-sets statistically significant. This was in part due to the large sample 
variance between replicate aliquots of medium. It is also likely that poor contrast that 
was observed between normoxic and hypoxic cells, was because only a small percentage 
of the total radioactivity was extracted. This high variability meant that it would not be 
possible to perform longitudinal uptake studies using a single culture. We therefore 
concluded that the tracer extraction method was too insensitive for the purpose of 
characterising our complexes. The only means of obtaining reliable longitudinal 
measurements would therefore be by directly measuring the intracellular accumulation of 
tracers. We achieved this by harvesting the cells at the end of each experiment, and 
measuring the amount of radioactivity associated with them. Unfortunately this required 
multiple ARVM cultures, one for each time point and experimental condition.  
 
3.4.3 Accumulation of 
64
Cu-ATSM: ARVM Attachment Culture 
ARVM that were used during the 
64
Cu-ATSM medium extraction study were harvested 
at the end of each experiment, after cell counting had been performed. The radioactivity 
associated with the cell pellets was measured, and 
64
Cu-ATSM accumulation expressed 
as mBq per cell (figure 3.4). While the results of this first experiment were not 
significantly different, we did observe a contrast in tracer uptake between oxygenated 
and hypoxic cells. This suggested that direct measurement of radioactivity within cells 
may be more suitable for characterising 
64
Cu-BTSC complexes. In this preliminary series 
of experiments, we observed a 1.5: 1 contrast ratio between hypoxic (2.6 ± 0.8 mBq/ 
cell) and oxygenated cells (1.7 ± 0.5 mBq/ cell) after 30 min, however the sample 
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variance was relatively large and this perhaps explains why the data-sets were not 
statistically different (these experiments were also only conducted in triplicate). We 




3.4.3.1 Effect of Time of the Accumulation of 
64
Cu-ATSM 
For our next series of experiments we measured the cellular accumulation of 
64
Cu-ATSM 
after 30, or 60 min. In this study we altered the way in which the culture medium was 
agitated, from stirring the cell incubation chamber to rocking. This was because during 
the first series of experiments we noticed that the centrifugal force generated by stirring 
the cultures forced the culture medium to edge of the Petri dish. This meant that at least 
15 ml medium was required to submerge ARVM at the centre of the dish. By switching 
to rocking, and because aliquots of culture medium were no longer being removed in 
order to measured tracer extraction, we were able to reduce the volume of medium from 
15 ml to 5 ml. However we continued to add 100 KBq of 
64
Cu-ATSM to the culture 
medium, and because of this the concentration of 
64
Cu-ATSM was higher than that used 
in the radiotracer extraction study.  This was favourable because increasing the 
concentration of radiotracer could potentially lead to an increase in its accumulation, and 
potentially lead to a greater contrast between hypoxic and oxygenated cells. The results 
of the second series of experiments demonstrated that this was indeed the case (figure 
3.5). Overall, radiotracer accumulation increased between ~5- 10-fold, depending upon 
the condition and incubation time. The results of these time-dependent experiments, 
demonstrated that the accumulation of 
64
Cu-ATSM was always greater during hypoxia. 
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Furthermore the hypoxic to normoxic contrast increased to 2: 1 after 30 min, but again 
the data were not statistically different. After 60 min 
64
Cu-ATSM accumulation had 
increased by 72.7 % and 64.1 % relative to the 30 min values, under oxygenated and 
hypoxic conditions respectively. While the hypoxic to normoxic contrast decreased to 
1.6: 1 at 60 min, the sample variance was less that at 30 min and therefore the data sets 
were significantly different. Reducing the volume of medium and increasing the 
incubation time had therefore caused a concomitant increase in both radiotracer 
accumulation, and the hypoxic to normoxic contrast ratio. We therefore concluded that 
ARVM should be incubated with 
64
Cu-BTSC complexes for a minimum of 1 h. However 
previous studies have demonstrated that ARVM exposed to anoxic conditions for more 
than 60-90 min are irreversibly damaged [265-267]. We therefore decided that in our 
experiments ARVM would not be incubated under any condition for more than 60 min to 
avoid cellular injury. We did this because damage to the cells could potentially have 
decreased the accuracy of our experiments. 
 
3.4.3.2 Effect of Oxygen Concentration on the Accumulation of 
64
Cu-ATSM  
For the radiotracer extraction and time dependent experiments we employed a 95 % O2/ 5 
% CO2 gas mixture, to generate and maintain oxygenated conditions. We employed such 
a high level of oxygen because we postulated that using these extremes (0% and 95 %) 
would provide the greatest hypoxic to normoxic contrast. However we were aware that in 
other cell based studies with Cu-ATSM and 
18
FMISO had previously used gas mixtures 
at around room air saturation ~20 % [112, 119, 162, 167, 197, 208-209, 241]. While this 
is still hyperoxic relative to intravascular or interstitial pO2, it is considerably closer to 
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physiological conditions when compared to 95 % oxygen. In our next series of 
experiments we therefore assessed 
64
Cu-ATSM accumulation using a gas mixture that 
contained 21 % O2, alongside the 0 % and 95 % O2 mixtures, to allow us to compare our 
results with those of others. This also allowed us to assess whether decreasing the level 




During our oxygen level dependent 
64
Cu-ATSM accumulation experiments we observed 
significantly greater tracer retention under hypoxic conditions, compared to either of the 
oxygenated conditions (figure 3.6). Contrast ratios of 1.3: 1 and 1.5: 1 were observed 
between hypoxic cells and those incubated under an atmosphere of 21 % O2 and 95 % O2 
respectively. No difference was observed between the data sets from cells incubated 
under oxygenated conditions. However when the data sets were normalised for the total 
protein content of the respective cell pellets, only the 0 % and 21 % oxygen data sets 
were significantly different. This was most likely because the average value at 21 % O2 
(25.2 ± 5.6 Bq/ µg protein) was marginally lower than the value obtained at 95 % O2 
(25.9 ± 4.1 Bq/ µg protein). We can only speculate that this was due to the inherent 
sample variance.  
 
The results of the time and oxygen level dependent experiments, demonstrated that while 
it was certainly possible to use a cell based assay to assess the myocardial accumulation 
of 
64
Cu-BTSC complexes, it is unlikely that the assay could be scaled-down and used as 
a high-throughput screen for multiple tracers/ replicates. This is because both tracer 





Cu-ATSM Accumulation: ARVM Compared to Other Cell Types  
In our time dependent 
64
Cu-ATSM accumulation studies the average amount that was 
retained by ARVM was 4.5 ± 1.5 % (95 % O2), and 8.2 ± 4.7 % (0 % O2) of the total 
radioactivity added at the start of each experiment. When we assessed the effect of 
reducing the level of oxygen in our aerobic controls, the values were similar: 7.3 ± 0.8 % 
(0 % O2), 5.6 ± 1.4 % (21 % O2) and 4.9 ± 0.9 % (95 % O2). These results demonstrate 
that the accumulation of 
64
Cu-ATSM in ARVM was rather low, relative to the total 
amount of radioactivity added to the vessel. This is highlighted by comparing our data 





Table 3.1. Maximum 64Cu-ATSM accumulation in other cell types. 
    Cu-ATSM Accumulation (% total radioactivity) 
Cell Type Anoxia/ Hypoxia Normoxia Reference 
Chinese hamster ovary ~15 ~9 [162] 
EMT6 ~60 ~10 [163, 167] 
MDA468 ~45 ~20 [241] 
FaDu ~60 ~15 [241] 
R3327-AT ~27 ~16 [241] 
FSaII ~25 - [241] 
MCF7 ~30/ 26 Bq/cell  ~6 Bq/cell [197, 241] 
DU-145 ~30 - [241] 
 
64Cu-ATSM Accumulation (% uptake)/ µg Protein 
LNCap ~0.40 ~0.20 [242] 
LAPC-4 ~0.35 ~0.30 [242] 
PC-3 ~0.35 ~0.18 [242] 






3.4.4.1 Metabolic Factors That May Affect 
64
Cu-ATSM Accumulation 
Due to the potential diagnostic, prognostic, and therapeutic applications of hypoxia 
tracers in oncology compared to cardiology, the majority of cell types that have been 
used to characterise 
64
Cu-ATSM in vitro have been tumour cell lines [167, 197, 209, 
241]. Chinese hamster ovary cells have also been used [162]. By comparing our data 
with those of others, we see that the accumulation of 
64
Cu-ATSM in ARVM was much 
lower than in tumour cells, although it was comparable to uptake in CHO cells. One 
possible explanation for this is that ARVM are quiescent when cultured in vitro, and are 
therefore much less metabolically active than myocytes in vivo. White and Wittenberg 
demonstrated that the level of mitochondrial NAD(P)H was approximately ~2-fold 
higher in unpaced isolated cardiac myocytes, compared to those that were paced at 5 Hz 
[268]. Furthermore, they also demonstrated that oxygen utilisation was ~2-fold higher in 
cells paced at 5 Hz, compared to those that were paced at 0.5 Hz. In addition to this 
ARVM are terminally differentiated cells they do not divide, and this further reduces 
their energy requirements relative to tumour cells which vigorously proliferate in vitro. It 
is therefore likely that the tumours cells used by other groups would have had a higher 
demand for nutrients and oxygen, compared to our cultured ARVM. During our hypoxia 
experiments we noticed that while the pO2 of the culture medium always fell below 0.8 
mmHg, it never reached 0.0 mmHg. Other groups have also employed a 0 % oxygen gas 
mixture. It is feasible that the higher metabolic activity of tumour cells would cause them 
to utilise any residual oxygen that was dissolved in the culture medium, effectively 
making the cells more hypoxic than ARVM in our experiments. With respect to tracer 
accumulation, the effect of this would be to further decrease the rate at which reoxidation 
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of Cu(I)-ATSM occurs, which would therefore increase tracer trapping. This may explain 
why the retention of Cu-ATSM under hypoxic conditions was higher in tumour cells. 
Tumour cells down-regulate oxidative phosphorylation and increase the rate of glycolysis 
by a process known as the Warburg effect [269], so mitochondrial consumption of 
oxygen may not be responsible for this. However, it is possible that the consumption of 
residual oxygen may have occurred through another metabolic pathway, such as 
cholesterol synthesis [36-37]. Cholesterol is an integral membrane lipid that is required 
by all cells, especially those that are dividing. Rapidly dividing cells could perhaps have 
higher oxygen consumption through this process than terminally differentiate myocytes, 
which are not undergoing growth. This is supported by data from Gal et al, who 
investigated cholesterol metabolism in cervical cancer cell lines and non-cancerous 
fibroblasts, and observed a significantly higher rate of uptake and degradation of low-
density lipoprotein by tumour cells compared to non-tumour cells [270].  
 
3.4.4.2 Cell Number and Population Density 
In our time- and oxygen-level dependent experiments the total number of ARVM, 
including rod-shaped, distorted, and rounded cells was in the range 2.0 x 10
5
- 2.7 x 10
5
 
cells/ 90 mm Petri dish. Considering that we used 5 ml of culture medium in these 
experiments, the cell density was in the range 4.0 x 10
4
- 5.2 x 10
4
 cells/ ml. Dearling et 
al employed CHO cells at 2- 4 x10
5
 cells/ ml in 50 ml medium [162]. Tumour cell lines 
were commonly used at a density of 1 x 10
6
 cells/ ml (1- 5 x 10
7
 cells in total) [167, 195, 
208, 242], while Burgman et al characterised 
64
Cu-ATSM accumulation in six tumour 
cell lines, seeded at 2x10
5
 cell/ culture vessel with 0.5 ml culture medium [241]. The cell 
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numbers and population density that we were able to achieve with ARVM was therefore 
relatively low compared to these other studies. Furthermore because in our experiments 
ARVM were attached to the surface of the culture vessel, they were not evenly dispersed 
throughout the culture medium. These two factors combined may also explain why the 
accumulation of 
64
Cu-ATSM was relatively low in ARVM, compared to other cell lines. 
 
3.4.4.3 Concentration of 
64
Cu-ATSM in the Culture Medium 
The amount of radiotracer that was added to the culture medium is another factor that 
could affect the rate or amount of accumulation. Cu-BTSC complexes are thought to 
enter cells by passive diffusion. Increasing the concentration of radiotracer in the 
medium would therefore increase the number of potential interactions between molecules 
64
Cu-ATSM and ARVM. It would also have the effect of increasing the rate of diffusion 
into cells, because there would be a larger concentration gradient between the 
extracellular and intracellular compartments, at least until the partitioning reached 
equilibrium. With the exception of Dearling et al’s work with CHO cells, the 
concentration of 
64
Cu-ATSM employed by other groups was ~2- 4-fold higher than the 
20 KBq/ ml used in our experiments [162, 167, 208, 241-242]. It is therefore likely that if 
more 
64
Cu-ATSM had been added to the culture medium, we may have observed greater 
tracer cellular accumulation and contrast between hypoxic and oxygenated cells.  
 
3.4.4.4 Comparison of 
64
Cu-ATSM accumulation with other Hypoxia Tracers 





I]IVM using ARVM based systems. After a 60 min incubation the hypoxic to 
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normoxic contrast ratio was 9.6: 1 for [
3
H]FMISO, and 4.4:1 (hypoxia) and 8.4: (anoxia) 
for [
131
I]IVM. We observed much lower contrast, with ratios between 1.3- 1.6: 1 after 60 
min. This does not agree with previous data from isolated perfused hearts, obtained by 




I]IVM were exposed to 
ARVM at a concentration of 50 µM, which is at least two orders of magnitude greater 
than the ~15 nM 
64
Cu-ATSM that we used. In our experiments we chose to restrict the 
concentration of 
64
Cu-ATSM to reflect the nano/ pico molar quantities that are employed 
for clinical PET imaging.  
 
3.4.4.5 ARVM Morphology after Exposure to Oxygenated and Hypoxic Conditions 
Another way in which our experiments differed from those of Martin, and Biskupiak was 
that their experiments were run for up to 3 h. As already discussed we limited the 
incubation time to 60 min to avoid irreversible cellular injury. As part of their 
experimental protocol Martin et al monitored the morphology of ARVM before the start 
and at the end each experiment. After 60 min anoxic they observed a 10 % decrease in 
the number of rod-shaped ARVM, compared to control samples. Although the authors 
reported that the decrease in the percentage of rod-shaped ARVM was not statistically 
significant. After 180 min anoxic gassing the number of rod-shaped myocytes was 25 % 
less than control samples. We also assessed cell morphology as part of our experimental 
protocol. Our data show that after 30 or 60 min incubation the number of rod-shaped 
ARVM was comparable to the 0 min control values, regardless of the level of 
oxygenation (figures 3.8 and 3.9). Furthermore the number of rod-shaped ARVM was 
similar for all conditions. Our data show that the morphology, and therefore viability, of 
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ARVM was not affected by increasing or decreasing the level of oxygen. We can 
therefore be confident that the contrast that we observed between 
64
Cu-ATSM retention 
in hypoxic cells compared to oxygenated cells was due to hypoxia selectivity, and not 
other factors which may be related to prolonged exposure to hypoxia or cellular injury.  
 
3.4.4.6 Assessment of 
64
Cu-ATSM accumulation in ARVM Maintained in 
Suspension 
We made a final attempt to develop an ARVM based model for characterising 
64
Cu-
BTSC complexes, using cells maintained in a suspension of M199. As discussed 
previously this is not conducive to the medium to long term viability of ARVM. 
However both Rumsey et al, and Ramalingham et al have previously applied this method 
to demonstrate significant hypoxia-dependent uptake of BMS181321 [132], and 
99m
Tc-
BAPN [138] respectively. With the potential advantages that suspension culture has, 
such as high cell number, and lower cost because laminin is not required, it was an 
attractive approach that was worth investigating.  
 
By using the cell suspension method we observed a maximum of 63.2 % retention of the 
total radioactivity, under hypoxic conditions. This is similar to the uptake that was 
observed in EMT6 [167], MDA468 [241], and FaDu [241] tumour cells, and 
considerably more than in CHO [163] cells, and other tumour cell lines [241]. However 
unlike these other studies we observed significant accumulation of 
64
Cu-ATSM under 
oxygenated conditions, equating to 53.4 % of the total radioactivity. The contrast ratio 
between the two experimental conditions was therefore only 1.2: 1, compared to values 
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of generally 1.7- 6.0: 1 in other cell types, with the exception of LAPC-4 cells. With 
respect to the screening of other hypoxia tracers that were characterised using ARVM, 
Rumsey et al observed a hypoxic to normoxic cell contrast of was between ~2: 1 with 




In our cell suspension experiments we observed a 10-fold increase in radiotracer 
accumulation, compared to those where ARVM were allowed to attach to the culture 
vessel. While this approach lead to significantly greater retention of Cu-ATSM in 
ARVM, and also allowed us to discern a contrast in tracer uptake between our 
experimental conditions, once again we observed a large variance in the replicate 
samples. The amount of tracer that was retained under oxygenated conditions was also 
relatively high compared to other cell types, and tracers. Without further experiments it is 
not possible to determine why this occurred. However it is plausible that up-regulation of 
the bioreductive mechanism/s responsible for the Cu-ATSM accumulation may occur in 
ARVM that are undergoing apoptosis, as they are no longer attached to other cells or the 
extracellular matrix. This may be the reason why the retention of 
64
Cu-ATSM retention 
was relatively high in these cells, even under oxygenated conditions.    
 
3.4.5 Conclusions 
During our experiments we observed considerable variation the number of cells that we 
obtained when isolating ARVM. We also observed large variance in the amount of 
64
Cu-
ATSM that accumulated within cells, even between replicates samples where cells had 





Cu-ATSM between our experimental conditions. This severely limited the 
potential usefulness of the ARVM based assays for the purposes that we had proposed. It 
was also unlikely that we would be able to scale-down our system, because lowering the 
cell number would further exacerbate these issues. We also planned to use an isolated 
myocyte approach to characterise the accumulation of our library of Cu-BTSC 
complexes at more physiologically relevant oxygen levels. However, as such poor 
contrast was observed under the extreme conditions that we tested, we concluded that 
this system was unlikely to be sensitive enough to monitor the accumulation of 
64
Cu-
BTSC complexes at low and intermediate levels of oxygenation. We therefore decided 
that the ARVM screening assay that we had developed was not suitable for 
characterising our library of 
64
Cu-BTSC complexes, and we shifted our focus to another 
well established technique the Langendorff isolated perfused heart, as a means of 





Calibration of Equipment Required for 






4.1  Introduction 
This chapter will introduce the techniques and equipment that we employed to 
characterise 
64
Cu-BTSC complexes, using Langendorff isolated perfused hearts. It will 
also describe the assembly, calibration, and optimisation of a purpose built Na/ I gamma 
radiation detector array for monitoring the flow of radioactivity into, through, and out of 
hearts in real-time. However before describing these experiments we will introduce the 
principles of ex vivo heart perfusion.   
 
4.1.1 The Langendorff Isolated Perfused Heart  
The isolated Langendorff perfused heart has been employed previously to characterise 
the myocardial tissue clearance/ accumulation of both perfusion and hypoxia targeting 
tracers. Before addressing how the method was previously employed it is pertinent to 
describe the principles of this widely used research tool, by first explaining how the heart 
is perfused in vivo.  
 
4.1.1.1 The Coronary Vasculature 
Blood carries with it not only oxygen but nutrients such as glucose, fatty acids and trace 
elements, as well as extra-cellular signalling molecules (e.g. insulin, glucagon). Blood 
also removes metabolic waste products such as CO2 and lactate.  The heart has a very 
limited store of nutrients, and because of its high work-rate nutrients need to be 





At the very end of each cardiac contraction (end systole), the left ventricle has expelled 
most of the blood in its lumen into the aorta.  Pressure in the aortic lumen is therefore 
high, while as the ventricular muscle begins to relax, the pressure within the ventricular 
lumen is relatively low. This rising back pressure forces the aortic valves to shut, thereby 
preventing the return of blood to the heart.  The majority of the blood in the aortic lumen 
will follow the route of the aorta and great arteries. However, the pressure inside the 
ascending aorta and aortic arch at the time of systole, forces some of the blood through 
the coronary ostia, and into the right (RCA) and left main (LM) coronary arteries. The 
LM branches into the left anterior descending (LAD) and circumflex coronary arteries 
(CIRC). A fifth main coronary artery, the post descending artery (PDA) may branch off 
of either the RC or CIRC. These coronary arteries reside on the outer surface of the 
epicardium, and follow ridges formed where the chambers of the heart meet. Branches 
off of these arteries permeate into the tissue and perfuse the myocardium through a 
network of arterioles and capillaries. Blood returns to the chambers of the heart via veins 
that run parallel to the coronary arteries, and drains into the right atrium via the coronary 
sinus [11]. 
 
4.1.1.2 The Isolated Heart Perfusion Technique 
Langendorff first described his method for the ex vivo perfusion of mammalian hearts in 
1895 [271]. The technique allows the heart to be studied independently, without the 
affects of neuronal or hormonal stimuli. The heart is then perfused in a retrograde 
manner with a physiological salt solution, which usually also contains glucose, and is 
also saturated with oxygen. The pressure exerted by this retrograde perfusion closes the 
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aortic valves, causing the perfusate to flow through the coronary ostia and into the 
coronary arteries. The buffer flows through the coronary vasculature and bathes the 
tissue beds, continues to flows through the coronary veins and into the right ventricle via 
the coronary sinus. The perfusate then exits the heart via a small incision made in the 
pulmonary artery (figure 4.1).  
 
 
Figure 4.1. Langendorff isolated heart perfusion. Retrograde perfusion forces the aortic valve to 
close, and buffer then flows through the coronary ostia and into the coronary vasculature via the 
coronary arteries. Buffer then elutes from right ventricle via the pulmonary artery. Adapted from 





4.1.1.3 Langendorff Isolated Heart Perfusion: Advantages and Disadvantages 
Although the Langendorff isolated heart technique has been and will no doubt continue 
to be used in cardiac research for many years, there are a number of limitations to the 
method that must be considered.  
 
The advantages to using the Langendorff method are that the excision, cannulation and 
perfusion procedures are relatively quick and simple. The heart is then free from 
neuronal and hormonal stimuli, and more amenable to biochemical, physiological or 
morphological investigation than when in situ. The constituents of the perfusion buffer 
can be manipulated with ease, as can the perfusate flow rate, for example to induce 
ischaemia. The effect of any stimulus, condition, or pharmacological agent can then be 
directly monitored through changes in cardiac function or electrophysiology. These 
parameters can easily be measured by inserting a fluid filled balloon into the left 
ventricle, which is coupled to a pressure transducer and a data acquisition system, or by 
attaching an ECG monitor to the heart. The Langendorff isolated perfused heart 
technique is therefore most conducive to studies on radiotracer characterisation, as will 
be demonstrated in the following discussion. 
 
The disadvantages of using isolated perfused hearts is that they are an ex vivo model that 
is constantly deteriorating from the moment the heart is excised from the donor. 
Although the heart is supplied with a variety of nutrients and minerals via the perfusion 
buffer, certain essential nutrients, for example amino- acids, are usually excluded and 
therefore the ex vivo conditions can do not exactly mimic those in vivo. Conversely the 
173 
 
isolated heart can withstand extreme conditions such prolonged anoxia, which in an in 
vivo scenario would cause the death of the animal. However the advantage of this is that 
it allows the study of these conditions. For these reasons the isolated perfused heart is 
considered to be one step further away from the physiological/ clinical setting. 
 
Oxygenation is also an issue because Langendorff hearts are usually perfused with 
Krebs-Henseleit Buffer (KHB), a physiological salt solution. While gassing with 95% 
O2/ 5% CO2 achieves buffer saturations in excess of 500 mmHg, KHB does not have the 
oxygen carrying capacity of blood [273]. This is apparent in that the coronary flow 
through a blood-perfused rat heart at 74 mmHg perfusion pressure is typically 3 ml/ min, 
while flow rates of 12- 16 ml/ min are typically needed in constant flow systems, to 
achieve similar levels of cardiac function in a buffer perfused heart [273]. Southworth et 
al have demonstrated that when rat hearts are perfused with oxygenated KHB, the 
thickness of the ventricular walls doubles due to this vasodilation [274]. However whilst 
the isolated perfused heart may be considered “physiologically compromised” with 
respect to oxygen delivery, NMR studies have demonstrated that the buffer perfused 
Langendorff heart is energetically normal with respect to intracellular phosphocreatine 
and ATP levels [275].  
 
4.1.2 Characterisation of Candidate Hypoxia Tracers Using Isolated Perfused 
Hearts 
The Langendorff method of isolated heart perfusion has been widely employed as a 
model for characterising the myocardial retention of candidate perfusion and hypoxia 
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specific tracers.  The nitroimidazole based tracers 
18
F-MISO [127] and BMS181321 
[115-116, 132-134], 
99m
Tc labelled- HL91 [149, 151, 276], and the Cu-
bis(thiosemicarbazones) 
64,67
Cu-PTSM [75] and 
62
Cu-ATSM [174], have all previously 
been assessed using this method. Invariably the washout/ accumulation of radiotracers in 
the heart has been measured and quantified using Na/I γ-detector systems. The 
radiotracer is either constantly infused or administered as a bolus, under oxygenated or 
ischaemic/ hypoxic conditions. The gamma detectors then measure radioactivity emitted 
from the heart in real-time. By using this method it is has been possible to determine the 
tissue retention, and potential normoxic to hypoxic tissue contrast of candidate hypoxia 
selective radiotracers. A number of studies have also used this method to produce kinetic 
analyses of radiotracer retention/ clearance. This was done in order to further quantify 
how changes to the structure and physiochemical properties, affect tracer performance 
[75, 115-116, 127, 134, 149, 151, 276].  
 
4.1.2.1 The Gina star™ Data Acquisition System and Na/ I γ- Detector Array 
For the radiotracer characterisation that we describe in this thesis, we designed and 
commissioned a purpose built Na/ I γ- radiation detector system from  Raytest 
Isotopenmessgeräte GmbH (Straubenhardt, Germany) [277]. The Gina Star™ data 
acquisition system is a modified version of the company’s standard GABI Star™ system, 
which is used for radio-HPLC. Our modified system was upgraded so that it was capable 
simultaneously receiving inputs from three Na/ I γ-detectors, instead of the two. The 
system was controlled by the Gina Star™ (version 4.0.2.75) software package, installed 
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on a laptop personal computer. Figure 4.2 provides a schematic representation of the 
combined γ-detector- isolated heart perfusion systems. 
 




Previous studies have tended to employ a single γ-detector positioned close to the heart 
[115-116, 132, 149, 151, 174, 276], although occasionally two γ-detectors have been 
used to provide coincidence counts, in order to decrease the system error [75, 127, 134]. 
Our system employed Na/ I γ-detectors that were arrayed over the perfusion apparatus, 
allowing us to produce time-activity curves for the heart, as well as establishing both 
input and output functions. We hypothesised that these parameters could then be used to 
perform pharmacokinetic modelling on the time-activity curves that we obtained. Apart 
from providing valuable information regarding the rate of radiotracer clearance and 
tissue accumulation, compartmental pharmacokinetic modelling could potentially 
determine the rate at which reduction of the Cu(II)-complexes occurs, and perhaps give 
some insight into the fate of the 
64
Cu- moiety. This information would allow for a more 
detailed and accurate characterisation, evaluation, and comparison of the 
64
Cu-BTSC 
complexes, relative to what has previously been achieved with a single Na/ I detector, or 




4.2  Materials and Methods 
4.2.1 Chemical and Reagents 
Unless stated otherwise all bulk chemicals were of analytical grade and were purchased 
from Sigma-Aldrich. 
 
4.2.2 Gas mixtures  
Gas mixtures used for this series of experiments were: oxygenated (95 % O2/ 5 % CO2), 
and anoxic (95 % N2/ 5 % CO2). 
 
4.2.3 Isolated Heart Perfusion Apparatus   
A schematic representation of the isolated heart perfusion rig is shown in figure 4.3. This 
particular set of perfusion apparatus was constructed as a constant flow system. The 
perfusion buffer flow rate was controlled via a peristaltic pump (Gilson, USA). All 
glassware was water-jacketed and supplied with warm water by a circulator/ heater, to 









4.2.3.1 Calibration of Perfusate Flow Rate 
A peristaltic pump (Gilson, USA) was incorporated into the system in order to maintain a 
constant flow of perfusate. During the preliminary experiments described in this chapter 
the pump was calibrated and controlled manually. This calibration was performed by 
measuring the flow rate volumetrically, against the arbitrary values displayed on the 
pump control interface.  
 
4.2.3.2 Calibration of Perfusion Buffer Temperature 
At the time that the perfusion rig was built and then before the start of each experiment, 
the temperature of the perfusion buffer was measured using a thermocouple inserted into 
the perfusion cannula. This was performed regularly to ensure that the perfusate was at a 
temperature of between 37.0 and 37.4 ºC as it entered the coronary vasculature. 
 
4.2.3.3 Measurement of Perfusion Buffer pO2 During Deoxygenated Perfusion  
The pO2 of the perfusion buffer was measured every 60 seconds for 60 min, after 
switching from non-gassed to hypoxic (95% N2/ 5%CO2) perfusion buffer. The Oxylab 
pO2™ combined with a pO2 and temperature sensor (described in section 2.2.12.1), was 
then used to measure the pO2 of the buffer as it flowed from the tip of the perfusion 
cannula.  
 
4.2.3.4 Calibration of Pressure Transducers 
In order to monitor cardiac function in isolated perfused hearts, and to assess the affects 
of perfusion with hypoxic buffer, a PowerLab/4SP data acquisition system and 
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LabChart® 7 (version 7.2) software package (ADInstruments, UK) were employed. This 
was coupled to two DTXPlus™ pressure transducers (BD, UK).  One pressure transducer 
was positioned on a side-arm of the perfusion cannula to monitor perfusion pressure, 
while the second was attached to a small balloon that was inserted into the left ventricle 
of hearts, and was used to measure left ventricular pressure. From the left ventricular 
balloon input the LabChart® software was able to calculate left ventricular developed 
pressure (LVDP), left ventricular end diastolic pressure (LVEDP), and heart rate.   
 
4.2.4 Langendorff Isolated Perfused Heart 
4.2.4.1 Isolated Heart Perfusion Buffer 
In this study isolated hearts were perfused with a modified Krebs-Henseleit buffer 
(mKHB) previously described by Cave and Garlick et al [278-279] (table 4.1). In our 
laboratory we use phosphate free KHB in all heart perfusion experiments to facilitate the 
analysis of cardiac phosphorus metabolism by 
31
P NMR when necessary.   The NMR 
signal from phosphate containing buffers would obscure the relatively weak intracellular 
31
P signal. While none of the experiments described here employed 
31
P NMR 
spectroscopy, we use the same perfusion medium is used in all studies in order to 
facilitate comparison of data across all experiments. Similarly EDTA is included to 
chelate any free heavy metal ions, which also potentially interfere with the NMR signal. 









Table 4.1 Preparation of modified Krebs-Henseleit buffer, for the perfusion of isolated hearts in 
the Langendorff mode.  
Chemical   Mol. Wt Concentration (mM) Amount (g)/ l 
Sodium Chloride 58.4 118.5 6.925 
Sodium Hydrogen Carbonate 84.0 25.0 2.01 
Magnesium Sulphate 246.5 1.2 0.30 
Potassium Chloride 74.6 6.0 0.44 
Di-sodium EDTA.2H2O 372.5 0.5 0.19 
D-Glucose 180.2 11.0 1.98 
Calcium Chloride 147.0 2.5 0.37 
 
4.2.4.2 Excision and Cannulation of Hearts 
Adult male Wistar rats (250-300 g) (B&K Universal, Hull, U.K.) were anaesthetised with 
pentobarbitone (Pentoject 1ml/ kg i.p.). When the animal was sedated to the point that no 
reflex actions were observed, heparin (200IU) was injected into the femoral vein. The 
heart was then rapidly excised and immersed in ice cold mKHB. Excess tissue was 
carefully removed and the heart was cannulated in the Langendorff mode. The heart was 
then perfused with mKHB (Table 4.1) under constant flow (14 ml/ min). 
 
 
4.2.4.3 Conformation of Isolated Perfused Heart Preparation Stability  
To establish the functional parameters upon which the heart preparations were to be 
accepted in any of our studies, we performed a stability study. By perfusing hearts at a 
constant flow (14 ml/ min), the perfusion apparatus and my cannulation technique were 
iteratively improved until the hearts were capable of developing a pressure 100- 140 
mmHg. Criteria where established for heart rate, left ventricular developed pressure 
(LVDP), left ventricular end diastolic pressure (LVEDP) and coronary perfusion 
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pressure, whereby hearts meeting these requirements within 20 min of cannulation were 
entered into an experiment, while those that did not were rejected.  
 
4.2.5 Preliminary Experiments with γ-Detection and Isolated Perfused Hearts 
Before the Gina Star™ system was purchased a series of preliminary experiments were 
performed using a crude detector system, as proof of principle.  
 
Hearts were cannulated as described above and a Na/ I γ-detector from a radio-HPLC 
was positioned ~1 cm from the heart. Hearts were first perfused with oxygenated mKHB 
(95% O2/ 5% CO2), which was then switched to deoxygenated buffer (95% N2/ 5% CO2). 







in mKHB), was administered via an injection port which was built into the perfusion 
line. Throughout each experiment the HLPC system software was used to record 
radioactive decay, to produce time-activity curves.  
 
4.2.6 Gina Star™ Na/ I γ-Detector Calibration 
The Gina Star™ data acquisition system was developed for the purpose of monitoring 
the accumulation and washout of radiotracers in isolated perfused hearts. In order to 
assess the relative sensitivity and response uniformity of three Na/I detectors, a series of 




4.2.6.1 Detector Response Uniformity 
Detector uniformity was tested to ensure that each of the three detectors responded 
equally to a given amount of radioactivity, and registered similar values for decay 
(counts per second). This was achieved by placing a vial containing 0.1- 50 MBq of 
64
Cu 
in front of each detector at a distance of 68 mm, which we had previously found to give 
rise to 1000cps with 1 MBq 
64
Cu. The decay was then measured for 1 min in triplicate, 
for each amount of radioactivity and each Na/ I γ-detector. 
 
4.2.6.2 Detector Dead Time and Response Linearity 
With the Gina Star™ system it was possible to amend the data sampling rate, allowing 
some control over the detector dead time or sample time. The system was setup to 
achieve the maximum sampling rate of 1 sample/ 0.2 sec. The linear range of the Na/I γ-
detectors, in terms of counts per second registered, was also established from the detector 
uniformity data. 
 
4.2.6.3 Shine Through 
Injection of radioactivity in the perfusate line delivers tracers to the heart before it is 
either trapped or washes out. In our dynamic system, radioactivity flows past each of the 
three detectors in series, allowing us to monitoring the flow of radioactivity through the 
system in real-time. However the passage of radioactivity through the system, and the 
fact that there is likely to be activity in several regions simultaneously, may increase the 
effect of shine-through. This is caused by inappropriate registration of radioactive decay 
from proximal or distal regions of the system. Each detector therefore could potentially 
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register higher counts than expected, with erroneous flow past curves being 
superimposed onto the actual time-activity data. It was therefore essential to minimise 
this effect. 
 
Shine-through was assessed after the construction of the perfusion rig and integration of 
the three Na/I detectors. A vial containing 1 or 10 MBq of 
64
Cu was placed at the 
position of detector 1 (arterial) and the cps was recorded at detectors 2 (heart) and 3 
(venous). The vial was then placed at the detector 2 position and cps measured by 
detector 1 and 3 was recorded. Finally the vial was placed at detector 3 and 




4.3  Results 
4.3.1 Langendorff Rig Calibration 
4.3.1.1 Calibration of Perfusate Flow Rate and Temperature 
A plot for the calibration of the perfusion pump is shown in figure 4.4. Actual flow rate 
measured volumetrically is shown against the arbitrary flow displayed on the pump 
control interface.  Using this example a displayed value of 24.0 would result in an actual 
flow rate of 12 ml/ min. This type of calibration was performed regularly (as pumping 
rate varies with tension on the peristaltic pump tubing), and flow rate was also confirmed 
at the start of each stabilisation period. 
 
 
Figure 4.4. Calibration of the perfusate flow rate. Actual flow rate (ml /min) plotted against the 





The heater/circulator was used to supply warm water to the water-jacketed glassware, 
and was adjusted so that the temperature of mKHB was between 37.0 – 37.4 ºC as it 
exited the cannula. The results of this exercise (figure 4.5) demonstrate that the 
temperature of KHB as it exited the cannula remained constant over 2 h. 
 
 
Figure 4.5. Temperature (ºC) of KHB exiting the perfusion cannula over a 2 h period. Data 




4.3.1.2 Perfusate pO2 
The partial pressure of dissolved oxygen in the perfusion buffer was monitored over 60 
min after switching to hypoxic buffer (figure 4.6). At the start of the experiments the pO2 
of non-gassed KHB was ~140 mmHg. This buffer was not oxygenated so we were able 
to measure the pO2 using the Oxylab pO2™ system, which saturates at levels above 150 
mmHg. After switching to hypoxic mKHB the perfusate pO2 decreased in two distinct 
phases. The first was rapid with the average pO2 falling from 144.3 ± 8.3 mmHg to 10.1 
± 4.1 mmHg within 10 min of switching to hypoxic buffer. The second phase was much 
slower with the level of oxygen steadily decreasing from 10.1 ± 4.1 mmHg to 5.8 ± 0.7 
mmHg over 55 min. 
 
 
Figure 4.6. Partial pressure oxygen (pO2) of KHB over time, after switching from non-gassed to 




4.3.2 Conformation of Preparation Stability  
To ensure that cardiac function and coronary perfusion pressure of isolated perfused 
hearts were within parameters previously defined by Hearse and Sutherland [273], and 
Skrzypiec-Spring et al [280] (Table 4.2), we conducted a series of preliminary 
experiments to assess my cannulation technique. Limits were set for left ventricular 
developed pressure (LVDP), left ventricular end diastolic pressure (LVEDP), heart rate 
and coronary perfusion pressure. Hearts were allowed a 20 min stabilisation period after 
cannulation, if during this time cardiac function failed to meet the established criteria 
they were discarded. Cardiac function was then monitored over 2 h. 
 
Table 4.2. Criteria for Cardiac Function. 
Cardiac Function (Parameter) Range 
Left Ventricular Developed Pressure > 100 mmHg 
Left Ventricular End Diastolic Pressure 4 – 8 mmHg 
Heart Rate > 280BPM 
Perfusion Pressure 60 – 80 mmHg 
  
Figure 4.7 displays the data for LVDP, LVEDP, heart rate, and coronary perfusion 
pressure that were used to establish exclusion criteria. On average over the 2 h perfusion 
period LVDP decreased by < 10 % per hour, as recommended by Sutherland and Hearse 
[273]. LVEDP rose from an average of 6 mmHg to ~11 mmHg during the same time. 
Heart rate slightly increased from 283 BPM to 293 BPM, and the coronary perfusion 





Figure 4.7. Establishment of exclusion criteria for cardiac function. LVDP (A), LVEDP (B), 






4.3.3 Preliminary Hypoxia Tracer Retention Experiments 
Time-activity curves from our preliminary ex vivo tracer characterisation experiments are 
shown in figure 4.8. Tissue retention was estimated as a proportion of the cps within the 
heart 10 min post injection, compared to the peak cps immediately after an injection. 
These data were considered as qualitative and not quantitative, because of the relatively 
simple system that was used for these initial experiments. ~5 % ID of 
64
Cu-ATSM was 
retained during normoxia, but this increased to between ~45- 60 % ID under hypoxic 
conditions. Please note that during the first period of oxygenated perfusion, what appears 
to be 100 % retention of the first injection of 
64
Cu-ATSM was actually due to an error 
where the detector was not in place, and the injection peak counts were missed. 
18
F-
MISO demonstrated negligible accumulation under oxygenated conditions, but ~5- 20 % 





Figure 4.8. Time-activity curves from preliminary ex vivo tracer characterisation experiments for 
64Cu-PTSM, 64Cu-ATSM and 18F-MISO. Each peak is representative of a single bolus 2 MBq 




4.3.4 Gina Star™ Na/ I γ-Detector Calibration 
4.3.4.1 Na/ I γ- Detector Response Uniformity 
The results of the detector response uniformity exercise (figure 4.9) demonstrated that 
between 0 – 30000 cps (0- 50 MBq 64Cu), each of the three detectors responded 
uniformly to a given amount of radioactivity.  There was however some discrepancy 
between the detectors. With the exception of measurements taken when the detectors 
were exposed to 12.5 MBq, Detector 1 always registered the highest number of counts 
and detector 3 the lowest. From ~5000 – 30000 cps the difference was 2% of the mean 
counts (triplicate runs), between 500 - 2600 cps it was between to 1 - 4 %, but at ~100 
cps there was 10 % discrepancy between the cps registered by detector 1 and detector 3. 
However with the exception of counts of ~30000 cps, the difference in the decay that was 








Figure 4.9. Na/I Gamma-detector response uniformity. Decay (cps) registered by each of the 
detectors when 0.1- 50 MBq of 64Cu was placed at a distance of 68mm. Data represent mean (n = 




4.3.4.2 Na/ I γ-Detector Linearity 
The detector linearity curves (figure 4.10) demonstrate that all three detectors displayed a 
good degree of linearity (R
2
 = 0.99) over the range ~ 100 -30000 cps.  
 
 
Figure 4.10. Gamma-detector linearity (0.1- 50 MBq/ 100- 30000 cps). Decay (cps) is plotted 





Between 100- 18000 cps the relationship between the amount of radioactivity and decay 
counts was also linear (R
2
 = 1.0) (figure 4.11). 
 
 
Figure 4.11. Gamma-detector linearity (0.1- 25 MBq/ 100- 18000 cps). Decay (cps) is plotted 






Analysis of cps at the lower range of radioactivity, between 0 – 2600cps (figure 4.12), 
demonstrated that the sensitivity of all three of the detectors remained linear (R
2
 = 1.0). 
 
 
Figure 4.12. Gamma-detector linearity (0.1- 2.5 MBq/ 100- 2600 cps). Decay (cps) is plotted 
against radioactivity (MBq). Data represent mean (n = 3) ± SD.  
 
4.3.4.3 Shine Through 
Each of the three detectors was shielded by a custom built 2 cm thick lead collimator to 
reduce shine-through. As a result of shielding exposure to 1 MBq of 
64
Cu resulted in a 
slight but insignificant increase of 15 cps above the background counts. When 10MBq 
was used the number of disintegrations registered also increased slightly, by 48 cps 




4.4  Discussion and Conclusions 
4.4.1 Calibration of Perfusion Apparatus and Perfusion Buffer pO2  
The perfusion pump was calibrated and least squares regression was used to determine 
the relationship between arbitrary flow and actual flow rate (figure 4.4). We also 
established that the temperature of the perfusion buffer was constant, and within the 
range 37.0- 37.4 ºC (figure 4.5). We were therefore confident that our perfusion 
apparatus was suitable for our experiments.  
 
Measurements of the pO2 of mKHB taken after switching to the perfusate pO2 decreased 
in two distinct phases (figure 4.6). This observation presented the opportunity to assess 
radiotracer performance at two levels of hypoxia; early and late. This will be discussed 
further in Chapter 5.  
 
4.4.2  Confirmation Isolated Perfused Heart Preparation Stability 
Exclusion criteria for cardiac function and coronary perfusion pressure were established 
(Table 4.2). These criteria were then used to determine whether the function of isolated 
perfused hearts was acceptable for experimental purposes, and also ensured that all hearts 
were of equal viability. The results of these preliminary experiments demonstrated that 
we were capable of isolating hearts and maintaining their cardiac function within 




4.4.3 Preliminary Ex Vivo Tracer Characterisation Experiments using γ-Detection  
It was not possible to properly quantify these data in terms of tissue retention, because 
this crude system was not capable of recording the time-activity data in a list form, for 
exporting into spreadsheet applications. The tissue retention of each of the tracers was 
therefore estimated from the time-activity curves.  
 
4.4.3.1 What Was Learnt from Preliminary Ex Vivo Experiments? 
Preliminary ex vivo experiments were performed in order to further assess the feasibility 
of using a combination of the isolated perfused heart and γ-radiation detectors, to 
characterise the candidate hypoxia tracers. As already discussed in section 4.1.2, this 
approach had been employed previously by other groups. However, it was thought 
necessary to repeat some of their work ourselves before purchasing dedicated perfusion 
apparatus and a γ-detector system. 
 
From our preliminary experiments we observed 
64
Cu-PTSM [75] accumulation in both 





F-MISO [127] (figure 4.8), as previously reported. Our crude reproduction of 
previous experiments and results, demonstrated to us that the isolated heart perfused 
heart combined with γ-radiation detectors, would provide an excellent model for 
characterising the myocardial retention and hypoxia avidity of our tracers. Furthermore 
these experiments demonstrated that when 
64
Cu-BTSC complexes are administered as a 
single bolus, the first pass extraction of radioactivity is sufficient to allow measurements 
by Na/ I γ- detectors. 
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4.4.4 Calibration of Gina Star™ Data Acquisition System and Na/ I γ-Detectors 
4.4.4.1 Detector Uniformity 
It was necessary to confirm that the sensitivity of the three γ-detectors was equal, as a 
large variation could potentially hinder our attempt to analyse the time-activity data using 
kinetic modelling. The detector uniformity data demonstrated some discrepancy between 
the counts that were registered by each of the detectors, but the error was still less than 
that of the triplicate measurements for a single detector (figure 4.9). We therefore 
considered this to be an acceptable level of error. 
 
4.4.4.2 Detector Linearity 
At a sampling rate of 0.2 sec/ sample the Gina™ data acquisition system was capable of 
accurately measuring the count rate in the range 0 – 30000 cps (Figures 4.10- 4.12). 
However, to maintain the highest degree of accuracy we decided to limit the amount of 
radioactivity, so that the counts would not exceed 18000 cps. We therefore chose to 
inject 1 MBq of radiotracer per bolus in our experiments, because of the excellent 
sensitivity of the γ-detectors. Nevertheless it was useful to know that larger amounts 
radioactivity could be used if necessary. This was particularly welcome with respect to 
minimising shine-through, and for personal radiation protection throughout the rest of the 
study. 
 
4.4.5 Construction of the Triple γ-Detector Array 
As the result of our positive preliminary experiments we designed and commissioned the 
Gina Star™ system. Following the calibration of the perfusion equipment, the 
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establishment of exclusion criteria, and after assessing the uniformity and linearity of the 
three Na/ I γ-detectors, we then integrated the Gina Star™ and isolated heart perfusion 
systems. This integrated system was referred to in-house as the ‘Triple γ- Detector Array’ 
(Figure 4.1). Of the three detectors, one was positioned on the perfusion line immediately 
after the radiotracer injection port, to provide an input function. The second detector was 
placed 4 cm from the heart. The third detector was positioned on the perfusion line after 
the heart, to monitor radioactivity in the coronary effluent. All of the detectors were 
shielded with a custom built 2 cm thick lead collimator. To allow detection of 
radioactivity in the heart a 2 cm diameter hole was drilled into the collimator, to expose 
the γ-detector. The perfusion line was threaded through holes drilled through the base of 
the other two collimators, and the detectors rested on the perfusion line. 
 
This completed our preliminary work, which had demonstrated the stability, sensitivity, 
and reproducibility of our purpose built radiotracer characterisation system. The 





Characterisation of  
64





5.1  Introduction 
After calibrating the heart perfusion apparatus, establishing exclusion criteria for isolated 
heart preparations, and assessing the sensitivity of the Gina Star™ γ-detector system, we 
began to utilise the triple detector array to characterise our library of Cu-BTSC 
complexes. This chapter will discuss why specific 
64
Cu-BTSC complexes were chosen, 
and how they performed during the characterisation experiments. The results of our 
experiments will then be compared to data from other groups, who have characterised 
Cu-BTSC complexes or other hypoxia selective tracers. 
 
5.1.1 Selection of Cu-BTSC Complexes for Characterisation 
The general structure of a Cu-BTSC complex is shown in figure 5.1, while table 5.1 
provides a summary of the 
64
Cu-BTSC complexes which we selected to further assess 
their hypoxia selectivity, and to evaluate them as myocardial hypoxia imaging agents. 
 
 




Table 5.1. Name, R1-4 –group substitution, and molecular weight and of Cu-BTSC complexes that 
were investigated during this study. Abbreviations: 2,3-butanedione bis(thiosemicarbazone) 
(ATS), Diacetyl bis(N4-ethlythiosemicarbazone) (ATSE), Diacetyl bis(N4-
methlythiosemicarbazone) (ATSM), 2,3-pentanedione bis(thiosemicarbazone) (CTS), 2,3-
pentanedione bis(N4-methylthiosemicarbazone) (CTSM), 3,4-hexanedione 
bis(thiosemicarbazone) (DTS), 3,4-hexanedione bis(N4-methylthiosemicarbazone) (DTSM), 
Pyruvaldehyde bis(N4ethylthiosemicarbazone) (PTSE), Pyruvaldehyde bis(N4-
methylthiosemicarbazone) (PTSM) 
 









ATSE CH3 CH3 C2H5 H 349.97 [208] 
 




CTS C2H5 CH3 H H 307.89 [162-163, 
167] 
 
CTSM C2H5 CH3 CH3 H 335.94 [162-163, 
167] 
 
DTS C2H5 C2H5 H H 321.91 [162-163, 
167] 
 
DTSM C2H5 C2H5 CH3 H 349.97 [162-163, 
167] 
 
PTSE CH3 H C2H5 H 335.94 [162-163, 
171] 
 







All novel Cu-BTSC complexes where chosen because Dearling et al [162-163, 167], and 
McQuade et al [208] have previously demonstrated that they display some degree of 
hypoxia selectivity, but to date none of the novel tracers have been assessed in cardiac 
tissue. Cu-PTSM has previously been shown to accumulate in myocardial tissue 
regardless of the intracellular oxygen status, and is widely regarded as a perfusion tracer 
[75-76] . It was therefore included in this study as a positive control. 
64
Cu-ATSM was 
included as the ‘gold standard’ hypoxia imaging tracer, against which all other 64Cu-
BTSCs would be compared. We also included 
64
CuCl2 as a negative control, as this is the 
form in which 
64
Cu is supplied for radiolabelling. 
 
5.1.2 Isolated Heart Perfusion and Tracer Administration 
5.1.2.1 Langendorff Isolated Heart Perfusion Protocol 
The application Langendorff perfused heart models for the characterisation of hypoxia 
imaging tracers is reasonably well reported, as discussed in Chapter 4. A variety of heart 
perfusion and tracer administration protocols have been employed. Studies with the 
nitroimidazole based tracers have generally used both low flow ischaemia, and/ or 
normal flow hypoxic buffer perfusion protocols [115-116, 127, 134, 151-152, 276]. The 
myocardial accumulation of 
62
Cu-PTSM was also evaluated using ischaemia, and 
hypoxia protocols [75]. The rationale for employing an ischaemia protocol is that it 
reflects most cardiac pathophysiologies that we are interested in imaging clinically. 
However to be able to directly compare radiotracer washout and retention under 
oxygenated or hypoxic conditions, it was advantageous to perfuse hearts at a constant 
flow rate. By negating the effects of flow on tracer accumulation (both with respect to 
delivery and washout), we could address whether 
64
Cu-BTSC retention is flow dependent 
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or due to hypoxia specificity alone. We therefore decided to employ hypoxia with a 
constant flow rate. 
 
5.1.2.2 Tracer Administration Protocol 
It was also important to identify the most appropriate method of tracer delivery. Both 
constant infusion and bolus delivery are conducive to assessing radiotracer performance. 
Constant infusion has often been employed for characterising nitroimidazole based 
tracers, because they demonstrate low single pass tissue accumulation. However, we and 
others [75, 174] have demonstrated that Cu-BTSC display rapid extraction from the 
perfusate, and high myocardial tissue accumulation using bolus administration. We 
therefore chose to employ the bolus method of tracer delivery for our experiments, as this 
is also more representative of the ultimate clinical application. 
 
5.1.3 Aims 
The purpose of these experiments was to assess how the structure of 
64
Cu-BTSC 
complexes affects their accumulation in cardiac tissue. To achieve this we determined the 
relative lipophilicity of our library of 
64
Cu-BTSC complexes, using radio-ITLC and 
octanol extraction, before characterising them using our isolated perfused heart model. In 
doing this we aimed to confirm whether these novel complexes (table 5.1) selectively 
accumulated in hypoxic cardiac tissue. The retention profiles of these radiotracers would 
then be compared to those of 
64
Cu-ATSM, to ascertain whether any of them performed 




5.2  Materials and Methods 
5.2.1 Synthesis of BTSC ligands and Confirmation of Structure 
All BTSC ligands were kindly provided by Prof. P Blower and Dr R. Paul (Dept. 
Imaging Sciences and Medical Engineering, King’s College, London). Ligands were 
synthesised as previously reported [172, 264].   
 
The molecular mass of each of the BTSC ligands was ascertained by Mr Levente 
Meszaros (Division of Imaging Sciences and Molecular Engineering, King’s College, 
London) using LC/MS as follows: the HPLC system was a 1200 system with degasser, 
quaternary pump, UV-visible variable wavelength detector, and an autosampler (Agilent, 
USA).  The mass spectrometer was a 6520 Accurate-Mass Q-TOF LC/MS (Agilent, 
USA).  Samples were acquired using Agilent Masshunter workstation acquisition 
software and data was analysed using Masshunter Qualitative analysis software (Agilent, 
USA).  
 
Dr Karen Shaw (Division of Imaging Sciences and Molecular Engineering, King’s 
College, London) confirmed the structure of each BTSC ligand by 
1
H NMR 
spectroscopy, using a Bruker widebore ultrashield plus with Avance III console operating 
at a 
1





xchannels (Bruker, Germany). Data were analysed using Topspin v2.1 software (Bruker, 
Germany). Key acquisition parameter were as follows: pulse sequence: zg30, number of 
scans (ns): 16, dummy scans (ds): 2, sweep width (swh):8223.685 Hz, Acquisition time: 
3.98 sec, D1: 1 sec 
1
H frequency: 399.47MHz, solvent: DMSO-d6. 
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5.2.2 Radiolabelling of Bis(thiosemicarbazone) Ligands with 
64
Cu 
Radiolabelling of all BTSC ligands with 
64
Cu was performed using a common protocol 
described in Section 3.2.3.1, using 40 MBq 
64
Cu for labelling. Once eluted from the Sep-
Pak column with 500 μl ethanol, stock solutions of 64Cu-BTSC complexes were then 
diluted to 10 MBq/ ml with mKHB. The radiolabelling efficiency was then assessed by 





Radio-ITLC was employed to monitor the stability of each of the 
64
Cu complexes over 
24 h, to determine whether the 
64
Cu-complexes remained stable throughout the course of 
a day’s experiments. Ligands were radiolabelled with 40 MBq 64Cu, according to the 
common protocol, and the volume was adjusted to 10MBq/ ml mKHB. Samples were 
then stored on the bench throughout the day, and in a refrigerator over-night. At 0, 1, 3, 6 
and 24 h, 2 µl aliquots were removed and assessed by radio-ITLC.   
 
5.2.4 Retention Factors of 
64
Cu-bis(thiosemicarbazones)  
Retention factor (Rf) values were obtained from radio-ITLC traces, and were used to 




 Rf values were calculated using data from radiolabelling quality control, and 
64
Cu 
complex stability experiments. These data were also obtained using the Laura (v. 




5.2.5  Partition Ratio of 
64
Cu-bis(thiosemicarbazones) 
The partition ratio of a substance also provides a quantitative index of hydrophilicity/ 
lipophilicity. Octanol extraction was employed to determine the partition ratio of the 
64
Cu-BTSC complexes. John and Green previously used a similar method when they 
assessed a library of 
67
Cu-BTSC complexes as perfusion tracers [171]. The partition ratio 
of the complexes was determined using both ultrapure water, and mKHB as the aqueous 
phase.  Ultrapure water is commonly used as the aqueous phase for octanol extraction 
experiments, and was therefore included to allow comparisons with data from other 
groups. Unlike water, mKHB is a physiological salt solution and this could potentially 
alter the partition ratio of Cu-BTSC complexes, relative to those obtained using water. 
An aqueous phase of mKHB was therefore also included as it is this solution that would 
deliver the 
64
Cu-BTSC complexes to the heart. 
 
500 µl ultrapure water or mKHB and 500 µl octanol were pipetted into three 2 ml vials. 
200 KBq (~20 μl) of each 64Cu-complex was added to separate vials. The vials were 
vortexed for 1 min and allowed to settle for 1 min. The vials were then centrifuged at 
3000 g for 5 min, to ensure complete separation of the organic and aqueous phases. 3x 
100 µl aliquots were then carefully removed from each of the layers, before the 
radioactivity in each of the fractions was measured by gamma well counting. This was 
repeated in triplicate for each 
64
Cu complex. Partition ratios were calculated using the 
equation: 




5.2.6 Characterisation of 
64
Cu-bis(thiosemicarbazones) in Isolated Perfused Rat 
Hearts 
The next stage in the characterisation of the 
64
Cu-BTSC complexes was to investigate 
their cardiac tissue clearance and tissue retention in isolated perfused rat hearts, using the 
triple γ-detector array.  
 
Hearts of male Wistar rats were excised, cannulated, and prepared for experiments, 
according the protocol described in section 4.2.4.2. Hearts were perfused with mKHB 
buffer gassed with 95 % O2/ 5% CO2, and allowed to stabilise for 20 min. During this 
time cardiac function (Heart rate, LVDP and LVEDP) and perfusion pressure were 
expected to remain within the range criteria that we had established in section 4.3.2. If 
these parameters were not attained during the stabilisation period the heart was 
discarded. Figure 5.2 provides a schematic representation of our experimental protocol.  
 
 
Figure 5.2. Schematic representation of the experimental protocol that was employed for the 
characterisation of 64Cu-BTSC clearance/ tissue retention, in isolated perfused rat hearts.  
 
 
In brief, at the end of a 20 min stabilisation period the experiments were initiated by 
administrating a 1 MBq bolus (100- 160 µl) of radiotracer, diluted in mKHB (10 MBq/ 
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ml). At 20 min the perfusate was switched to hypoxic buffer, which was achieved by 
gassing with 95% N2/ 5% CO2. This continued until the end of each experiment at 65 
min. A second bolus was administered at 25 min (5 min hypoxia), followed by a final 
bolus at 45 min (25 min hypoxia). 
 
5.2.6.1 Determining Percentage Tissue Retention of Radiotracers 
The retained fraction of each bolus of 
64
Cu-BTSC complexes was determined using a 
similar method to that employed by Fujibayashi et al [174].  
 
Background counts were recorded by the Gina data acquisition system before the start of 
each experiment. The initial background (iBkG) was determined by averaging the cps 
over 30 sec, just prior to the first injection. The iBkG was then subtracted from all 
subsequent measurements, and also served as the baseline cps for the first injection of 
radiotracer. For the second and third injections, by which time radioactivity had 
accumulated within the heart, the baseline was the sum of the iBkG and residual 
radioactivity (Rcps). Rcps was derived by averaging the number of counts recorded over 
1 sec (at a sample rate of 5 measurements/ sec) immediately before an injection of 
radiotracer, such that at 0 min Rcps was equal to iBKG. In order to determine the 
accumulated cps (Acps) at 20 min post-injection, measurements were again averaged 
over 1 sec. The tissue retention factor (TRF) was then calculated as follows:  
 
TRF = (Acps - iBkG)decay corrected - (Rcps – iBkG)decay corrected (eqn. 5.2) 
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Following each injection of radiotracer the decay counts that were registered increased 
rapidly. In order to determine the amount of tissue retention (TR) of each tracer, the five 
highest recorded cps measurements were averaged to obtain the mean peak cps (Pcps). 
Tissue retention was expressed as the percentage of each bolus that was retained in the 
heart, and was determined by the following equation: 
 
TR (%) = (100 / Pcps) × TRF      (eqn. 5.3) 
 
With the exception of iBKG, and Rcps at 0 min all data were corrected for decay. 
 
5.2.6.2 Lactate Release from Isolated Perfused Hearts 
The production and release of lactate from isolated perfused hearts was used as further 
index of cardiac hypoxia, as the heart switches from the β-oxidation of fatty acids to 
anaerobic glycolysis. For measuring the concentration of lactate in the coronary effluent 
a 2300 STAT Plus™ glucose and lactate analyser (YSI UK Ltd, UK), fitted with an 
immobilised L-lactate oxidase membrane was used (YSI 2329). L-lactate oxidase 
converts lactate to pyruvate and hydrogen peroxide. Hydrogen peroxide is then oxidised 




. The current produced by these electrons 
is proportional to the amount of lactate in the initial sample. 
 
At 0, 10, 20-25, 35, 45 55 and 65 min, 0.5 ml of the coronary effluent was collected. The 
analyser was first calibrated using 15 and 30 mMol/ l lactate standard solutions, before 
the concentration of lactate in the aliquots of coronary effluent was measured. 
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5.2.7 Data and Statistical Analysis 
Data analysis was performed using Microsoft Office Excel® 2007. Statistical analyses 
were performed using GraphPad Prism® (Version 5.04) (GraphPad Software Inc, USA). 
All values are expressed as the mean ± SD. A paired t-test was used for all pair-wise 
comparisons. For multiple tests a one way ANOVA with the Bonferroni correction was 
applied. The Dunnett’s post analysis test was applied when multiple comparisons were 




5.3  Results 
5.3.1 Stability of 
64
Cu-BTSC Complexes 
The stability of 
64
Cu-BTSC complexes was monitored over 24 h using radio-ITLC 
(figure 5.3). At 0 h the labelling efficiency for each of the BTSC ligands was greater than 
97 %. After 24 h the percentage of radiolabelled complex was greater than 96 % for all 
complexes, with the exception of 
64
Cu-ATSM which decreased to 94 %. However at 3 h 
the amount of
 64
Cu-ATS that was radiolabelled was to 92 %, and at 3 and 6 h post-
labelling 
64





Cu-PTSM and perhaps 
64
Cu-ATSM were possibly due to operator, when 
loading and running the samples. 
 
 
Figure 5.3. Stability of 64Cu- bis(thiosemicarbazone) complexes over 24 h determined by radio-





5.3.2 Physicochemical Properties of 
64
Cu-BTSC Complexes 
5.3.2.1 Retention Factor of 
64
Cu-BTSC Complexes Determined by Radio-ITLC 
All 
64




 remained at the 
origin (figure 5.4). The Rf values of each of the 
64
Cu-complexes were compared to that 
of 
64
Cu-ATSM (0.79 ± 0.01). Values for the 
64
Cu-complexes of: ATS (0.70 ± 0.001), 
PTSM (0.74 ± (0.01), CTS (0.78 ± 0.01), and DTS (0.78 ± 0.01) were lower, while those 
of PTSE (0.80 ± 0.01), CTSM (0.82 ± 0.01) and ATSE (0.83 ± 0.01) and DTSM (0.85 ± 




Figure 5.4. Retention factors of 64Cu-BTSC complexes, shown in order of increasing lipophilicity 
with 64CuCl2 included for comparison. Data were obtained by radio-ITLC and are expressed as 





Rf values were then plotted against the molecular weight of the corresponding 
64
Cu-
BTSC (figure 5.5). The results demonstrate that the relationship (R
2
= 0.87) between 
these two parameters. 
 
 
Figure 5.5. Retention factor of 64Cu-BTSC complexes plotted against corresponding molecular 






5.3.2.2 Partition Ratios of 
64
Cu-BTSC Complexes 
For conventional purposes logP values are summarised in table 5.2. Our values were 
similar to those reported by Dearling et al [162, 167].  
 
Table 5.2. LogP values of 64CuCl2 and 
64Cu-BTSC complexes, determined by octanol extraction, 
with an aqueous phase of either water or mKHB. Data represent mean (n= 3) ± SD.  
 
64Cu-Complex Log p  (Octanol/ Water) Log p (Octanol/ mKHB) 
64CuCl2 -1.52 ± 1.09 -1.86 ± 0.71 
ATS 0.88 ± 0.01 0.91 ± 0.01 
ATSE 1.86 ± 0.17 1.85 ± 0.13 
ATSM 1.69 ± 0.01 1.72 ± 0.11 
CTS 1.31 ± 0.14 1.45 ± 0.05 
CTSM 1.97 ± 0.04 1.94 ±0.06 
DTS 1.70 ± 0.07 1.77 ± 0.07 
DTSM 2.01 ± 0.17 2.02 ± 0.10 
PTSE 1.74 ± 0.21 1.68 ± 0.25 







Partition ratios were then used to compare the relative lipophilicity of the 
64
Cu-BTSC 
complexes, theses are summarised in table 5.3.  
 
Table 5.3. Partition ratios for 64CuCl2 and 
64Cu-BTSC complexes, determined by octanol 
extraction. An aqueous phase of either water or mKHB was used. Data represent mean (n= 3) ± 
SD.  
 
64Cu-Complex Partition Ratio (p)  
(Octanol/ Water) 
Partition Ratio (p) 
(Octanol/ mKHB) 
64CuCl2 0.17 ± 0.30 0.04 ± 0.04 
ATS 7.60 ± 0.17 8.19 ± 0.23 
ATSE 96.31 ± 14.81 90.75 ± 20.63 
ATSM 51. 68 ± 7.80 54.08 ± 14.62 
CTS 21.14 ± 6.42 28.10 ± 3.10 
CTSM 93.38 ± 7.55 88.38 ± 11.31 
DTS 50.68 ± 8.80 59.45 ± 10.39 
DTSM 116.33 ± 39.74 106.51 ± 24.97 
PTSE 65.25 ± 20.56 54.94 ± 26.79 





For each of the 
64
Cu-BTSC complexes the partition ratios that were obtained using water 
were compared to values obtained using mKHB (figure 5.6). The corresponding values 
were similar regardless of the aqueous phase that was used. The partition ratios for each 




Cu-Complexes of ATS, 
CTS, PTSM and DTS were less lipophilic, but those of PTSE, CTSM, ATSE and DTSM 




Figure 5.6. Partition ratio (octanol/ water or KHB) of 64CuCl2 and 
64Cu-BTSC complexes. Data 
are shown in order of increasing lipophilicity, and compare partition ratios obtained using water 






Partition ratios (octanol/ mKHB) were then plotted against the molecular weight of the 
corresponding 
64
Cu-BTSC complex (figure 5.7). A relationship (R
2
 = 0.80) was also 




Figure 5.7. Partition ratio (octanol/ KHB) plotted against the molecular weight of 
64
Cu-BTSC 
complexes. Data for partition ratios represent mean (n = 3). 
 
5.3.3 Parameters Recorded Throughout 
64
Cu-BTSC Characterisation in Isolated 
perfused Hearts 
During all of our 
64
Cu-BTSC characterisation experiments where isolated perfused hearts 
were employed, the pO2 of the perfusate, heart rate, LVDP, LVEDP and perfusion 
pressure were monitored in real-time. This was to ensure that cardiac function was within 
the range of the exclusion criteria established in section 4.3.2. However these parameters 
were also monitored to confirm that hearts received an adequate supply of oxygen during 




5.3.3.1 Partial Pressure of Oxygen of Coronary Perfusate 
The graphs presented in figure 5.8 demonstrate that the pO2 of the perfusate was 
measurable after 22 min (2 min hypoxia), and was in the range 92.4- 61.3 mmHg. At 25 
min, when the second bolus of tracer was administered, the buffer pO2 had decreased to 
between 31.5- 40 .6 mmHg. At 45 min, when the final bolus was administered, the pO2 
had further decreased to between 9.8 and 14.4 mmHg. By the end of the experiments at 
65 min the perfusate pO2 was between 6.6 and 10.2 mmHg. This was consistent and 





Figure 5.8. Partial pressure of dissolved oxygen in coronary perfusate during deoxygenated 
buffer perfusion. Values were measured using the OxyLab™ system. Values shown are from 22- 
65 min, as readings taken before this time were above the accurate measurement range of the 
oxygen sensor.   Data represent mean (n = 3 – 5) ± SD. 
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5.3.3.2 Release of Lactate from Isolated Perfused Rat Hearts 
From 0- 20 min the average concentration of lactate was 0.036- 0.078 mMol/ l. Within 1- 
2 min of switching to hypoxic mKHB the concentration of lactate increased significantly. 
The highest concentrations of lactate were observed at 21- 25 min (0.42- 1.01 mMol/ l). 
In all experiments the lactate concentration then steadily decreased up to 65 min (0.10- 
0.21 mMol/ l), but values were always higher than was observed when hearts were 






Figure 5.9. Concentration of lactate (mMol/ l) in coronary effluent, for all data sets. Data 




5.3.3.3 Coronary Perfusion Pressure 
During the stabilisation period and for the first 20 min of each experiment the coronary 
perfusion pressure was in the range 60- 80 mmHg. All hearts reacted similarly when the 
perfusate was switched to hypoxic mKHB at 20 min. There was a small decrease in 
perfusion pressure of between 4.3- 9.9 mmHg for the first 3- 4 min. Then from 24 - 65 
min the perfusion pressure steadily increased. At 65 min the average perfusion pressure 









5.3.3.4 Left Ventricular Developed Pressure 
Left ventricular developed pressure (LVDP) was calculated automatically by the 
LabChart® 7 (version 7.2) software package, as a function of the left ventricular systolic 
pressure minus left ventricular diastolic pressure. These data are shown in figure 5.11.  
 
Under oxygenated conditions the LVDP fluctuated slightly between each heart, and each 
data set. During the first 20 min LVDP for all hearts was in the range 130- 180 mmHg. 
The switch to deoxygenated mKHB perfusion was marked by a sharp decrease in LVDP 
for all data sets that continued until 25- 30 min. Between 30 and 35 min there was a 
slight recovery in LVDP for up to 5 min. However after this period the LVDP began to 
decrease once again, and this continued up until the experiments were terminated at 65 
min. During experiments with 
99M
Tc-Sestamibi the recovery phase was absent and the 




Figure 5.11. Left ventricular developed pressure for all data sets. Data represent mean (n = 3 – 




5.3.3.5 Left Ventricular End Diastolic Pressure 
During the stabilisation period and at the start of each experiment the LVEDP of all 
hearts was between 5 and 8 mmHg. By 20 min this average LVEDP for all data sets was 
in the range 4- 13 mmHg. Upon initiating hypoxia the LVEDP began to increase 
steadily, which continued until the end of each experiment. By 65 min LVEDP was 
markedly higher than the initial 5- 8 mmHg, with the LVEDP of all hearts in the range 
85- 136 mmHg (figure 5.12). 
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Figure 5.12. Average left ventricular end diastolic pressure (LVEDP) for all data sets. Data 
represent mean (n = 3 – 5) ± SD. 
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5.3.3.6 Heart Rate 
During normoxic perfusion the average heart rate for all data sets was 280- 300 BPM. 
After 1- 2 min of deoxygenated buffer perfusion, heart rate began to decrease rapidly. 
After 35 min, heart rate no longer responded to sinus rhythm and the heart began to 
fibrillate, causing large variation in the sampling values. For this reason only time points 






Figure 5.13. Heart rate (BPM) of all data sets over the first 35 min of each experiment. Data 




5.3.4 Characterisation of 
64
Cu-Complexes in Isolated Perfused Rat Hearts 
5.3.4.1 Triple γ-Detector Raw Data 
An example of a set of traces acquired using the triple γ-detector array, are shown in 
figure 5.14. All of these traces were acquired simultaneously and in real-time. 
Immediately after administrating 1 MBq of radiotracer into the perfusion line, the cps 
registered by detector 1 (arterial) began to increase rapidly. This was followed within 8 
sec by an increase in cps by detector 2 (heart), and 17 sec post-injection by detector 3 
(venous). Focusing on detector 2 and using 
64
Cu-ATSM as an example hypoxia avid 
tracer, a clear distinction can be made between tracer retention under oxygenated 





Figure 5.14. A typical set of time-activity curves from the Triple γ-detector array, displaying cps 
against time for the three Na/I γ-detectors. Acquired using the triple γ-detector array, Gina data 
acquisition and control interface, and produced by the Gina Star™ (v. 5.01) software package. 
Each peak represents a 1MBq bolus injection of 64Cu-ATSM, under oxygenated (injection 1) and 
deoxygenated (injections 2 and 3) conditions.  
 
 
The qualitative time—activity curves data that were obtained using the triple γ-detector 
array are shown in figure 5.15. Only traces obtained from detector 2 (heart) are 
displayed. From these curves we see that 
64
Cu-complexes of: ATS, ATSE, ASTM, CTS, 




Cu-PTSM were retained regardless of the oxygen status, while retention of the negative 
control 
64
CuCl2 was negligible under all conditions. However the perfusion tracer 
99m
Tc-
sestamibi accumulated in well oxygenated tissue, but eluted from hearts during hypoxia 







Figure 5.15. Example of time-activity curves that demonstrate the myocardial clearance/ 
accumulation of 64Cu-BTSC complexes, 64CuCl2 and 
99mTc. Regions highlighted in pink represent 
periods of oxygenated buffer perfusion, those shown blue represent perfusion with deoxygenated 
buffer.  Each peak represents the administration of a 1 MBq bolus of radiotracer .Curves were 






Cu-BTSC Accumulation in Isolated Perfused Rat Hearts 
5.3.4.2.1 Comparison between Oxygenated and Hypoxic Tissue Retention 
The initial qualitative observations made in section 5.2.1 were confirmed by manually 
analysing the time-activity data (available in a list form), that were recorded and stored 
by the Gina Star™ software. Figure 5.16 demonstrates the tissue retention of each tracer. 
Results were calculated as described in section 5.2.6.1, and expressed as a percentage of 
the total radioactivity injected (% ID). The accumulation of 
64
Cu-BTSC complexes are 




Figure 5.16. Percent retention of 64Cu-BTSC complexes, 64CuCl2, and 
99mTc-Sestamibi 20 min 
post-injection. Experiments were performed using isolated perfused rat hearts, under oxygenated 
conditions (red) and after 5 min (light blue) and 25 (dark blue) min hypoxia. Data represent 
mean (n = 3 – 5) ± SD. * = significantly different from control (normoxia) (p<0.05).  
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Cu-PTSM (complexes with a single 
methyl group on the di-imine backbone at the R
1
 position), displayed significantly higher 
tissue retention than 
64
Cu-ATSM, (p<0.05) with 54.5 ± 3.5 % ID and 63.6 ± 2.1 % ID 
respectively. Under hypoxic conditions the retained fraction increased to 86.2 ± 7.5 % ID 
and 90.1 ± 3.3 % ID after 5 min, and 90.1 ± 3.3 % ID and 89.5 % ID after 25 min, also 
respectively. 
 






Cu-BTSC complexes that were 




 positions displayed significantly different retention profiles. 
Under oxygenated condition the retention of these tracers ranged from 4.3 ± 0.7 % ID 
(
64
Cu-CTS) to 14.4 ± 1.4 % ID (
64
Cu-DTSM). However after 5 min hypoxia the retained 
fraction increased significantly to between 41.8 ± 5.7 % ID (
64
Cu-CTS) and 59.4 ± 5.5 % 
ID (
64
Cu-DTSM) (p<0.05). After 25 min hypoxia this increased further still, to between 
64.0 ± 11.65 ID (
64






CuCl2 in myocardial tissue was negligible regardless of the level of 
oxygenation. On average 0.9 ± 0.7 % ID was retained during normoxia. Under hypoxic 
conditions retention increased marginally, to 1.0 ± 0.4 % ID after 5 min, and 1.7 ± 0.7 % 
ID after 25 min. However the slight increase in the retention of 
64
CuCl2 was not 




Tc-Sestamibi an average of 15.8 ± 5.4 % ID was retained under oxygenated 
conditions. However under hypoxic conditions the retained fraction decreased 
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significantly to -1.5 ± 5.0 % ID after 5 min, and -5.2 ± 6.8 % ID after 25 min. 
99m
Tc-
Sestamibi therefore did not accumulate during hypoxia; moreover, the fraction that had 
previously been retained under oxygenated conditions eluted from the heart during 
hypoxia. 
 
5.3.4.2.2 Comparison of 
64
Cu-BTSC Accumulation after 5 and 25 Minutes Hypoxia 
When the tissue retention after 5 min hypoxia was compared to the corresponding 25 min 
values (figure 5.17), the accumulation of the 
64
Cu-complexes of ATS, ATSE, ATSM, 






Tc-Sestamibi, tissue retention values were similar at these times.  
 
 
Figure 5.17. Comparison of tissue retention after 5 and 25 min hypoxia. Tissue retention (% 
injected dose) of each tracer after 5 min hypoxia (light blue), are compared to the corresponding 
uptake values after 25 min (dark blue) hypoxia. Data represent mean (n = 3 – 5) ± SD. * = 





5.3.4.2.3 Comparison between the Retention of Novel 
64
Cu-BTSC Complexes and 
64
Cu-ATSM 
The tissue retention of 
64





positions (hypoxia selective) were compared to 
64
Cu-ATSM, under oxygenated 
conditions (Fig. 5.18), and after 5 min (Fig. 5.19) and 25 min (Fig. 5.20) hypoxia. Please 
note that in these figures the complexes are in order of increasing partition ratio (octanol/ 
mKHB). Under oxygenated conditions there was less accumulation of 
64
Cu-ATS (5.8 ± 
1.1 % ID), 
64
Cu-CTS (4.3 ± 5.7 % ID) and 
64
Cu-DTS (6.9 ± 0.8 % ID), compared to 
64
Cu-ATSM (8.0 ± 1.7 % ID). Conversely, accumulation of 
64
Cu-CTSM (11.9 ± 3.8 % 
ID), 
64
Cu-ATSE (11.4 ± 2.6 % ID), and 
64
Cu-DTSM (14.3 ± 1.4 % ID) was higher. 
However, the tissue retention values were only statistically significant for the 
64
Cu-
complexes of CTS, CTSM and DTSM (p<0.05) (figure 5.18). 
 
Figure 5.18. Comparison of tissue retention values for hypoxia selective 64Cu-BTSCs under 
oxygenated conditions. The tissue retention (% injected dose) of novel 64Cu-BTSC complexes that 
displayed hypoxia selectivity were compared to 64Cu-ATSM. Complexes are shown in order of 
increasing lipophilicity (octanol/ mKHB) Experiments were performed using isolated perfused 
hearts. Data represent mean (n = 3 – 5) ± SD. * = significantly different.  
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After 5 min hypoxia all novel 
64
Cu-BTSC complexes, with the exception of 
64
Cu-CTS 
(41.8 ± 5.7 % ID), demonstrated greater tissue retention compared to 
64
Cu-ATSM (48.9 
± 5.2 % ID). Values were as follows: 
64
Cu-ATS (54.2 ± 5.2 % ID), 
64
Cu-DTS (53.2 ± 
0.5.), 
64
Cu-CTSM (59.7 ± 3.2 %ID), 
64
Cu-ATSE (52.9 ± 6.2 % ID), and 
64
Cu-DTSM 









Figure 5.19. Comparison of the tissue retention values for hypoxia selective 64Cu-BTSC after 5 
min hypoxia. The tissue retention (% injected dose) of novel 64Cu-BTSC complexes that displayed 
hypoxia selectivity were compared to 64Cu-ATSM. Complexes are shown in order of increasing 
lipophilicity (octanol/ mKHB). Experiments were performed using isolated perfused hearts. Data 







After 25 min hypoxia the tissue retention values of all complexes were statistically 
comparable to that of 
64
Cu-ATSM (63.9 ± 11. 7 % ID). For each 
64
Cu-complex the 
retained fraction was as follows: ATS (78.2 ± 7.2 % ID), CTS (70.7 ± 14.5 % ID), DTS 
(72.1 ± 3.2 % ID), CTSM (71.2 ± 7.1 % ID), ATSE (67.0 ± 8.9 % ID), and DTSM (68.2 
± 11.6 % ID) (figure 5.20).  
 
 
Figure 5.20. Comparison of the tissue retention values for hypoxia selective 64Cu-BTSC after 25 
min hypoxia. The tissue retention (% injected dose) of novel 64Cu-BTSC complexes that displayed 
hypoxia selectivity were compared to 64Cu-ATSM. Complexes are shown in order of increasing 
lipophilicity (octanol/ mKHB). Experiments were performed using isolated perfused hearts. Data 
represent mean (n = 3 – 5) ± SD. * = significantly different (p<0.05).  
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5.3.4.2.4 Contrast between Hypoxic and Oxygenated Tissue Retention 
The hypoxic to normoxic tissue retention ratios of 
64
Cu-BTSC complexes are 
summarised in table 5.4, and shown in figure 5.21. The 
64
Cu-complexes of PTSE and 










Cu-CTS displayed significantly higher hypoxic tissue retention 
ratios (p<0.05).  
 
Table 5.4. Hypoxic to normoxic tissue retention ratios of 64Cu-complexes. Data represent mean 
(n = 3 – 5) ± SD. * denotes significantly different from 64Cu-ATSM. 
 
Ligand 5 min Hypoxia 25 min Hypoxia 
ATS *9.5 ± 1.7 *13.9 ±3.6 
ATSE 4.9 ± 1.1 6.1 ± 1.5 
ATSM 6.2 ± 1.2 8.2 ± 2.0 
CTS *9.8 ± 1.6 *16.6 ± 2.9 
CTSM 5.5 ± 2.0 6.5 ± 2.1 
DTS 8.2 ± 2.7 11.5 ± 4.8 
DTSM 4.2 ± 0.4 4.8 ± 1.1 
PTSE *1.6 ± 0.2 *1.7 ± 0.1 





Figure 5.21. Contrast between the tissue retention of 64Cu-BTSC complexes under oxygenated 
and hypoxic conditions. Ratios are for injections administered after 5 (light blue) and 25 min 
(dark blue) hypoxic buffer perfusion. A comparison was made between 64Cu-ATSM and all other 
64Cu-BTSCs, at 5 and 25 min post- hypoxia. Complexes are shown in order of increasing 
lipophilicity (octanol/ mKHB). Data represent mean ± SD. * = significantly different (p = 0.05). 
 
5.3.4.2.5 Comparison between 
64
Cu-BTSC Molecular Weight, Partition Ratio, and 
Tissue Retention 
In this section the results demonstrated thus far will be compared graphically, to ascertain 
whether there are any relationships between the physicochemical properties and 
accumulation of the 
64
Cu-BTSC complexes, which demonstrated a hypoxic to normoxic 
tissue retention ratio of greater than 3: 1. 
 
Under oxygenated conditions a positive relationship (R
2
= 0.81) was observed between 
the molecular weight of 
64
Cu-BTSC complexes, and the amount of radiotracer that was 
retained within the heart. However during hypoxia these parameters did not correlate. R
2
 





Figure 5.22. Comparison between the molecular weight and tissue retention (% injected dose) of 
hypoxia selective 64Cu-BTSC complexes during normoxia, and after 5 min, and 25 min hypoxia. 





Under oxygenated conditions there was a positive relationship (R
2
 = 0.84) between the 
partition ratio and tissue retention of this class of tracers (figure 5.23). However after 5 
min (R
2
 = 0.41), and 25 min hypoxia (R
2
 = 0.29) no relationship was observed between 
these parameters (figure 5.23). 
 
 
Figure 5.23. Comparison between the partition ratio (octanol/ mKHB) and tissue retention (% 
injected dose) of hypoxia selective 64Cu-BTSC complexes during normoxia, and after 5 min and 






A relationship was observed between the hypoxic to normoxic tissue retention ratios and 
the molecular weight of the corresponding 
64
Cu-BTSC complex, with R
2
 values of 0.87 




Figure 5.24. Comparison between the hypoxic to normoxic tissue retention ratio and molecular 
weight of hypoxia selective 64Cu-BTSC complexes after 5 min, and 25 min hypoxia. Data 
represent mean (n= 3 – 5). 
 
A relationship was also observed between the hypoxic to normoxic tissue retention ratios 
and the molecular weight of the corresponding Cu-BTSC complex, with R
2
 values of 





Figure 5.25. Comparison between the hypoxic to normoxic tissue retention ratio and partition 
ratio (octanol/ mKHB) of hypoxia selective 64Cu-BTSC after 5 min, and 25 min hypoxia. Data 
represent mean (n= 3 – 5). 
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5.4  Discussion and Conclusions 
5.4.1 BTSC Radiolabelling efficiency and
 64
Cu-Complex Stability 
The radiolabelling efficiency of all BTSC ligands was always greater than 97%. In a 
solution of mKHB the radiolabelled complexes displayed a high degree of stability over 
24 h (figure 5.3). With the exception of 
64
Cu-ATSM (94 % radiolabelled), less than 4 % 
free 
64
Cu was present in each of the tracer stocks at 24 h. It was therefore decided that 
complexes that were radiolabelled in the morning could be used for the entire day’s 
experiments. 
 
5.4.2 Retention Factor of 
64
Cu-BTSC 
Rf values were determined to ascertain how the alkylation pattern of a particular ligand 
affects the relative lipophilicity of the corresponding 
64
Cu-complex. The values that we 
obtained were somewhat higher than those reported by Dearling et al [162, 167], which 
is likely due to the fact that they used ethyl acetate as the mobile phase, while we 
employed ethanol. However, although the solvent phase and therefore the actual Rf 
values reported here are higher than previously reported values, the relative order of 
lipophilicity is comparable (Fig. 5.4), and we also observed a positive relationship (R
2
= 
0.87) between molecular weight and the Rf values of the Cu-complexes (figure 5.5).    
 
 
5.4.3 LogP Values and Partition Ratios 
Octanol extraction was also employed to assess the relative lipophilicity of 
64
Cu-BTSC 
complexes, in order to allow us to draw comparisons with data from Dearling et al [162, 
167] and McQuade et al [208]. When ultrapure water was used as the aqueous phase, the 
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logP values that we obtained (table 5.2) were similar to those previously reported. We 
then replaced water with aqueous phase of mKHB, to assess whether this would have an 
effect on the partition ratio, or relative lipophilicity of the complexes. The values were 
largely unaffected (table 5.3 and figure 5.6), and we again observed a positive 
relationship (R
2
= 0.80), between the molecular weight of the 
64
Cu-BTSC complexes and 
their partition ratios (octanol/ mKHB) (figure 5.7). 
 
5.4.4 Perfusate pO2, Cardiac Function and Lactate Release 
The Oxylab pO2™ system and oxygen probes are extremely sensitive, but the 
measurement range is limited to pO2 ≤ 100mmHg. In a personal communication, a 
representative of the manufacturer stated that the Oxylab™ system can detect and 
measure up to a pO2 of 150 mmHg, but when 100 mmHg is exceeded the error can be as 
much as ± 15 %. The pO2 of oxygenated KHB typically exceeds 500 mmHg [283], in 
excess of the Oxylab pO2™’s operating range. Measurements of buffer oxygen saturation 
were therefore only taken upon commencement of gassing with anoxic gas mixtures. 
After switching to hypoxic buffer the decrease pO2 was biphasic. The initial rapid phase 
lasted ~5 min, before it slowed. However, the pO2 continued to decrease for the duration 
each experiment (figure 5.8).   
 
At the start of each experiment, cardiac function and perfusion pressure were within the 
ranges defined in section 4.3.2. These parameters then remained stable for the 20 min of 
oxygenated buffer perfusion, which followed the first injection of radiotracer (figures 
5.10- 5.13). During this time the efflux of lactate into the coronary effluent was stable, at 
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a concentration of between 0.036- 0.078 mMol/ l (figure 5.9). Cardiac function was 
therefore considered normal while hearts were perfused with oxygenated mKHB.  
 
Within 2 min of switching perfusion to hypoxic mKHB, the buffer pO2 fell to within the 
detection range of the Oxylab pO2™ (92.4- 61.3 mmHg) (figure 5.8). However, after just 
1 min of commencing perfusion with hypoxic mKHB, LVDP (figure 5.11) and heart rate 
(figure 5.13) began to decrease, and LVEDP (figure 5.12) and lactate efflux (figure 5.9) 
began to rise. The rise in lactate release demonstrated that by perfusing the hearts with 
hypoxic buffer they lost the capacity to metabolise energy substrates via the electron 
transport chain, and upregulated their metabolism of glucose via anaerobic glycolysis. 
Contractility concomitantly decreased because glycolysis alone cannot supply enough 
ATP to maintain cardiac contractility, as discussed in sections 1.4.3 and 1.5. 
 
From the onset of hypoxia LVEDP (figure 5.12) gradually increased, but heart rate 
continuously decreased. Conversely LVDP initially decreased for all hearts (except 
inexplicably those that were administered with 
99m
Tc-Sestamibi). There was a brief 
recovery in LVDP which occurred after 5- 10 min perfusion with hypoxic mKHB, and 
which lasted between 1- 10 min. In general, other researchers who have also 
characterised hypoxia tracers have not included cardiac function data in their reports, as 
we did. We are therefore unaware of whether they observed a similar recovery in cardiac 
function during their hypoxia protocols. However, Kusuoka et al also observed a 
decrease in LVDP and a rise in LVEDP in isolated rat hearts subject to hypoxia [115]. In 
a more recent study Suner and Jay compared the effects on cardiac function of hypoxia 
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and carbon monoxide poisoning, using isolated perfused hearts [284]. They also 
observed a decrease in LVDP and heart rate, and a rise in LVEDP and lactate release. 
However, they did not observe a recovery of LVDP during their hypoxia protocol 
(perfusion with KHB gassed with 30 % N2 70 % O2, for 15 min). While the period of 
hypoxia employed by Sun and Jay was longer than the time-frame within which we 
observed a recovery of LVDP, neither they or other researchers have observed this [284-
286]. In contrast to our experiments, others have generally paced hearts using an 
externally applied electrical stimulus. We on the other hand did not use pacing, and 
therefore contractility was allowed to match the delivery of oxygen, at least in the early 
stages of hypoxia. We postulate that the brief period of recovery of LVDP was due to a 
transient recovery of ATP, following the rapid cessation of contractility that occurred 
immediately upon perfusing hearts with hypoxic buffer. This overshoot perhaps led to a 
temporary ATP surplus, which allowed a short functional recovery before metabolism 
and contractility became more closely matched, and the decline in contractile function 
resumed. 
 
Heart rate began to decrease from the onset of hypoxia, and after just 15 min hearts 
began to fibrillate and all contractility effectively ceased, which led to large variations in 
the average heart rate interpreted by the PowerLab™ system, between each replicate. We 
therefore omitted all measurements of heart rate that were recorded after 15 min hypoxia 




Although it was not possible to measure the intracellular pO2 of cardiac cells during 
tracer characterisation experiments, the results presented in section 5.3.3 demonstrate 
that the hearts were severely oxygen deprived. Significant decreases in heart rate and 
LVDP, and increases in perfusion pressure, LVEDP, and lactate release all serve to 
confirm this. Our observations of cardiac function, coronary perfusion pressure, and 
lactate release are in accordance with those of Serizawa et al, who investigated the 
effects of 3 min ischaemia or hypoxia on left ventricular relaxation time and diastolic 
stiffness [287]. They demonstrated that in isolated rabbit hearts subject to low flow 
ischaemia (~35 % normal flow) for 3 min, LVDP, LVEDP, and coronary perfusion 
pressure decreased, but efflux of lactate into the coronary perfusate increased. However, 
while ischaemia caused a decrease in LVEDP, it increased during hypoxia, which we 
also observed. Similarly we observed a slight decline in the coronary perfusion pressure 
after switching to hypoxic buffer, which lasted for between 2- 4 min, before it then began 
to rise. The authors suggested that the initial decline in perfusion pressure was due to 
coronary vasodilation, to counteract decreased oxygen delivery. Of particular interest and 
relevance to our study is the fact that they observed an increase in LVEDP during 
hypoxia, but not during low flow ischaemia. Serizawa et al also observed ~4-fold 
increase in the diastolic relaxation time and incomplete relaxation of the myocardial 
contractile apparatus, which they suggested caused a rise in LVEDP in hypoxic hearts. 
They proposed that this occurred because the sarcoplasmic reticulum became saturated 
with Ca
2+
, but that there was still sufficient Ca
2+ 
within the cytosol to prevent complete 
relaxation. However, during ischaemia the effect of this is somewhat masked by the loss 
of coronary turgor pressure. This agrees with observations made by Kihara et al, who 
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demonstrated that the cytoplasmic concentration of Ca
2+
 increases during hypoxia [285]. 
While this explains why in our experiments LVEDP rose during hypoxia, it also 
highlights how more physiologically relevant ischaemia protocols differ from hypoxic 
buffer perfusion. As we already discussed in section 5.1.2.1, we chose to use a hypoxic 
buffer to confirm that the retention of our complexes was due to hypoxia alone, 
maintaining constant flow perfusion to avoid variations in the rate of tracer delivery, 
which would interfere with modelling of our tracer time-activity curves. Our 
observations were similar to those of Serizawa et al, although we exposed hearts to 
hypoxia for considerably more time (45 min compared 2 min). Furthermore, Wardle et al 
exposed isolated rat hearts to hypoxia for 30 min and also observed a marked increase in 
the release of lactate from hearts [288], with profiles similar to our own. Our own data in 
conjunction with data from these other studies provide supportive evidence that the 
hearts used in our experiments were severely oxygen deprived when perfused with 
hypoxic mKHB.  
 
Finally, we are aware that the extremely low level of hypoxia that we employed during 
our experiments may not necessarily reflect that which is observed in vivo. This series of 
experiments was a screening process, which was conducted to identify candidate tracers 
which shall be taken forward into a more in depth study, where we will first determine 
the level of oxygenation that is clinically relevant. This will be done using 
31
P NMR to 
measure transitions in cardiac ATP levels, and tracer retention will then be determined at 
these levels of oxygenation. We will discuss these future experiments in Chapter 6. 
While we measured cardiac function during our tracer washout/ accumulation 
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experiments we did not determine myocardial viability, for example by tissue sectioning 
and staining or by measuring cardiac function upon reoxygenation. We are therefore 
unaware of whether there was tissue infarction or necrosis during hypoxia. However as 
discussed in Chapter 1, Cu-BTSC complexes are only retained in cells that are able to 
synthesise the bioreductants necessary for tracer trapping. We therefore concluded by 
inference, that while the hearts were severely oxygen deprived during hypoxia, and some 
degree of infarction may have been present in the tissue, the majority of the myocardium 
must still have been viable. This is because the retention of all 
64
Cu-BTSC increased 
following the switch to hypoxic buffer perfusion. Furthermore, tracer retention was 
always greater after 25 min hypoxia compared values obtained at 5 min. 
 
5.4.5 Characterisation of 
64
Cu-BTSC complexes in Isolated Perfused Rat Hearts 
While not able to provide quantitative data regarding tracer washout/ retention, the time-
activity curves from hearts (figure 5.15) were able to indicate whether a tracer displayed 
hypoxia selectivity. From these traces it is clear that 
64
CuCl2, which was used as a 
negative control, demonstrated negligible accumulation under both normoxia and 
hypoxia. 
64
Cu-PTSM has previously been reported as a potential perfusion agent, for 
monitoring myocardial and cerebral blood flow because it is retained in tissue 




Cu-PTSM, both of which are protonated at the R
2
 position, displayed 
significant tissue accumulation under oxygenated conditions. In contrast, the time 
activity curves for the 
64
Cu complexes of ATS, ATSE, ATSM, CTS, CTSM, DTS and 




By manually analysing the time-activity curve raw data, using the method described in 
Section 5.2, it was possible determine the actual tissue retention of each tracer. The tissue 
retention values (figure 5.16) proved that the initial observations of the real-time time-
activity curves were correct, but also allowed us to quantify tracer retention. 
 
When using the bolus method of tracer delivery it is important to obtain a true peak in the 
decay counts emitted from the heart [134]. Otherwise because of the rapid kinetics that 
these tracers display, their retention within the myocardium as a percentage of the 
injected dose cannot be accurately determined. In our experiments the Gina Star™ 
system was set up to acquire cps measurements every 0.2 seconds, which is considerably 
higher than the sampling rates of 1 sample/ sec used by Ng et al [134], and 1 sample/ 5 
sec used by Rumsey et al [132]. To ensure that the Gina Star™ system was able to detect 
the peak counts we considered the time-activity curves of 
64
CuCl2. This tracer cleared 
from the heart faster than any of the 
64
Cu-BTSC complexes. It was therefore rational to 
assume that if the Gina Star system could detect a true peak for 
64
CuCl2, then it would be 
able to do so for the 
64
Cu-BTSC complexes. Upon injecting 
64
CuCl2 into the perfusion 
line the decay counts registered from the heart (detector 2) began to increase, and the cps 
peaked after ~3 sec. The majority if not all of the bolus had therefore entered the heart 
within this time. The cps peak was also very sharp, lasting only 1 sec before the counts 
began to fall, reflecting the rapidity with which the tracer then distributed through the 
coronary vasculature. If 
64
CuCl2 had entered the heart at a slower rate then one would 
perhaps have expected the cps gradually increase over time before reaching a plateau, as 
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the concentration of radiotracer entering the heart would equal that which was eluting 
from it, before it began to decrease. The total time taken for the counts to go from the 
background level, up to maximum counts, and then back down once again to a steady 
state was ~27 sec, after 
64
CuCl2 first entered the heart. As the majority if not all of the 
radioactivity had entered the heart within ~3 sec, and because it took ~27 sec for a bolus 
of 
64
CuCl2 to completely pass through the heart, we can be confident that the Gina Star™ 
system was able to detect the true cps peak, especially considering the rate at which 
measurements were acquired. We were therefore also confident that our calculations of 
percentage tissue retention were accurate.   
 





Tc-Sestamibi is SPECT imaging tracer that is used to assess myocardial perfusion.  It 
is a lipophilic cation that passively diffuses into cells, and accumulates within the 
mitochondrial matrix. As 
99m
Tc-Sestamibi is positively charged it is only retained in the 
negatively charged matrix of mitochondria with an active electron transport chain. 
99M
Tc-
Sestamibi is therefore used clinically as a negative contrast imaging agent that 
accumulates within normally perfused tissue, but is not retained in regions of the 
myocardium where blood or oxygen is supply is restricted. In our experimental model of 
hypoxia with constant flow, loss of 
99m
Tc-Sestamibi retention in the myocardium cannot 
be due to lack of tracer delivery, must be due to a loss of mitochondrial membrane 
potential [289]. For this reason 
99m
Tc-Sestamibi retention was used in conjunction with 
measurements of the perfusion buffer pO2 and lactate release, to demonstrate that hearts 
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were subjected to severe oxygen deprivation during hypoxia. 
99m
Tc-Sestamibi 
accumulated in hearts perfused with oxygenated mKHB but cleared from those perfused 
with hypoxic buffer. It is interesting to note that the rate of washout of the bolus that was 
administered during early hypoxia was higher than observed during normoxia. Even at 
this early hypoxia time point, it seems that the mitochondrial membrane potential is 
compromised. From this point on the myocardium seems unable to retain 
99m
Tc-
Sestamibi, and there was even washout of tracer that was originally retained during 






CuCl2 is the form in which 
64
Cu(II) is supplied for radiolabelling, it has also been 
employed previously as a negative control during 
64
Cu-BTSC characterisation studies 
[162]. We therefore also included 
64
CuCl2 in this study as a negative control. In an 
aqueous solution 
64










 is unable to passively diffuse across cell membranes. It should not therefore be 
able accumulate within hearts to the same degree as the lipophilic Cu-BTSC complexes. 




 it should be independent of the 
level of oxygenation. As discussed previously, in our experiments a bolus of 
64
CuCl2 
passed through the heart in ~27 sec, which suggests that the tracer does not get taken up 
by cells, but rather it passes directly through the coronary vasculature, and elutes from 










 was 2-fold higher after 25 min hypoxia, compared to normoxic 
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retention. The reason for this is unknown, but it is feasible that during hypoxia the 
biological mechanisms responsible for importing copper into the heart may be 
upregulated. It also feasible that prolonged exposure to hypoxia may have led to damage 
being caused to the membranes of cells with the heart. This may have caused some 




 to enter the 




 compared to the 
64
Cu-BTSCs suggests that copper is not removed from the complex, and then transported 
into the cells via a receptor or transporter protein mediated mechanism, but rather that it 
is the ligand that is responsible for transporting copper moiety through the cell membrane 






Cu-PTSM has previously been investigated as a perfusion agent, for monitoring 
myocardial, cerebral [73, 75, 165, 170] and renal [76, 291] blood flow. It has been 
proposed that its relatively low redox potential (-0.51 V) compared to Cu-ATSM (-0.59 
V), allows the intracellular reduction of Cu(II)-PTSM to Cu(I)-PTSM in normoxic tissue. 
This in turn leads to the dissociation of the complex, and the intracellular accumulation 
of radiocopper [165]. 
 
In our study the single pass extraction of
 64
Cu-PTSM under oxygenated conditions was 
63.6 % ± 2.1 % ID. During hypoxia this increased significantly to 82.7 ± 5.7 % ID and 
89.5 ± 5.2 % ID, after 5 min and 25 min hypoxia respectively. However while 
64
Cu-
PTSM accumulation increased during hypoxia, the maximum hypoxic to normoxic tissue 
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contrast was only 1.4: 1, which as other have suggested precludes the use of 
64
Cu-PTSM 
as a hypoxia imaging agent. The tissue retention values that we obtained for 
64
Cu-PTSM 
are higher than those reported by Shelton et al, as they did not observe any difference in 
retention between oxygenated and hypoxic conditions [75]. Using isolated perfused 
rabbit hearts Shelton et al characterised 
67
Cu-PTSM under a variety of conditions. The 
tracer was administered as a bolus during ischaemia (10 % control flow) (46 % ID), 
hypoxia (perfusion without erythrocytes) (49 % ID), and hyperaemia (200 % control 
flow) (51 % ID), but under each of these conditions the fraction of tracer that was 
retained was comparable to normally perfused control hearts (48 % ID). There are two 
possible explanations for this. Firstly, the method that we used for initiating and 
maintaining hypoxia, may have been more severe than that employed by Shelton et al. 
Secondly, we used much smaller hearts and perfused them at a higher flow rate. Instead 
of gassing the perfusion buffer as we did, Shelton et al chose to use isolated erythrocytes 
to deliver oxygen to the hearts, and during their hypoxia protocol they simply omitted 
erythrocytes from the perfusate. We on the other hand continually gassed the perfusion 
buffer with either an oxygenated or anoxic gas mixture. As the results in figure 5.8 show, 
after perfusing hearts with hypoxic buffer for 45 min the pO2 of mKHB dropped to 
between 10 -15 mmHg. Furthermore, in a set of preliminary experiments we attempted to 
measure the pO2 of non-gassed mKHB but it was still above 150 mmHg, too high to be 
measured using the Oxylab pO2™ system. Is it therefore likely the ‘hypoxic’ buffer used 
by Shelton et al had a higher pO2 than our corresponding buffer. As our data shows, 
while 
64
Cu-PTSM is not hypoxia selective its accumulation within the heart certainly 
appears to be oxygen sensitive, with the retention profile of 
64
Cu-PTSM inversely related 
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to the pO2 of the perfusion buffer. Shelton et al used hearts from rabbits (1.5- 2.0 kg) 
which would have been considerably larger hearts than the rat hearts that we used in our 
study. However, this group perfused hearts at only 6 ml/ min, whereas we perfused at 14 
ml/ min. It is therefore feasible that although the hearts used by Shelton’s group were 
perfused with erythrocytes, even the control hearts may not have been sufficiently 
oxygenated. Unfortunately this group did not report the concentration of erythrocytes in 
their perfusion buffer, but it is likely to have been lower than the in vivo concentration. 
This combined with a relatively low flow rate is perhaps why they did not observe a 
contrast between control and test conditions.  
 
Results from Dearling et al have also suggested that the accumulation of 
64
Cu-PTSM 
may be sensitive to the level of oxygenation, as they observed an hypoxic to normoxic 
contrast of ~1.3: 1 using CHO cells [162]. As both Dearling’s group and our own have 
observed oxygen level-dependent retention of Cu-PTSM, it suggests that once inside the 
cell the tracer may be more stable than previously thought. Minkel et al [173] and 
Fujibayashi et al [169, 174] have suggested that Cu-PTSM dissociates even in normoxic 
cells. However both our own and Dearling et al’s data suggest that the intracellular 
bioreduction of Cu-PTSM may be reversible in the presence of oxygen, as is thought to 
occur with Cu-ATSM, otherwise we would also have observed a hypoxic to normoxic 
contrast of 1: 1. While this is an interesting observation, the contrast for 
64
Cu-PTSM is 
still insufficient for delineating hypoxic tissue, and Cu-PTSM should still only be 







Our data show that the time-activity curves and therefore myocardial accumulation of 
64
Cu-PTSE were similar to those of 
64
Cu-PTSM. Under oxygenated conditions 54.5 ± 3.5 
% ID was retained, which rose to 86.2 ± 7.5 % ID after 5 min hypoxia, and 90.9 ± 3.3 % 
ID after 25 min. 
64
Cu-PTSE was first described and investigated as a perfusion tracer by 
John and Green [171], before being studied further as a hypoxia tracer by Dearling et al, 
using CHO and EMT6 tumour cells [162-163, 167]. Dearling and co-workers observed 
low hypoxic to normoxic tissue contrast of ~1.3: 1 with 
64
Cu-PTSE. However, when they 
employed a mathematical model termed the ‘hypoxia selectivity index (HSI)’, which 
compared the logarithm of the intracellular to extracellular concentration of radiotracers, 
under oxygenated and hypoxic conditions [163, 167], they showed that Cu-PTSE 
displayed some degree of hypoxia selectivity. In fact when the mean HSI 5- 60 min was 
plotted against redox potential, the HSI of Cu-PTSE (~0.45) was comparable to Cu-
ATSM and the other novel Cu-BTSC complexes that we have assessed. However, by 
using isolated hearts to assess the single pass extraction of 
64
Cu-PTSE in oxygenated or 
hypoxic tissue, we have shown that although the accumulation of this tracer appears to be 
oxygen sensitive it is poorly hypoxia selective, much like Cu-PTSM. This is not 
surprising considering that the redox potential of Cu-PTSE (-0.52 V) is similar to that of 
Cu-PTSM (-0.51 V) [167]. We can therefore confirm that because of its high uptake in 
normoxic tissue, and low hypoxic to normoxic tissue contrast (1.7: 1), 
64
Cu-PTSE is not 
















 positions, and demonstrated very different tissue retention profiles from 
the tracers that have already been discussed. 
 
Under oxygenated conditions the retention of the 
64
Cu complexes of ATS, ATSE, 
ATSM, CTS, CTSM, DTS, and DTSM was between 4.3- 14.3 % ID. 
64
Cu-CTS (4.3 ± 
5.7 % ID) demonstrated significantly lower retention than 
64
Cu-ATSM (8.0 ± 1.7 % ID), 
while the accumulation of 
64
Cu-CTSM (11.9 ± 3.8 % ID) and 
64
Cu-DTSM (14.3 ± 1.4 % 
ID) was significantly higher (p<0.05). The tissue retention values for all other tracers 
were comparable to that of 
64
Cu-ATSM. Following the switch from oxygenated to 
hypoxic buffer, a 38- 49 % increase in tissue retention was observed for the 
64
Cu-
complexes of ATS, ATSE, ATSM, CTS, CTSM, DTS and DTSM compared to normoxic 
values. With the exception of the 
64
Cu-DTSM (59.3 ± 5.5% ID) and 
64
Cu-CTSM (59.7 ± 
3.2 % ID), after 5 min hypoxia the tissue retention of all other tracers was statistically 
comparable to 
64
Cu-ATSM (48.9 ± 5.2 % ID). After 25 min hypoxia, the tissue retention 
values of all of these complexes increases by a further 9- 24 % ID. However, at this late 




After 5 min hypoxia the significant increase in tissue retention of these tracers, gave rise 
to hypoxic to normoxic tissue contrast ratios of between 4.2: 1 (
64
Cu-DTSM) and 9.8: 1 
(
64
Cu-CTS), with a ratio of 6.2: 1 for 
64
Cu-ATSM. Interestingly the contrast ratio for 
64
Cu-ATS (9.5: 1) was also higher than that of 
64
Cu-ATSM. After 25 min hypoxia the 
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contrast was greater still. A ratio of 4.8: 1 was observed for 
64
Cu -DTSM, 13.9: 1 for 
64
Cu-ATS and 16.6: 1 for 
64
Cu-CTS, with a ratio of 8.2: 1 for 
64
Cu-ATSM. In this study 




 positions demonstrated 
hypoxia selectivity. Furthermore, all of them displayed hypoxic to normoxic tissue 
retention ratios of greater than 3: 1, which Nunn et al suggested was the minimum 





Cu-CTS, which demonstrated lower accumulation in 
oxygenated tissue, and significantly greater hypoxic to normoxic tissue contrast 
compared to the current “gold standard” tracer 64Cu-ATSM.  
 
In terms of how these data fit in with previous reports there is much to compare and 
contrast, and a discussion of the hypoxia selective radiotracers should begin with the lead 
compound Cu-ATSM.   This tracer was introduced by Wada et al in 1994 [205], and 
since then reports have shown that Cu-ATSM displays selective retention in isolated 
hearts [174], and cells [162-163, 167, 209, 241] exposed to hypoxic conditions. As we 
have demonstrated, our data from this study concur with these reports. 
 
Fujibayashi and co-workers were the first group to demonstrate the hypoxia selectivity of 
62
Cu-ATSM, also employing the isolated perfused rat heart model [174]. They observed 
20 % retention of the injected dose under normoxic conditions, but more than 80 % 
during hypoxia. Their normoxic value is a slightly higher than we observed in our study 
(8.0 ± 1.5 % ID), but during hypoxia our value was slightly lower (64.0 ± 11.7 % ID). 
Nonetheless in our study the hypoxic to normoxic contrast was 8.2: 1, which was higher 
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than the 4: 1 ratio observed by Fujibayashi [174]. This was mostly likely due to fact that 
the hearts used by the Fujibayashi group were excised from larger animals (350- 450 g) 
than those that we used (250- 300 g), and theirs were perfused at a lower flow rate of 6 
ml/ ml, in contrast to 14ml /min that we used. The 14 ml/ min flow rate that we 
employed ensured that the coronary perfusion pressure was ~70 mmHg, comparable to 
the aortic pressure in vivo. For a larger heart the flow rate required to achieve this 
pressure would be even higher. It is therefore likely that at 6ml/ min their larger hearts 
were under perfused and on the cusp of low flow ischaemia, even in their control group. 
This may explain why the control tissue retention values were greater than we observed 
in our study. Unfortunately the authors did not provide any data regarding the pO2 of the 
perfusion buffer or contractile function data, so we were unable to compare these 
parameters. 
 
One of purposes of conducting this research was to further characterise a number of 
novel Cu-BTSC complexes, which have previously demonstrated hypoxia selectivity, but 
which are at the moment poorly represented in the scientific literature. Studies by 
Dearling et al were the first to report on the screening of these novel 
64
Cu-labelled BTSC 
complexes, to assess them as candidate hypoxia selective tracer [162-163, 167]. Using 
both CHO and EMT cells in conjunction with their HSI model, they showed that the 
64
Cu-complexes of: ATS, ATSM, CTS, CTSM, DTS, DTSM, PTSE, and PTSM 
demonstrated some degree of hypoxia selective accumulation. However they also 
assessed a number of other complexes which we did not. This was because the HSI 
values for these complexes were comparable to or lower than that of Cu-PTSM. We also 
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characterised the myocardial retention of Cu-ATSE, which was first described by 
McQuade et al [208], but which also had yet to be screened in cardiac tissue.   
 
The results of Dearling et al suggested that a number of their novel Cu-BTSC complexes 
were hypoxia selective. However the cell based methods that have been used thus far to 
characterise Cu-BTSC complexes, have generally only given a rough indication of 
whether a particular complex is in fact hypoxia selective. Our own data from ARVM, 
which is described in chapter 3, is testament to this. As discussed above, even though the 
uptake of Cu-PTSE in hypoxic cells was lower than in normoxic cells, the HSI method 
used by Dearling’s group suggested that Cu-PTSE may be hypoxia selective, however 
our data do not agree with this. The accumulation of Cu-CTSM in CHO cells is another 
example of how unreliable cell based assays can be. In these cells the uptake of Cu-
CTSM was only marginally higher under hypoxic compared to normoxic conditions, 
although the HSI did correctly predict that this tracer would be hypoxia selective. 
However by employing a more robust and dynamic system, which monitored 
radioactivity as it passed through the heart in real-time, we were able to assess the first 
pass extraction of 
64
Cu-BTSC complexes. This method enabled us to demonstrate with 




Cu-complexes of ATS, ATSE, CTS, CTSM, DTS, and DTSM all 
display significant hypoxic tissue selectivity. We also demonstrated that during hypoxia 
the fraction of radioactivity that was retained in the heart, was similar for all of these 
tracers. This suggests that the greater improvements in hypoxic to normoxic tissue 
contrast of this series of radiotracers, was largely gained by decreasing the non-specific 
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retention during normoxia, which as we will now show was governed not by redox 




Cu-BTSC complexes a positive relationship between molecular weight and 
lipophilicity has been demonstrated by John and Green [171], Green et al [170] and 
Dearling et al [167]. We also report similar findings in this study (Figure 5.5 and 5.7 
Partition). Earlier work by Minkel et al [173] and Dearling and co-workers [167], did not 
show a relationship between the cellular uptake of Cu-BTSC complexes and their relative 
lipophilicity. Our data on the other hand suggest that there is in fact an important 
relationship between these two parameters. By employing a more robust and dynamic 
system, and by assessing the first pass extraction of 
64
Cu-BTSC complexes by 
administering a bolus of tracer, we demonstrate that under oxygenated conditions there is 
a relationship between the tissue retention of these tracers and their molecular weight or 
partition ratio, with R
2
 values of 0.81 and 0.84 respectively (figures 5.22 and 5.23). We 
also observed a relationship between the molecular weight or partition ratio, and the 
hypoxic to normoxic tissue contrast ratio of hypoxia selective 
64
Cu-BTSCs (figures 5.24 
and 5.25), with R
2
 values for these comparisons of 0.87 and 0.81 (5 min hypoxia), and 
0.79 and 0.78 (25 min hypoxia) respectively. This suggests that the relative lipophilicity 
of Cu-BTSC complexes also governs their hypoxic to normoxic tissue contrast. However 
for data that were obtained under hypoxic conditions, when we plotted values for tissue 
retention or hypoxic to normoxic contrast against either molecular weight or partition 
ratio, we did not observe a relationship between any of these parameters. Thus while 
lipophilicity may govern the accumulation of Cu-BTSC during normoxia, lipophilicity is 
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certainly not the mechanism for hypoxia selectivity. Rather complexes with relatively 
high partition ratios may interact more with the cell membrane, this would have the 
effect of slowing their rate of elution from cells, or possibly lead to irreversible trapping 
within the membrane. Thus, as the relative lipophilicity of the complexes increase they 
take longer to clear from normoxic tissue, which in turn decreases the hypoxic to 
normoxic tissue contrast. This has previously been  suggested by Minkel et al [173], but 
we are the first to demonstrate it experimentally.  
 
Another important observation that we made, was that during hypoxia the tissue retention 
of the all Cu-BTSC complexes increased from 5 to 25 min hypoxia. Of the hypoxia 
selective complexes only 
64
Cu-DTSM did not display a significant difference between 5 
and 25 min hypoxia, although the average retention at 25 min was 8.8 % higher than at 5 
min. This indicates that these tracers should not be considered as ‘all or nothing’ markers 
of hypoxia, but that they may demonstrate graded hypoxia selectivity. When we consider 
the intracellular retention mechanisms proposed for these tracers [167, 174, 241, 292], a 
number of observations that we have made during this study, may add extra insight into 
intracellular fate of Cu-BTSC complexes. It has been suggested that Cu-PTSM 
dissociates rapidly once taken up by cells, irrespective of their oxygenation status [174]. 
However we have shown that retention of Cu-PTSM and similarly Cu-PTSE is oxygen 
sensitive, although these tracers are poorly hypoxia selective. If we consider that after a 
bolus of tracer is administered, an equal amount of tracer should enter the cells of the 
heart, regardless of whether it is receiving oxygenated or hypoxic buffer. Once Cu-PTSM 
or Cu-PTSE have traversed the cell membrane and been reduced, if they rapidly 
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dissociate to form free ligand and Cu(I), one would expect their retention during 
normoxia and hypoxia to be equal. However if these complexes do not rapidly dissociate 
they could be reoxidised back to the Cu(II) form, and be free to traverse the cell 
membrane and elute from the heart. This would explain why the retention of Cu-PTSM 
increased during hypoxia. The retention mechanism for Cu-PTSM is therefore likely to 
be that same as that of Cu-ATSM (figure 1.15). The only difference being that because 
Cu-PTSM has a lower redox potential (relative to hypoxia selective Cu-BTSCs), it is 
more likely to dissociate or have the copper moiety removed by biomolecules before it 
can be reoxidised, which would increase its retention compared to more hypoxia 
selective Cu-BTSCs. This is further supported by the slight increase in tracer retention at 
5 and 25 min hypoxia when the buffer pO2 was ~20- 30 mmHg lower. Furthermore, 
similar but more conclusive observations were made for the hypoxia selective 
complexes. This agrees with the observation made by Maurer et al, who proposed that in 
cells Cu-BTSC are reduced to the Cu(I) form regardless of the level of oxygenation, but 
in the presence of oxygen they can be oxidised back to the Cu(II) form [293]. This 
suggests that all 
64
Cu-BTSC complexes share the same retention mechanism, and while 
not all of them are hypoxia specific, they are all oxygen sensitive.  
 
It was originally thought that Cu-BTSCs enter cells by passively diffusing across the cell 
membrane [164-165, 174]. However the results of a recent study by Price et al, have 
suggested that Cu-BTSC complexes may also be transported into cells by membrane 
protein mediated mechanisms [294], as well as by passive diffusion. Price and co-
workers demonstrated that the accumulation of Cu-GTS and Cu-ATSM in M17 (human 
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neuronal) and U87MG (glial) cells was dependent up on temperature and the availability 
of ATP, as well as the presence of membrane proteins. Tracer accumulation was not 
saturated by increasing concentration, which supports the hypothesis that passive 
diffusion also takes place. With respect to our study, the relationship that we observed 
between lipophilicity/ molecular weight and tracer retention, further suggests that passive 
diffusion is the predominate method by which these tracers enter cells. The Price group 
also suggested that the efflux of Cu from cells is facilitated by ATP dependent transport 
proteins. Furthermore Cu efflux also decreased when protein synthesis was inhibited. 
While we did not investigate Cu efflux directly during our experiments our results 
support this proposal, as we did not observe a relationship between lipophilicity/ 









6.1  Summary of Major Findings 
The aim of this thesis was to build upon the structure activity work of Dearling, Lewis, 
Blower, McQuade et al, focusing on whether any of the novel Cu-BTSC complexes that 
they synthesised were suitable for cardiac imaging, or more specifically showed greater 
promise than Cu-ATSM. We initially set out to develop an ARVM based high-
throughput screen for characterising 
64
Cu-BTSC complexes. After designing and 
calibrating a novel cell incubation chamber, and determining the optimum ARVM 
culture conditions, we applied our relatively large scale system. In doing so we 
successfully demonstrated for the first time, the hypoxia selective accumulation of 
64
Cu-
ATSM in ARVM. Unfortunately, for a number of reasons this system had a large 
inherent variability, i) the number of cells that is obtained when isolating ARVM can 
vary considerably between isolations, and is difficult to control for, ii) the accumulation 
of 
64
Cu-ATSM within cells was also extremely variable. These factors gave rise to a poor 
contrast between 
64
Cu-ATSM uptake in hypoxic and normoxic cells. While there are a 
number of parameters that may have improved this contrast, for example increasing the 
concentration of radiotracer or incubating the cells for longer, our data suggested that it 
would not be possible to downscale the system to allow us to screen multiple tracers or 
replicates simultaneously. Furthermore, the ARVM isolation and purification process 
was relatively long and costly compared to using isolated perfused hearts, which can be 
excised rapidly and have to be used immediately. We therefore concluded that the cell 
based screen would not be suitable for characterising the myocardial tissue accumulation 
of our library of 
64
Cu-BTSC complexes. In light of this we decided to focus our efforts 
on developing a more dynamic system that could model the single pass extraction of 
270 
 
these tracers. For this purpose we chose to employ isolated perfused hearts in 
combination with γ-radiation detectors. 
 
The “triple detector array” proved to be a considerably more reliable, accurate, and 
reproducible method for characterising the hypoxia specificity and myocardial 
accumulation of our complexes. Although the isolated perfused heart is an ex vivo 
preparation, by using the bolus method of tracer delivery we were able, to a certain 
degree, to mimic the first pass extraction of radiotracers as would occur in vivo. For our 
initial experiments we used a single γ-detector from a radio-HPLC with promising 
results, similar to those obtained for 
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FMISO by Shelton et al [75-76]. This preliminary work suggested that 
the isolated perfused heart-γ-detector method would be a superior means of assessing our 
tracers. We therefore designed and commissioned the purpose built “triple detector 
array”. After carefully calibrating and optimising this system, as well as establishing 
exclusion criteria for cardiac function we began to screen and characterise our library of 
tracers.  
 
The results from our experiments using isolated hearts have provided further insight into 
the structure activity relationships within the class of Cu-BTSC complexes, and 
demonstrated how the physicochemical properties of these tracers affect their 
accumulation in cardiac tissue. The first major finding from our work is that all of the 
64
Cu-BTSCs were able to readily accumulate within cardiac tissue, and that the retention 
profiles of these tracers are dependent upon their redox potential, as well as the 
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oxygenation status of the heart. We have also shown that Cu-PTSE like Cu-PTSM is not 
hypoxia selective. While Fujibayashi et al and Dearling et al have previously suggested 
that complexes with only a single alkyl group on the di-imine backbone are less likely to 
be hypoxia selective, we have shown this without ambiguity. However as we observed 
that the percentage tissue retention of these tracers was inversely related to the level of 
oxygenation, our data also suggest that Cu-PTSM and Cu-PTSE display a degree of 
oxygen sensitivity. We also observed this for 
64
Cu-BTSCs where the ligand was 




 positions (strongly hypoxia selective). This may explain 
why Dearling et al observed some degree of hypoxia selectivity with Cu-PTSM, and 
mid-range selectivity for Cu-PTSE when they applied the HSI model [167]. Our data 
suggest that the mechanism of retention of Cu-PTSM that was proposed by Fujibayashi 
et al [174], whereby Cu-PTSM enters the cell and is reduced and trapped regardless of 
the oxygenation status, may not accurately portray the intracellular fate of this complex. 
Our observations that Cu(I)-PTSM (and Cu(I)-PTSE) retention does increase under 
hypoxia, suggest that once reduced these tracers can also undergo reoxidation back to the 
uncharged Cu(II) species, which is then free to elute from the cell. It is therefore more 
likely that the trapping mechanism proposed for Cu-ATSM by Dearling et al and Maurer 
et al, better reflects the true mechanism by which all Cu-BTSC complexes are retained 
within cells. They proposed that the retention of Cu-ATSM may not just be dependent 
upon the rate at which the complex is reduced, but that the trapping of the copper moiety 
is dependent upon an interplay between the rate at which the complex dissociates, and 
the rate at which reoxidation of the Cu(I)-complex occurs [167]. Our data do not entirely 
agree with Dearling et al, as they also suggested that because of its relatively high redox 
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potential Cu-PTSM is unlikely to undergo reoxidation, and will be irreversibly trapped 
within the cell .  
 
In this thesis we have provided further evidence in support of observations that were 
made by Dearling et al [162-163, 167] and McQuade et al [208], that Cu-BTSC 




 positions invariably display 
hypoxia selectivity. Furthermore the retention of these compounds in hypoxic cardiac 
tissue was very similar (42- 59 % ID after 5 min, and 64- 78 %ID after 25 min hypoxia), 
which is not surprising considering that they have similar redox potentials of between (-
0.58- -0.59 V) [167]. Dearling’s data combined without ours suggest that it will not be 
possible to further refine the redox potential, and therefore hypoxia selectivity of Cu-
BTSCs, beyond the change that occurs between Cu-PTSM and Cu-ATSM, by merely 




 positions. Our data from well oxygenated 
hearts suggest that the relative lipophilicity of these complexes may also be an important 
factor to consider, when developing and assessing this class of tracers. The importance of 
lipophilicity to the biological activity of Cu-BTSC complexes is widely reported [162, 
167, 171, 173], but we have demonstrated for the first time that there is a relationship 
between their first pass extraction and relative lipophilicity. We have also shown that the 
least lipophilic and lowest molecular weight complexes Cu-ATS and Cu-CTS, 
demonstrate the lowest uptake in normoxic tissue but greater accumulation in hypoxic 
tissue compared Cu-ATSM, which led to them displaying the highest degree of hypoxic 
to normoxic tissue contrast. We have therefore identified from a library of Cu-BTSC 
complexes, two tracers that warrant further investigation not only as imaging radiotracers 
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for cardiac hypoxia but also in oncology, as we believe these tracers have the potential to 
supersede Cu-ATSM, because of the superior pharmacokinetics that they have 
demonstrated in our ex vivo model. However we should note that we are aware that Cu-
ATS does not cross the blood brain barrier [282], while biodistribution of Cu-CTS has 
yet to be assessed.   
 
6.2  Further Work 
In our recent review we described what needs to be done in order to develop and further 
validate the Cu-BTSC complexes as hypoxia tracers [106], these were as follows: 
 Screening of the current Cu-BTSC library and new Cu-BTSC-like complexes  
 Assessing the role of oxygen  
 Assessing the effect of acidosis 
 Assessing the effect of perfusion 
 Identifying the intracellular bioreductants 
 Determining the fate of radio-copper once removed from the ligand   
 
Addressing these issues now represents the core of the research in our group. The 
research that is described in this thesis was just the first step towards characterising our 
library of Cu-BTSC complexes. In the “triple detector array” we have established a 
model system, which is capable of assessing the first pass extraction and hypoxia 
specificity of candidate hypoxia tracers. We then used this system to identify novel 
tracers that could potentially display more desirable pharmacokinetics, and better 
hypoxic to normoxic tissue contrast in vivo, compared to the lead complex Cu-ATSM.  
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With respect to work which directly follows on from the research that has been presented 
in this thesis, our suggestions for future work are as follows:  
 
By determining the redox potentials of the Cu-BTSC complexes that we also assessed 
during our study, Dearling et al demonstrated that it may not be possible to refine the 
redox potential of Cu-BTSC complexes, beyond the change that occurs between Cu-
PTSM and Cu-ATSM. With the exception of the more lipophilic complexes Cu-CTSM 
and Cu-DTSM during early hypoxia, our data from isolated hearts subjected to hypoxia 
support this proposal, because we did not observe a significantly different amount of 
retention for any of hypoxia selective the tracers relative to Cu-ATSM. Our next series of 
experiments should therefore address the effect of oxygenation, to determine whether any 
of the complexes screened in this study are retained at more pathophysiologically 
relevant pO2 levels. This would involve using a gas mixer to carefully moderate the level 
of oxygen in the coronary perfusate. The pO2 would then be gradually titrated down, and 
at each level of oxygenation an injection of tracer would be administered. The percentage 
retention of each tracer at each level of oxygen should then be compared to ascertain if 
there are any differences or improvements over that of Cu-ATSM. 
 
In addition to screening the complexes at pathophysiologically relevant oxygen levels, it 
is also necessary to compare the percentage tissue retention of these tracers with the level 
of energy substrates, such as ATP and creatine kinase, within the heart using 
31
P NMR 
spectroscopy. This would allow us to establish the biological relevance of the 
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accumulation of any given tracer within the heart, and perhaps provide greater diagnostic 
or prognostic insight clinically. 
 
We designed the “triple detector array” specifically so that it was able to acquire an input 
and output function as well as measuring the radioactivity within the heart, with a view 
to allowing us to perform pharmacokinetic compartmental modelling on the radiotracer 
time-activity curves. We should therefore focus on developing these pharmacokinetic 
models incorporating these input and output functions, to ascertain whether they can 
provide further evidence of structure activity relationships that we have indentified 
during this present study. Pharmacokinetic modelling in this manner may also provide 
further information on the rate of uptake, bioreduction, and dissociation of Cu-BTSC 




The work described in this thesis has been solely based on in vitro, and ex vivo models, 
we should therefore aim to employ or develop suitable in vivo models of cardiac 
ischaemia. This would include performing biodistribution studies on all of the 
complexes, as well as using microPET imaging to asses their cardiac accumulation. This 
should be done using normal animals and also the wide variety of animal models of 
cardiovascular disease, which available to us within our own division and the adjacent 
Division of Cardiovascular Research at King’s. 
 
Finally we would hope that larger in-patient trials are conducted with Cu-ATSM or other 





Tc-Sestamibi imaging as suggested in chapter 1. Such trials would be able to 
determine whether any member of this class of tracers is suitable for delineating 
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